VacCiencia

FINLAY EDICIONES

Boletín Científico

No. 24 (12-22 noviembre / 2024)

EN ESTE NÚMERO

VacCiencia es una publicación dirigida a investigadores y especialistas dedicados a la vacunología y temas afines, con el objetivo de serle útil. Usted puede realizar sugerencias sobre los contenidos y de esta forma crear una retroalimentación que nos permita acercarnos más a sus necesidades de información.

- Noticias más recientes en la Web sobre vacunas.
- Artículos científicos más recientes de Medline sobre vacunas.
- Patentes más recientes en Patentscope sobre vacunas.

IFV INSTITUTO FINLAY DE VACUNAS

SiViFinlay

VaCyT

CUBA

Noticias en la Web

La FDA avanza con la vacuna neumocócica VAX-31 de Vaxcyte

12 nov. Vaxcyte, Inc. (NASDAQ:PCVX), una empresa de vacunas en fase clínica, anunció avances regulatorios para su candidata a vacuna neumocócica conjugada, VAX-31. La Administración de Alimentos y Medicamentos de EE. UU. (FDA) ha aprobado la solicitud de Nuevo Fármaco en Investigación (IND) para VAX-31 en bebés y ha otorgado la designación de Terapia Innovadora para su uso en adultos.

VAX-31 se está desarrollando para prevenir la enfermedad neumocócica invasiva (ENI), una infección grave que puede resultar en afecciones como meningitis y bacteriemia. Diseñada para cubrir la mayoría de las cepas de ENI en EE. UU., se espera que VAX-31 proporcione una protección más amplia en comparación con las vacunas actuales.

Para uso pediátrico, la empresa planea iniciar un estudio de Fase 2 a finales de enero de 2025. Este ensayo evaluará la seguridad, tolerabilidad e inmunogenicidad de la vacuna en una serie de dosis administradas a bebés sanos junto con las vacunas pediátricas de rutina.

La formulación para adultos de VAX-31 recibió la designación de Terapia Innovadora de la FDA, que acelera el desarrollo y la revisión de medicamentos para afecciones graves cuando la evidencia preliminar sugiere una mejora significativa sobre las terapias existentes. Vaxcyte tiene como objetivo comenzar un estudio pivotal de Fase 3 de no inferioridad para adultos a mediados de 2025.

Estos avances siguen a los resultados positivos de estudios anteriores de Fase 1/2, que respaldaron las decisiones de la FDA. El CEO de Vaxcyte, Grant Pickering, expresó optimismo sobre la exploración completa de la utilidad clínica de VAX-31 en ambas poblaciones.

VAX-31 es parte del esfuerzo más amplio de Vaxcyte para crear vacunas contra enfermedades bacterianas utilizando técnicas sintéticas modernas. La plataforma de la empresa tiene como objetivo producir vacunas con beneficios inmunológicos mejorados de manera eficiente.

El desarrollo de VAX-31 se alinea con la recomendación ampliada de vacunación neumocócica del Comité Asesor sobre Prácticas de Inmunización para adultos estadounidenses de 50 años o más. Esta decisión subraya la importancia de una protección más amplia contra la enfermedad para este grupo demográfico.

Este artículo se basa en un comunicado de prensa de Vaxcyte, Inc.

En otras noticias recientes, Vaxcyte ha logrado avances significativos en su programa de desarrollo de vacunas. VAX-31 ha mostrado resultados prometedores en ensayos de Fase 1/2, lo que ha llevado a varias firmas a aumentar sus objetivos de precio. Jefferies aumentó su objetivo a 146 dólares desde 129 dólares, Leerink Partners reiteró su calificación de Superar el rendimiento del mercado con un objetivo de 135,00 dólares, BTIG mantuvo su calificación de Compra con un objetivo de 160,00 dólares, y Mizuho aumentó su objetivo a 163 dólares desde 113 dólares.

VAX-31 está en camino de avanzar a ensayos de Fase 3 para mediados de 2025, con ensayos de Fase 2 en bebés previstos para el primer trimestre de 2025.

Los recientes desarrollos han posicionado a VAX-31 a la vanguardia de la industria.

Vaxcyte completó recientemente una oferta pública, recaudando aproximadamente 1.500 millones de dólares. La empresa reportó gastos operativos de 140 millones de dólares y un saldo de caja de 3.300 millones de dólares al 30 de septiembre.

Finalmente, Vaxcyte ha anunciado el nombramiento de John P. Furey en su Consejo de Administración, indicando cambios recientes en la estructura corporativa de la empresa.

Perspectivas de InvestingPro

El progreso regulatorio de Vaxcyte con VAX-31 se alinea con su sólido desempeño en el mercado. Según InvestingPro, la capitalización de mercado de la empresa se sitúa en 12.920 millones de dólares, reflejando la confianza de los inversores en su pipeline de desarrollo de vacunas.

Las acciones de la empresa han mostrado una notable fortaleza, con un rendimiento total del precio del 115,29% en el último año y un 58,98% en los últimos seis meses. Esta trayectoria ascendente sugiere optimismo sobre las perspectivas futuras de Vaxcyte.

Sin embargo, es importante señalar que Vaxcyte aún no es rentable, lo cual es consistente con su estatus de empresa biotecnológica en fase clínica que invierte fuertemente en investigación y desarrollo.

Un consejo relevante de InvestingPro destaca que Vaxcyte mantiene más efectivo que deuda en su balance. Esta sólida posición de liquidez es crucial para financiar los ensayos clínicos en curso y navegar el largo proceso de aprobación de medicamentos.

Para los inversores que buscan un análisis más completo, InvestingPro ofrece 9 consejos adicionales que podrían proporcionar más información sobre la salud financiera y la posición en el mercado de Vaxcyte.

Fuente: Investing.com. Disponible en https://acortar.link/HQ2zn8

First bivalent mRNA vaccine candidate against RSV goes under clinical trial

Nov 13. The world's first bivalent mRNA vaccine candidate against respiratory syncytial virus, or RSV, kicked off Phase I clinical trial in China on Wednesday, as an adult received a shot at a clinical research center of a major Shanghai hospital.

The developer of the vaccine candidate said that the adult participant was in stable condition and under medical observation after the vaccination.

The vaccine candidate was developed by Innorna, a Shenzhen-based biotechnology enterprise, with a technology platform whose independent intellectual property rights it holds. The clinical trial was approved by the Center for Drug Evaluation of China's National Medical Products Administration in June.

No vaccine against RSV has been approved for marketing on the Chinese mainland so far.

RSV is one of the pathogens that became familiar to Chinese residents recently, especially after it swept many parts of the country last winter and infected populations, especially young children and the elderly.

The pathogen can severely affect children's lung function, and the vulnerable group stands a higher chance of

developing into severe cases after getting infected, said medical experts.

"Official figures showed that RSV caused more than 80 percent of respiratory viral infection cases in infants and young children in the country last year," said Gu Weirong, vice-president of the Obstetrics and Gynecology Hospital of Fudan University in Shanghai.

Compared with the three RSV vaccines already approved overseas, the new vaccine candidate has its own advantages, according to Innorna.

"The vaccine is bivalent, meaning that it can cover both subtypes of RSV that cause most RSV infections at the same time. Moreover, the technical route of mRNA makes the vaccine design more flexible in case the virus mutates," said Chen Zhangjing, head of clinical development at Innorna.

"Also, as an mRNA vaccine, it is expected to help individuals realize a similar level of immune response after being vaccinated repeatedly every other year or two years - if applicable - as what they do after the initial vaccination," he said.

According to its clinical study plan, a total of 240 adult participants, including half aged 59 years and younger and the other half aged 60 years and older, will be enrolled in this phase I clinical trial, which is expected to last about two and a half years.

The vaccine candidate is developed for adults aged 60 years and older as a prioritized population, according to its developer, which also plans to promote the development of indications for adults with poor immunity, pregnant women, and infants.

Fuente: China Daily. Disponible en https://goo.su/Ypn9

Merck to present new data from Gardasil 9 studies reinforcing the importance of gender-neutral HPV vaccination in adults up to age 45 at IPVC 2024

13 nov. Merck, known as MSD outside of the United States and Canada, announced that new clinical and real-world data for the company's 9-valent Human Papillomavirus (HPV) vaccine, Gardasil 9 (Human Papillomavirus 9-valent Vaccine, Recombinant), evaluating the burden and incidence of certain HPV-related cancers and diseases, will be presented at the International Papillomavirus Conference (IPVC) 2024 in Edinburgh, UK, from November 12-15.

Data to be presented include results from the BROADEN and PROGRESS studies evaluating the prevalence of oral HPV infection and burden of HPV-related oropharyngeal and other head and neck cancers, as well as studies evaluating the age of disease-causal HPV infection among females and highlighting the importance of protecting both females and males from HPV-related cancers and diseases through vaccination.

"These data support the value of adult vaccination and strengthen our understanding that disease-causal HPV infection can happen later in life, reinforcing the importance of HPV vaccination for both females and males beginning at age 9," said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. "While historically the HPV vaccination conversation has focused on preventing certain HPV-related cervical cancers in women, we also continue to see the growing incidence of HPV-related oropharyngeal and other head and neck cancers, particularly in men. In both men

and women globally, there are approximately 666,000 new diagnoses of certain HPV-related cancers annually. The breadth of data we are presenting at the conference continues to demonstrate the link between HPV and certain HPV-related cancers in males and females and the role HPV vaccination can play in prevention."

Gardasil 9 is a vaccine indicated in females 9 through 45 years of age for the prevention of cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by human papillomavirus (HPV) Types 16, 18, 31, 33, 45, 52, and 58; cervical, vulvar, vaginal, and anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11 .

Gardasil 9 is indicated in males 9 through 45 years of age for the prevention of anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58; anal precancerous or dysplastic lesions caused by HPV Types 6, 11, 16, 18, 31, 33, 45, 52, and 58; and genital warts caused by HPV Types 6 and 11.

The oropharyngeal and head and neck cancer indication is approved under accelerated approval based on effectiveness in preventing HPV-related anogenital disease. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Gardasil 9 does not eliminate the necessity for vaccine recipients to undergo screening for cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers as recommended by a health care provider.

Gardasil 9 has not been demonstrated to provide protection against diseases caused by: HPV types not covered by the vaccine - HPV types to which a person has previously been exposed through sexual activity. Not all vulvar, vaginal, anal, oropharyngeal and other head and neck cancers are caused by HPV, and Gardasil 9 protects only against those vulvar, vaginal, anal, oropharyngeal and other head and neck cancers caused by HPV Types 16, 18, 31, 33, 45, 52, and 58.

Gardasil 9 is not a treatment for external genital lesions; cervical, vulvar, vaginal, anal, oropharyngeal and other head and neck cancers; or cervical intraepithelial neoplasia (CIN), vulvar intraepithelial neoplasia (VIN), vaginal intraepithelial neoplasia (VaIN), or anal intraepithelial neoplasia (AIN).

Vaccination with Gardasil 9 may not result in protection in all vaccine recipients.

Merck is committed to ensuring adequate global supply and supporting broader, equitable access to our HPV vaccines to help protect against certain HPV-related cancers and diseases.

This commitment is enabled through significant capital investments, including more than $2 billion to help increase capacity through additional manufacturing facilities that allowed for a nearly doubling of supply of our HPV vaccines from 2017-2020 and then, supply was doubled again between 2020-2024 to address increasing global demand. As a result, we expect to supply sufficient quantities of our HPV vaccines to meet anticipated demand and will continue to expand supply capacity in the future.

Global equitable access to our HPV vaccines is a key part of our efforts and key partnerships help us achieve these goals. In 2024, Merck reaffirmed its commitment to Gavi, the Vaccine Alliance, through an agreement with UNICEF, to supply low- and middle-income countries with over 115 million doses of HPV vaccine by 2025, to appropriately support local immunization programs. Merck has consistently increased our supply commitment to Gavi from 1.7 million doses in 2017 to more than 30 million doses in 2024.

Fuente: PHARMABIZ. Disponible en https://goo.su/oms2

Shingles Vaccine Could Protect Cardiovascular Health

15 nov. Shingles vaccination has proved to be effective for the prevention of herpes zoster and related complications. However, researchers said that the vaccine could also protect cardiovascular health—emphasizing the importance of receiving a shingles vaccine.

Shingles occurs when the varicella-zoster virus (VZV), which causes chickenpox, reactivates and causes a painful rash illness. According to the CDC, an estimated 1 million individuals experience shingles each year in the US. In most cases, individuals only develop shingles once in their lifetime; however, the illness can reoccur. The risk of developing shingles increases with age, medical conditions that impact the immune system, along with medications that do not allow the immune system to work properly.

The virus commonly presents as a rash around the side of the body, which could lead to serious complications, including postherpetic neuralgia—which is long-term nerve pain. The CDC provided that individuals that never had the chickenpox or did not receive the chickenpox vaccine can get infected with VZV if in contact with an individual that has shingles. The virus can spread through direct contact with the fluid from the shingles rash blister, or by breathing in virus particles that come from the blisters.

The CDC recommends all individuals 50 years and older to receive 2 doses of the recombinant zoster vaccine (RZV, Shingrix) to protect against shingles, and also recommends individuals 19 years and older to get vaccinated if they have a weakened immune system. Clinical trials conducted on the safety and efficacy of shingles provided that the vaccine was 97% effective in preventing shingles in adults 50 to 69 years and 91% effective in individuals 70 years and older, which could also prevent further complications.

According to the Journal of the American Heart Association, a 2022 study found that shingles was associated with higher long-term risk of major cardiovascular events. The study assessed the link of shingles with the risk of stroke or heart disease among 3 large US cohorts—the NHS (Nurses' Health Study), NHS II (Nurses' Health Study II), and HPFS (Health Professionals Follow-Up Study). The study provided data from a total of 205,030 individuals.

The results displayed that, among all 3 cohorts, individuals with shingles had a 30% increased risk of developing future cardiovascular events. The study authors noted that individuals with shingles also had a 38% higher chance of experiencing a stroke compared to individuals without shingles. Additionally, the risk of having a heart attack or needing a heart procedure was 25% higher in the shingles group.

"There is a growing body of evidence that links the varicella zoster virus to vascular disease, the only human virus demonstrated to replicate in arteries and lead to vasculopathy," Sharon G. Curhan, MD, ScM, said in the press release.

The findings suggest that shingles vaccination could reduce the risk of cardiovascular complications that could develop among individuals with the virus. Pharmacists can continue to spread awareness of the importance of receiving a shingles vaccine, especially among those at greater risk.

Fuente: Pharmacy Times. Disponible en https://goo.su/5q49Y

La inmunización de la bronquiolitis evita más de ocho de cada diez hospitalizaciones de bebés en la Región de Murcia

17 nov. La vacuna contra la bronquiolitis, una de las enfermedades de mayor riesgo en los bebés, está consiguiendo unos resultados espectaculares en España y aquí en la Región, una de las comunidades españolas con un calendario vacunal más ambicioso, que ya ha conseguido evitar durante el pasado año más de ocho de cada diez hospitalizaciones en bebés. En el caso de España, se han evitado más de 10.000 hospitalizaciones e ingresos en la UCI, según ha confirmado en Hora 14 Matilde Zornoza, técnico del programa de vacunación de la consejería de Salud.

El objetivo de cobertura de esta inmunización es del 90%. Zornoza considera importante que los recién nacidos no salgan del hospital sin inmunizar, porque aumenta el riesgo.

Las bronquiolitis es la principal consecuencia de este virus respiratorio sincitial (VRS), y suponen una de las primeras causas de hospitalización en menores de cinco años. Provoca problemas de respiración, deshidratación y falta de oxígeno.

Por otra parte, la consejería de Salud también tiene en marcha la vacunación escolar de la gripe para niños de cinco años o menos, que pretende alcanzar a unos 54.000 menores. Esta campaña, según Zornoza, aumenta la equidad de las familias de la Región, algunas con más dificultades de acceso a la vacuna en su centro de salud por cuestiones laborales.

En el caso de los menores de seis meses no hay vacuna de la gripe en el mercado, por lo que se hace fundamental la vacunación a través de la madre durante el embarazo, lo que protege tanto a la madre como al bebé.

Esta vacuna de la gripe supone, según Zornoza, evitar complicaciones derivadas por el virus. "Hay que concienciar de que la gripe no es algo menor, no es un catarro", y recuerda que más de la mitad de niños que ingresan en la UCI por la gripe eran niños sanos, y señala que el objetivo de cobertura de esta vacuna es del 50%, algo que ya se ha superado.

También se evitan complicaciones derivadas de la gripe a las personas mayores en residencias y personas con discapacidad, cuyo objetivo de cobertura es mucho mayor y supera el 80%. La vacuna de la gripe se abrirá a la población en general, previsiblemente a mitad de diciembre, en función de la disponibilidad.

Fuente: CADENA SER. Disponible en https://goo.su/OYHe

La controversia sobre la vacuna de Pfizer atemoriza la humanidad

18 nov. En los últimos años, la farmacéutica Pfizer ha estado en el centro de controversias globales. Sin embargo, lo que muchos consideran “crímenes contra la humanidad” rara vez han recibido cobertura en los grandes medios tradicionales de comunicación, que, a menudo, optan por silenciar o minimizar estas acusaciones y su impacto en los seres humanos.

Pfizer no es nueva en los titulares por razones polémicas. Desde multas por publicidad engañosa hasta acusaciones de ensayos clínicos sin consentimiento en países vulnerables, la compañía ha acumulado un historial que plantea preguntas importantes sobre ética corporativa.

Este articulo examina algunos de los casos más polémicos atribuidos a Pfizer y analiza por qué los medios de comunicación tradicionales han optado por una cobertura limitada o sesgada. Mas allá de las

implicaciones para una sola empresa, esta omisión señala una crisis más profunda en la relación entre periodismo y el poder corporativo, poniendo en riesgo el derecho del público a recibir información veraz.

Recientemente la periodista Naomi Wolf publicó una investigación titulada The Pfizer Papers: Pfizer' Crimes Against Humanity, donde detalla las graves lesiones relacionadas con las vacunas que Pfizer y la FDA (Administración de Alimentos y Medicamentos) conocían a principios de 2021; pero que intentaron ocultar al público.

"Pfizer conocía las deficiencias de sus ensayos de vacunas contra la COVID-19 y los muchos efectos adversos de las vacunas, al igual que la Administración de Alimentos y Medicamentos (FDA) de Estados Unidos. Pero la FDA promovió las vacunas de todo modo, y luego trató de ocultar los datos al público, según la periodista Naomi Wolf".

En el texto citado más arriba, Wolf detalló las graves lesiones relacionadas con las vacunas que Pfizer y la FDA conocían desde el principio del 2021, basándose en los datos de los ensayos clínicos de la farmacéutica y los estudios posteriores a la comercialización. Para producir "The Pfizer Papers", Wolf, periodista y directora ejecutiva de Daily Clout, juntamente con Amy Kelly, convocaron a miles de científicos y médicos voluntarios para analizar los datos de Pfizer y los datos complementarios de otros sistemas de informes públicos para capturar el alcance total de los efectos de las vacunas.

Otro de los casos mas preocupantes en lo que estuvo implicado Pfizer, fue el "ensayo clínico en Nigeria en 1996, en el que niños fueron sometidos a pruebas de un antibiótico experimental sin un consentimiento adecuado, resultando en muertes y secuelas permanentes. Este hecho generó demandas y fue calificado como una violación de derechos humanos".

Wolf y Kelly obtuvieron los reportes de "public Heath and Medical Profesional for Transparency, un grupo de más 30 profesionales médicos y científicos que demandaron a la FDA en el 2021 para obligar a la agencia a publicar los datos, después de que la FDA se negara a cumplir con una solicitud de la Ley de Libertad de Información. Un Tribunal Federal ordenó en el 2022 a la agencia que publicara 450 mil documentos internos relacionados con la licencia de la vacuna contra el COVID-19 de Pfizer-BioNTech.

"La captación de los reportes fueron fundamentales y también altamente técnicos y científicos. Ningún periodista podría desglosarlo por sí mismo", dice Wolf en el precitado ensayo, por lo que tuvo que valerse de unos 3250 científicos altamente acreditados para descodificar los datos proporcionados por la FDA. "Los hallazgos por los grupos de científicos emitido de forma sistemática, son clave sobre lo que Wolf revela en el texto: que "resulta ser el mayor crimen contra la humanidad en la historia registrada".

"Los documentos de Pfizer son una sorprendente revelación de la codicia y la deshonestidad corporativas, con total desprecio por la ley y la salud real de los estadounidenses y los seres humanos del mundo", escribió Steve Bannon en su introducción al libro.

Un "crimen contra la humanidad". Wolf destaca que debido a que sus abuelos perdieron ocho hermanos en el Holocausto, no usó el lenguaje "crimen contra la humanidad" a la ligera. Sin embargo, subraya, que los informes dejan claro, dado lo que Pfizer sabia el daño a la salud humana causada por las vacunas de ARNm contra el COVID-19,"no hay forma de evitar concluir que esto no es descuido, no es codicia, no es descuido en la planta de producción".

"Como dicen en tecnología, no es un error, es una característica "dijo. "En otras palabras, dañar a los seres

humanos de maneras muy específicas, desde el principio, fue obviamente el resultado de estas inyecciones. Y en lugar de detenerlos, o retirarlos del mercado, Pfizer redobló la apuesta, la FDA redobló la apuesta y los CDC (Centros para el Control y la Prevención de Enfermedades) redoblaron la apuesta.

El periodista Wolf dice que Pfizer, la FDA y los CDC tomaron esas decisiones sabiendo que un millón 223 mil personas murieron a causa de las vacunas en los primeros tres meses. “Lo hicieron sabiendo que la vacuna no detenia la infección, que causaba una larga lista de efectos secundarios graves en decenas de millones de personas”.

Wolf destaca que Pfizer también manipuló los datos para que la FDA aprobara la autorización de uso de emergencia (EUA, por sus siglas en inglés). En lo que Wolf llamó “uno de los informes mas condenatorios de este caso”, el equipo del anestesiólogo australiano DR Jevanthi Kunadhashan descubrió que Pfizer retrasó el registro de las muertes para que no tuvieran que incluirse como parte de su presentación de datos de EUA.

Los investigadores concluyeron que, si Pfizer hubiera registrado e informado las muertes de manera oportuna, la FDA no habría podido otorgarles una EUA para la vacuna.

Los efectos adversos graves en los primeros tres meses suman unos 42 mil pacientes.

Los analistas de “Pfizer Papers” encontraron más de 42 mil informes de casos que detallan 158,893 eventos adversos reportados a Pfizer en los primeros tres meses posteriores a la EUA de diciembre 2020.

Para procesar el gran volumen de informes, la compañía agregó 600 empleados adicionales, según los documentos, con planes de contratar a un total de 1,800 personas para junio de 2021.

Wolf refiere que los efectos negativos de la vacuna “se trata de decenas de miles de coágulos de sangre, coágulos pulmonares, coágulos de piernas, trastornos neurológicos, epilepsias, demencia, Alzheimer, parálisis de Bell, temblores, convulsiones, daño ocular, ceguera, enfermedades respiratorias”.

El efecto secundario más común fue mialgia o dolor muscular, y el segundo efecto secundario más común fue el dolor de las articulaciones, que las personas con frecuencia no se dan cuenta de que esta relacionada con la inyección, puntualiza Wolf en la investigación. Pero expresa que el tercer efecto secundario más común fue la COVID-19 porque la vacuna no detuvo la transmisión.

A pesar de la gravedad de estas revelaciones plasmadas por Wolf en: “Pfizer Papers”: Otros crímenes contra la humanidad, así como otras acusaciones, la cobertura mediática en torno a Pfizer y otras grandes farmacéuticas ha sido en gran parte superficial, enmarcada como parte de una narrativa que prioriza la confianza en los desarrollos farmacéuticos por encima del cuestionamiento ético.

El financiamiento de anuncios por parte de las farmacéuticas y los vínculos corporativos con conglomerados de medios podrían ser razones por las que ciertos temas se reportan de forma sesgada o se pasan por completo por alto.

En los últimos años, la industria farmacéutica ha estado bajo la lupa debido a su papel central en la salud global. Entre las corporaciones más destacadas, Pfizer ha sido protagonista de éxitos en el desarrollo de medicamentos y vacunas; pero también ha enfrentado controversias que suscitan dudas sobre su ética corporativa.

Desde acusaciones de ensayos clínicos sin el consentimiento adecuado hasta sanciones por prácticas engañosas, las alegaciones en contra han sido graves y persistentes. Sin embargo, un factor inquietante

acompaña estas acusaciones: el aparente silencio de los grandes medios de comunicación tradicionales.

A medida que la sociedad enfrenta la necesidad de informarse con precisión sobre la salud y las grandes corporaciones, surge una pregunta: ¿por qué los grandes medios, que actúan como guardianes de la verdad, han fallado en su misión de investigar y reportar de manera imparcial sobre estas denuncias? ¿Qué rol juegan los intereses económicos y las conexiones entre la industria farmacéutica y las plataformas mediáticas en esta falta de cobertura?

La falta de transparencia y cobertura rigurosa sobre temas tan serios como "los crímenes contra la humanidad "no solo mina la confianza pública en los grandes medios y las instituciones, sino que también permite que grandes corporaciones operen sin el escrutinio adecuado. Es hora de exigir una cobertura mediática más imparcial y responsable.

Fuente: Acento. Disponible en http://surl.li/ventqb

Situación epidemiológica actual de la enfermedad neumocócica invasora en España

18 nov. Recientemente, han aparecido dos artículos, el primero del Centro Nacional de Epidemiología (CNE) y el segundo del Laboratorio Nacional de Referencia de Neumococo, que actualizan la situación de la epidemiología de la enfermedad neumocócica invasora (ENI) en nuestro país. Aunque la metodología es distinta, ambos estudios arrojan, con alguna diferencia, resultados similares.

Un hallazgo, ya anticipado, es que tras el paréntesis de la pandemia de la COVID-19, en la que las infecciones neumocócicas (y otras infecciones bacterianas de transmisión respiratoria) disminuyeron -en gran parte por la ausencia de circulación de los virus respiratorios debido a las medidas de confinamiento- se han alcanzado e incluso superado la incidencia y el número de casos de la prepandemia, sobre todo en los niños menores de 4 años, como ha sucedido en otros países.

También, y como era de esperar, en ambos estudios se demuestra que hasta el 60-70 % de los casos de ENI están producidos en la actualidad por serotipos no contenidos en la vacuna neumocócica conjugada 13-valente (serotipos no vacunales o SNV), fenómeno común con la mayoría de los países en los que se ha utilizado esta vacuna. Sin embargo, un hallazgo relevante es que una proporción sustancial de ENI está causada por serotipos vacunales (SV) incluidos en la VNC13: el 3, el 19A, el 19F, el 14 y el 4. Esa persistencia de SV se ha constatado en muchos países europeos con coberturas de vacunación altas.

Serotipos más prevalentes causantes de ENI en España

Se identificaron los 10 serotipos más frecuentes causantes de ENI en ambos estudios y en todas las edades con resultados similares: los tres primeros son el 8, el 3 y el 22F. El llamativo aumento del serotipo 3 después de la pandemia ha ocurrido también en otros países, hasta llegar a ser la primera causa de ENI.

En los niños menores de 5 años, la distribución de los serotipos causantes de ENI es diferente. En los dos estudios, el serotipo más frecuente es el 3, seguido de los serotipos 24F y 22F. El serotipo 8 es mucho menos prevalente en niños que en adultos, y además afecta, sobre todo, a los niños de mayor edad.

El serotipo 24F, esencialmente pediátrico, se ha mantenido constante durante los últimos 3 años y afecta, con preferencia, a los menores de 4 años. Propende a causar meningitis y con frecuencia asocia resistencias a antibióticos (4,6). En Francia, experimentó un rápido aumento tras la introducción de la VNC13 que contrarrestó la diminución de los casos de meningitis por otros serotipos.



En las personas mayores de 65 años, el serotipo 3 es el más frecuente. Dada la elevada letalidad de las infecciones neumocócicas en este grupo de edad no es de extrañar que, en 2023, el 75 % de las defunciones por ENI se hayan debido a este serotipo en nuestro país. En Portugal, después de la pandemia, el serotipo 3 ha sido también el más frecuente como causa de ENI seguido de los serotipos 8, 10A y 24 F (4).

Razones de la persistencia de los serotipos vacunales

Las razones de la persistencia de los SV no son del todo conocidas. La VNC13 es efectiva frente a la ENI por el serotipo 3, aunque la efectividad sea menor que frente a otros serotipos. Esta puede ser la razón de que el serotipo 3, junto con el 19A y el 19F sean los más frecuentes en los fallos vacunales. Es un hecho demostrado que la protección frente a ENI por estos tres serotipos requiere mayores niveles de anticuerpos antipolisacáridos, lo que probablemente se relaciona con una pérdida más rápida de efectividad de la VNC13 frente a los serotipos 3 y 19A.

Quizás, el hecho que mejor explica el pobre impacto de la VNC13 en la ENI producida por el serotipo 3, es su escaso o nulo efecto en la colonización nasofaríngea por este serotipo. En Inglaterra, después de 10 años de vacunación con la VNC13, los únicos SV que persisten en la nasofaringe, son el 3 y el 19A. Lo mismo sucede en un país tan próximo al nuestro como Portugal, donde los serotipos vacunales más frecuentes son el 19F, 3 y 19A. En este mismo país, los SNV más frecuentes en la nasofaringe son: 15B/C, 11A, 23A, y 23B.

Serotipos no vacunales más destacados causantes de ENI

Entre los serotipos no vacunales (SNV) merecen algún comentario los serotipos 4, 10A y 11A.

El serotipo 4 afecta casi exclusivamente a adultos y su aumento ha sido constatado en otros países, como por ejemplo Inglaterra. El serotipo 10A, cuya presencia parece estar aumentando, afecta, sobre todo, a niños menores de 4 años, tiene una capacidad invasiva alta y tiende a producir meningitis. El serotipo 11A se asocia a resistencia a penicilina y amoxicilina y es, de todos los serotipos neumocócicos, el de mayor letalidad.

Los datos de ambos estudios proporcionan estimaciones detalladas sobre la potencial cobertura de las vacunas VNC15 y la VNC20 en diferentes franjas de edad. Así, mientras que en los adultos el porcentaje de

cobertura para la VNC15 y VNC20 oscila alrededor del 40 % y 75 %, respectivamente, en los niños menores de 5 años esta diferencia es menor (alrededor del 45-50 % para la VNC15 y del 60-70 % para la VNC20).

El 50 % de los serotipos causantes de ENI no están cubiertos ni por la VNC15 ni por la VNC20, por lo que un seguimiento de la ENI será fundamental para evaluar el posible impacto de las VNC de valencia ampliada que irán llegando los próximos años.

Fuente: Comité Asesor de Vacunas e Inmunizaciones. Disponible en http://surl.li/mpkqcu

Evalúan inmunogenicidad de vacuna cubana anti-covid-19 luego de transferencia tecnológica

18 nov. El producto, que se denominó PastoCovac Plus, fue transferido en la etapa de formulación y se evaluaron tanto el ingrediente farmacéutico activo como sus atributos de calidad clínica.

Sin cambios significativos en la seguridad y eficacia, tampoco hubo diferencias en los niveles de anticuerpos anti-espiga ni en los neutralizantes, tanto frente a la cepa original de Wuhan como ante Ómicron.

Los resultados de la transferencia tecnológica de la vacuna cubana anti-covid-19 Soberana Plus al Instituto Pasteur de Irán, son comentados en el artículo *Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects*, publicado en la revista *Scientific Reports*.

Los autores concluyeron que, para lograr una transferencia de tecnología exitosa de empresa a empresa, se adquiere un equipo capacitado clínicamente, así como un proceso de fabricación bien definido y documentado y procedimientos de control de calidad validados. Estos elementos contribuyen a minimizar el riesgo de cambios en la calidad de la vacuna después de la transferencia de tecnología. En conjunto, los resultados de la evaluación clínica y de calidad de la investigación mostraron los atributos de calidad aceptables y los límites aceptables en términos de seguridad y eficacia de las vacunas antes y después de la transferencia de tecnología. Los resultados confirmaron que PastoCovac Plus, como la tecnología de vacuna transferida, se encuentra en el límite de producto aceptable en comparación con la vacuna Soberana Plus. Además, la evaluación clínica de PastoCovac Plus/ Soberana Plus mostró que la vacuna basada en proteínas recombinantes contra COVID-19 es una opción de refuerzo adecuada después de una vacuna basada en adenovirus.

Fuente: Infomed Temas de Salud. Disponible en https://goo.su/M83Ly0K

Pfizer Korea's Prevenar 20 becomes pneumococcal vaccine with the broadest serotype coverage in Korea

Nov 20. "Prevenar 20 could address roughly half of pneumococcal infection cases in Korea." Prevenar 20 is Pfizer Korea's first new pneumococcal conjugate vaccine since the approval of Prevenar 13 in 2010.

At a press conference on Tuesday marking the domestic approval of the vaccine, Professor Park Su-eun of pediatrics at Pusan National University School of Medicine said the vaccine is expected to be "particularly

effective against serotype 10A, which is highly prevalent in Korea."

Prevenar 20 is a 20-valent vaccine that expands on the 13 serotypes covered by Prevenar 13 by adding seven more—serotypes 8, 10A, 11A, 12F, 15B, 22F, and 33F—providing the broadest serotype coverage among pneumococcal conjugate vaccines approved in Korea.

The Ministry of Food and Drug Safety approved Prevenar 20 on Oct. 31, allowing its use for preventing invasive pneumococcal diseases and pneumonia in infants, children, adolescents (six weeks to under 18 years), and adults (18 years and older). The release date and potential joint sales agreements for Prevenar 20 have not yet been determined.

Despite a decline in pneumococcal disease incidence due to national vaccination programs, Professor Park emphasized that it remains a significant cause of infections, particularly because serotypes not covered by the 13-valent vaccine continue to contribute to the disease burden.

"Approximately 90 percent of invasive pneumococcal disease cases in Korean children from January 2018 to December 2020 involved serotypes not covered by the 13-valent vaccine," she said, referencing a study that found 51 out of 57 cases were caused by these serotypes. Another study from 2014 to 2019 showed that 24 percent of 168 pneumococcal infections in Korean children were caused by serotype 10A.

Further analysis of 67 pneumococcal strains isolated from infected pediatric patients in Korea between January 2018 and July 2021 revealed that the 20 serotypes covered by Prevenar 20— including the most frequently identified serotypes 10A (20 cases) and 15B (6 cases)—accounted for approximately 54 percent of all cases.

Similarly, an analysis of 116 strains from adult patients showed that 53 percent of cases were caused by serotypes covered by Prevenar 20. According to Professor Park, this suggests that Prevenar 20 could address roughly half of pneumococcal infection cases in Korea.

While Prevenar 20 offers broader coverage, its side effect profile is similar to that of Prevenar 13. Phase 3 clinical trials demonstrated its immunogenicity and safety for both the 13 shared serotypes and the additional seven serotypes in children, as well as in adults, compared to Merck's 23-valent pneumococcal polysaccharide vaccine, Pneumovax 23.

Kim Sun-ju, primary care medical lead of medical affairs at Pfizer Korea, noted that Prevenar 20 showed strong immunogenicity and good tolerability across all 20 serotypes when administered as a four-dose series to healthy infants.

"For adults, Prevenar 20 showed tolerability similar to Prevenar 13 for the shared serotypes, with confirmed immunogenicity data for both the shared serotypes and the additional seven serotypes compared to Pneumovax 23," she explained.

Professor Park added that Prevenar 20 caused similar adverse reactions to Prevenar 13, with no serious adverse events reported. "Based on these results, the vaccine has been approved in many countries, including the U.S., Europe, and Japan," she said.

Kim Eun-ji, marketing lead at Pfizer Korea, noted that Prevenar 13 will not be withdrawn from the market despite the introduction of Prevenar 20. Currently, Prevenar 13 is co-marketed, but it is still undecided whether Prevenar 20 will follow the same path or which company will manage its sales.

Fuente: Korea Biomedical Review. Disponible en https://goo.su/nncv

WHO Grants Permission For Second Mpox Vaccine For Emergency Use

21 nov. The World Health Organization has granted permission for emergency use in the treatment of mpox.

WHO granted Emergency Use Listing for the LC16m8 mpox vaccine, making it the second mpox vaccine to be supported by the UN health agency after the disease was declared a public health emergency of international concern in August.

This decision is expected to facilitate increased and timely access to vaccines in communities where mpox outbreaks are surging. In 2024, mpox cases have been reported across 80 countries, including 19 in Africa. The Democratic Republic of the Congo is the hardest-hit country, where a large majority of suspected cases - more than 39 000 - as well as more than 1000 deaths were recorded.

WHO decision comes in the wake of the Government of Japan announcing that it will donate 3.05 million doses of the LC16m8 vaccine, along with specialized inoculation needles, to the Democratic Republic of the Congo. This is the largest donation package announced to date in response to the current mpox emergency.

LC16m8 is a vaccine developed and manufactured by KM Biologics in Japan. The Technical Advisory Group (TAG) for EUL of vaccines recommended the vaccine for use in individuals over one year of age as a single dose vaccine.

"WHO emergency use listing of the LC16m8 vaccine against mpox marks a significant step in our response to the current emergency, providing a new option to protect all populations, including children," said Dr Yukiko Nakatani, WHO Assistant Director-General for Access to Medicines and Health Products.

Fuente: RTT News. Disponible en https://goo.su/hPJU4Ca

Respiratory Vaccines Update

Nov 22. Thus far into the respiratory virus season, COVID-19, influenza, and RSV vaccine uptakes have been low across all 3 immunizations, with the flu shot having the highest utilization. A Centers for Disease Control and Prevention's (CDC) MMWR report published yesterday offered insights on the statistics so far into the respiratory virus season (Table).

"As of November 9, 2024, cumulative estimated coverage with 2024–2025 influenza and COVID-19 vaccines among adults aged ≥18 years was 34.7% and 17.9%, respectively. Estimated RSV vaccination coverage was 39.7% among adults aged ≥75 years and 31.6% among those aged 60–74 years at increased risk," the authors wrote.

And in addition to the low uptake for respiratory virus vaccines, federal public health guidance and FDA approvals have been evolving. This year, federal public health officials have made changes and updated recommendations on a number of these vaccines, including RSV, COVID-19, and pneumococcal disease. Updates have been reflected in the CDC Advisory Committee on Immunization Practices (ACIP) meeting in October as well as recent FDA approval decisions. Here is some more information about a few of the changes regarding respiratory virus vaccines.

RSV Vaccines

Last month, the FDA approved Pfizer's RSV vaccine for adults aged 18 to 59 years who are at increased risk.

This is a departure from previous approvals and guidance.

“RSV vaccines, manufactured by Pfizer, GlaxoSmithKline and Moderna are all now FDA approved for use in older adults,” said Robert H. Hopkins, Jr, MD, medical director, National Foundation for Infectious Diseases (NFID) and ACIP liason. “Pfizer sought expanded approval from FDA based on a clinical trial which looked at immunogenicity, and looked at safety and tolerability of this vaccine in persons 18 to 49 with chronic medical conditions...It's important to note that ACIP also approved the GlaxoSmithKline RSV vaccine for use in adults 50 to 59 in June based on somewhat similar data in a trial.”

COVID-19 Vaccines

During the CDC’s ACIP meeting in October, the committee recommended a second COVID-19 vaccine dose for individuals aged 65 and older and younger individuals with moderate to severe immunocompromised conditions, spaced 6 months apart.

Although ACIP offered a recommendation looking at seniors and the immunocompromised, Hopkins believes vaccine coverage should extend beyond those populations.

“I would strongly recommend that everyone 6 months of age and older—who's not already done so since September—to get the 2024-2025 COVID-19 vaccine,” Hopkins said.

As part of his reasoning, he points to racial and ethnic disparities in terms of groups being more susceptible to severe forms of COVID-19. “It's much less well known that we continue to have significant racial and ethnic disparities in the rate of COVID-19 hospitalizations,” Hopkins said. “The rate for Native American, Alaskan natives, and Black Americans are significantly higher than for white, Hispanic, and Asian Americans.

Lastly, he points to the pediatric population and hospitalization.

“The highest rate of hospitalization for COVID in children is less than 4 years and particularly in children from 6 months to 40 or 6 months and younger. Kids 6 months and younger are too young to be vaccinated on their own, obviously, and they're best protected by maternal vaccination during pregnancy, only half of the kids admitted to the hospital with COVID 19 had underlying medical conditions. Eighteen percent of those kids ended up in the ICU. Of children 6 months to 17 years admitted to the hospital, less than 5% had received the current vaccine prior to admission,” Hopkins said.

“So, this all comes down to the fact we're missing far too many opportunities to save lives, hospitalizations, and morbidity with the COVID vaccine.”

Vaccine	Age Group	Immunization Rate (%)
Influenza	Adults (≥18 years)	34.7%
COVID-19	Adults (≥18 years)	17.9%
RSV	Adults (≥75 years)	39.7%
	Adults (60–74 years at increased risk)	31.6%

Pneumococcal Vaccines

During that same round of ACIP meetings, the committee recommended the pneumococcal conjugate vaccine for PCV-naive adults aged 50 and older. Again this recommendation is a departure from previous guidance.

Hopkins says this change is from 2 newer pieces of information that includes risk-based criterio.

“A significant portion of persons 50 and older who have chronic medical conditions, which would put them into a risk-based recommendation that we previously had in place, either are unvaccinated and know they have those risk factors, or don't know they have those risk factors,” Hopkins said. “Second, there's a significant risk disparity based on race and ethnicity. For example, Black men are at increased risk for invasive pneumococcal disease in that 50 plus age group, and that's not been a risk-based group. And so, it's the hope that moving to an age-based recommendation will allow us to close some of these gaps, protect more of these people from hospitalization and other adverse outcomes, including death.”

The Continued Need for Vaccination

The beginning of the holiday season is starting next week with Thanksgiving, and typically incidence rates for seasonal viruses increase during this time of year as people travel and gather together with family and friends. This is another good reason for people to protect themselves as well as loved ones, especially those who are in vulnerable populations including seniors, people with existing health conditions, and those who are immunocompromised.

Fuente: Contagion Live. Disponible en https://goo.su/hhC5

Artículos científicos publicados en Medline

Filters activated: (vaccine[Title/Abstract]) AND (("2024/11/11"[Date - Publication] : "2024/11/22"[Date - Publication])) 436 records.

Vaccine effectiveness of 3rd generation mpox vaccines against mpox and disease severity: A systematic review and meta-analysis.

Pischel L, Martini BA, Yu N, Cacesse D, Tracy M, Kharbanda K, Ahmed N, Patel KM, Grimshaw AA, Malik AA, Goshua G, Omer SB.Vaccine. 2024 Nov 14;42(25):126053. doi: 10.1016/j.vaccine.2024.06.021. Epub 2024 Jun 21.PMID: 38906763

Never waste a measles outbreak.

Durrheim DN.Commun Dis Intell (2018). 2024 Nov 21;48. doi: 10.33321/cdi.2024.48.62.PMID: 39566184

Thoughts on the research of African swine fever live-attenuated vaccines.

Chu X, Ge S, Zuo Y, Cui J, Sha Z, Han N, Wu B, Ni B, Zhang H, Lv Y, Wang Z, Xiao Y.Vaccine. 2024 Nov 14;42(25):126052. doi: 10.1016/j.vaccine.2024.06.020. Epub 2024 Jun 20.PMID: 38906762

Unbiased phage display screening identifies hidden malaria vaccine targets.

Jacobs-Lorena M, Cha SJ.Emerg Microbes Infect. 2024 Dec;13(1):2429617. doi: 10.1080/22221751.2024.2429617. Epub 2024 Nov 22.PMID: 39529575

Design and development of mRNA and self-amplifying mRNA vaccine nanoformulations.

Omidi Y, Pourseif MM, Ansari RA, Barar J.Nanomedicine (Lond). 2024 Nov 13:1-27. doi: 10.1080/17435889.2024.2419815. Online ahead of print.PMID: 39535127

William David Smith.

[No authors listed]Vet Rec. 2024 Nov 16;195(10):427-428. doi: 10.1002/vetr.4947.PMID: 39545546

Factors impacting vaccine uptake among adult Medicaid beneficiaries: a systematic literature review.

Moss E, Eiden AL, Hartley L, Carrico J, Farkouh R, Poston S, Gabriel M, Golden AH, Bhatti A.Health Aff Sch. 2024 Nov 12;2(11):qxae143. doi: 10.1093/haschl/qxae143. eCollection 2024 Nov.PMID: 39584147

Advancing Cancer Vaccines with Radionuclide Imaging.

Cheng S, Long X, Zhang Y, Lan X, Jiang D.Small. 2024 Nov 12:e2406950. doi: 10.1002/smll.202406950. Online ahead of print.PMID: 39530610

Bridging gene therapy and next-generation vaccine technologies.

Bloom K, Ely A, Maepa MB, Arbuthnot P.Gene Ther. 2024 Nov 18. doi: 10.1038/s41434-024-00502-9. Online ahead of print.PMID: 39558149

IL-7 promotes mRNA vaccine-induced long-term immunity.

Wang L, Wan J, He W, Wang Z, Wu Q, Zhou M, Fu ZF, Zhao L.J Nanobiotechnology. 2024 Nov 16;22(1):716. doi: 10.1186/s12951-024-02993-5.PMID: 39550592

An updated review of HSV-1 infection-associated diseases and treatment, vaccine development, and vector therapy application.

Su D, Han L, Shi C, Li Y, Qian S, Feng Z, Yu L.Virulence. 2024 Dec;15(1):2425744. doi: 10.1080/21505594.2024.2425744. Epub 2024 Nov 13.PMID: 39508503

Adult vaccination in three Eastern Mediterranean countries: current status, challenges and the way forward.

Koksal I, Al Awaidy S, Assiri AM, Ozudogru O, Khalaf M, Yeşiloğlu C, Badur S.Expert Rev Vaccines. 2024 Nov 13. doi: 10.1080/14760584.2024.2428806. Online ahead of print.PMID: 39539060

Lnc-H19-derived protein shapes the immunosuppressive microenvironment of glioblastoma.

Chen J, Gao Y, Zhong J, Wu X, Leng Z, Liu M, Wang Y, Wang Y, Yang X, Huang N, Xiao F, Zhang M, Liu X, Zhang N.Cell Rep Med. 2024 Nov 19;5(11):101806. doi: 10.1016/j.xcrm.2024.101806. Epub 2024 Oct 30.PMID: 39481387

Polio: Background and perspective on how international travel can be made safe against polio.

Dharmapalan D, John TJ, Steinglass R, Hirschhorn N.Ther Adv Infect Dis. 2024 Nov 13;11:20499361241298857. doi: 10.1177/20499361241298857. eCollection 2024 Jan-Dec.PMID: 39544851

Applications of microfluidics in mRNA vaccine development: A review.

Fardoost A, Karimi K, Govindaraju H, Jamali P, Javanmard M.Biomicrofluidics. 2024 Nov 14;18(6):061502. doi: 10.1063/5.0228447. eCollection 2024 Dec.PMID: 39553921

Nano-enhanced immunity: A bibliometric analysis of nanoparticles in vaccine adjuvant research.

Elhassan Taha MM, Abdelwahab SI, Moni SS, Farasani A, Aljahdali IA, Oraibi B, Alfaifi HA, Alzahrani AH, Ali Jerah A.Hum Vaccin Immunother. 2024 Dec 31;20(1):2427464. doi: 10.1080/21645515.2024.2427464. Epub 2024 Nov 14.PMID: 39539151

Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review.

Titanji BK, Hazra A, Zucker J.JAMA. 2024 Nov 19;332(19):1652-1662. doi: 10.1001/jama.2024.21091.PMID: 39401235

Humoral Immunogenicity of mRNA-1345 RSV Vaccine in Older Adults.

Goswami J, Baqui AH, Doreski PA, Perez Marc G, Jimenez G, Ahmed S, Zaman K, Duncan CJA, Ujiie M, Rämet M, Pérez-Breva L, Lan L, Du J, Kapoor A, Mehta S, Tomassini JE, Huang W, Zhou H, Stoszek SK, Priddy F, Lin N, Le Cam N, Shaw CA, Slobod K, Wilson E, Miller JM, Das R.J Infect Dis. 2024 Nov 15;230(5):e996-e1006. doi: 10.1093/infdis/jiae316.PMID: 38889247

Seasonal influenza vaccines: Variability of immune responses to B lineage viruses.

Miller MS, Montomoli E, Leshem E, Schotsaert M, Weinke T, Vicic N, Rudin D.Hum Vaccin Immunother. 2024 Dec 31;20(1):2421096. doi: 10.1080/21645515.2024.2421096. Epub 2024 Nov 17.PMID: 39552079

Impact of rotavirus vaccination in Malawi from 2012 to 2022 compared to model predictions.

Pitzer VE, Ndeketa L, Asare EO, Hungerford D, Lopman BA, Jere KC, Cunliffe NA.NPJ Vaccines. 2024 Nov 19;9(1):227. doi: 10.1038/s41541-024-01008-6.PMID: 39562592

Categorising interventions to enhance vaccine uptake or reduce vaccine hesitancy in the United Kingdom: A systematic review and meta-analysis.

Kafadar AH, Sabatini S, Jones KA, Dening T.Vaccine. 2024 Nov 14;42(25):126092. doi: 10.1016/j.vaccine.2024.06.059. Epub 2024 Jul 2.PMID: 38960789

Cardiac Arrhythmias and Autonomic Dysfunction Associated With COVID-19: A Scientific Statement From the American Heart Association.

Gopinathannair R, Olshansky B, Chung MK, Gordon S, Joglar JA, Marcus GM, Mar PL, Russo AM, Srivatsa UN, Wan EY; American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular and Stroke Nursing; Council on Genomic and Precision Medicine; and Council on Hypertension.Circulation. 2024 Nov 19;150(21):e449-e465. doi: 10.1161/CIR.0000000000001290. Epub 2024 Oct 14.PMID: 39397661

Application of plant-derived products as adjuvants for immune activation and vaccine development.

Zou M, Lei C, Huang D, Liu L, Han Y.Vaccine. 2024 Nov 14;42(25):126115. doi: 10.1016/j.vaccine.2024.07.016. Epub 2024 Jul 9.PMID: 38987109

Pediatric asthma and COVID-19 vaccination: unveiling patterns of hesitancy and acceptance.

Tavakol M, Gharagozlou S, Abbasi M, Zamani Z, Gharagozlou M.Ther Adv Vaccines Immunother. 2024 Nov 13;12:25151355241297874. doi: 10.1177/25151355241297874. eCollection 2024.PMID: 39544988

H5 Influenza Vaccines-Moving Forward Against Pandemic Threats.

Goodman JL, Bright RA, Lurie N.JAMA. 2024 Nov 19;332(19):1609-1610. doi: 10.1001/jama.2024.17488.PMID: 39230884

Perceptions of vaccine requirements among students at four Pennsylvania universities.

Anderson S, Kuter BJ, Brien K, Bauerle Bass S, Gutierrez L, Winters S, Whitfield C, Moser CA, Faig W.Vaccine. 2024 Nov 14;42(25):126138. doi: 10.1016/j.vaccine.2024.07.039. Epub 2024 Jul 17.PMID: 39025697

COVID-19 vaccine hesitancy, trust, and communication in Sarlahi District, Nepal.

Manandhar P, Katz J, Lama TP, Khatry SK, Moss WJ, Erchick DJ.Vaccine. 2024 Nov 14;42 Suppl 5:126034. doi: 10.1016/j.vaccine.2024.06.002. Epub 2024 Jun 10.PMID: 38862309

Quantitation and characterization of serotype 6A activation for pneumococcal conjugate vaccine by cryo-EM and SEC methods.

Lin M, Deng JZ, Scapin G, Yuan Y, Gomez-Llorente Y, Tong W, Porambo R, Kong J, Ikemoto N, Lancaster C, Kaelber J, Winters M, Zhuang P.Vaccine. 2024 Nov 14;42(25):126067. doi: 10.1016/j.vaccine.2024.06.034. Epub 2024 Jun 24.PMID: 38918102

Live-attenuated vaccine failure after liver transplantation: A 20-year cohort study.

Furuichi M, Ohnishi T, Yaginuma M, Yamada Y, Hoshino K, Nakayama T, Shinjoh M.Vaccine. 2024 Nov 14;43(Pt 1):126527. doi: 10.1016/j.vaccine.2024.126527. Online ahead of print.PMID: 39547018

Mpox-Specific Immune Responses Elicited by Vaccination or Infection in People With HIV.

Grüner E, Grossegesse M, Stern D, Ober V, Eser TM, Reiling G, Stirner R, Ibarra G, Postel N, Conca R, Dächert C, Grifoni A, Sette A, Bogner J, Seybold U, Roider J.J Infect Dis. 2024 Nov 15;230(5):1110-1119. doi: 10.1093/infdis/jiae138.PMID: 38478746

Use of Digital Tools in Arbovirus Surveillance: Scoping Review.

Melo CL, Mageste LR, Guaraldo L, Paula DP, Wakimoto MD.J Med Internet Res. 2024 Nov 18;26:e57476. doi: 10.2196/57476.PMID: 39556803

Prevalence of hepatitis A and E viruses in wastewater in Asian countries.

Raya S, Tandukar S, Kattel HP, Sharma S, Sangsanont J, Sirikanchana K, Ngo HTT, Inson JGM, Enriquez MLD, Alam ZF, Setiyawan AS, Setiadi T, Haramoto E.Sci Total Environ. 2024 Nov 15;951:175473. doi: 10.1016/j.scitotenv.2024.175473. Epub 2024 Aug 12.PMID: 39142413

Vaccine Confidence Among Young Adults During COVID-19: A Cross-Sectional Study from Turkey.

Türkmen L.J Multidiscip Healthc. 2024 Nov 13;17:5105-5115. doi: 10.2147/JMDH.S487424. eCollection 2024.PMID: 39553267

Parental hesitancy about COVID-19, influenza, HPV, and other childhood vaccines.

Santibanez TA, Black CL, Zhou T, Srivastav A, Singleton JA.Vaccine. 2024 Nov 14;42(25):126139. doi: 10.1016/j.vaccine.2024.07.040. Epub 2024 Jul 16.PMID: 39019662

Preferences of US adolescents and parents for vaccination against invasive meningococcal disease.

Schley K, Whichello C, Hauber B, Krucien N, Cappelleri JC, Peyrani P, Presa JV, Coulter J, Heidenreich S.Vaccine. 2024 Nov 14;42(25):126264. doi: 10.1016/j.vaccine.2024.126264. Epub 2024 Sep 5.PMID: 39241319

Development of a safe and broad-spectrum attenuated PEDV vaccine candidate by S2 subunit replacement.

Zhang D, Xie Y, Liao Q, Jiao Z, Liang R, Zhang J, Zhang Y, Tan Y, Wang H, Zhang W, Xiao S, Peng G, Shi Y.J Virol. 2024 Nov 19;98(11):e0042924. doi: 10.1128/jvi.00429-24. Epub 2024 Oct 15.PMID: 39404450

Does Policy Uncertainty Boost Vaccine Hesitancy? Political Controversy, the FDA and COVID-19 Vaccine Hesitancy in Fall 2020.

Carpenter D, Dardet ME, Bhaskar A, Rand LZ, Feldman W, Kesselheim AS.J Health Polit Policy Law. 2024 Nov 15:11670184. doi: 10.1215/03616878-11670184. Online ahead of print.PMID: 39545681

Animal models of Long Covid: A hit-and-run disease.

Schäfer A, Leist SR, Powers JM, Baric RS.Sci Transl Med. 2024 Nov 13;16(773):eado2104. doi: 10.1126/scitranslmed.ado2104. Epub 2024 Nov 13.PMID: 39536118

Comparison and consideration of vaccine injury compensation programs in the Republic of Korea, Japan, and Taiwan.

Kang CR, Choe YJ, Moon J, Kim D, Kim T, Lee JK.Osong Public Health Res Perspect. 2024 Nov 12. doi: 10.24171/j.phrp.2024.0129. Online ahead of print.PMID: 39557574

Global vaccination against hepatitis E virus: position paper from the ESGVH-ESCMID.

Dudman S, Zerja A, Hasanoğlu İ, Ruta S, van Welzen B, Nicolini LA, Yonga P, Øverbø J, Rawat S, Habibovic S, Kim TB, Rivero-Juarez A; ESGVH members.Clin Microbiol Infect. 2024 Nov 14:S1198-743X(24)00542-1. doi: 10.1016/j.cmi.2024.11.016. Online ahead of print.PMID: 39550032

Meeting report: Considerations for trial design and endpoints in licensing therapeutic HPV16/18 vaccines to prevent cervical cancer.

Dull PM, Achilles SL, Ahmed R, Barnabas RV, Campos NG, Chirgwin K, Cohen JA, de Sanjosé S, Doorbar J, Einstein MH, Emerson CI, Gottlieb SL, Hildesheim A, Qiao Y, Ruff P, Sampson JN, Sasieni P, Schiffman M, Shin H, Stanley MA, Trimble CL, Wentzensen N, Riemer AB, Schiller JT, Kreimer AR.Vaccine. 2024 Nov 14;42(25):126100. doi: 10.1016/j.vaccine.2024.07.001. Epub 2024 Jul 14.PMID: 39004526

Influenza neuraminidase mutations and resistance to neuraminidase inhibitors.

Xu J, Luo Q, Huang Y, Li J, Ye W, Yan R, Zhou X, He Z, Liu G, Zhu Q.Emerg Microbes Infect. 2024 Nov 12:2429627. doi: 10.1080/22221751.2024.2429627. Online ahead of print.PMID: 39530458

Sex differences in response to COVID-19 mRNA vaccines in Italian population.

Ferroni E, Mateo-Urdiales A, Bietta C, Cesaroni G, Anticoli S, Di Maggio E, Ancona A, Petrone D, Cannone A, Sacco C, Fabiani M, Del Manso M, Riccardo F, Bella A, Ruggieri A, Pezzotti P.Epidemiol Infect. 2024 Nov 18;152:e139. doi: 10.1017/S0950268824001079.PMID: 39552125

Vaccine spillover effects in Africa: A cross-national study of vaccine spillover and confidence in Kenya, Nigeria, and South Africa.

Lockman A, Callaghan T, Blackburn CC, Colwell B.Vaccine. 2024 Nov 12;43(Pt 2):126528. doi: 10.1016/j.vaccine.2024.126528. Online ahead of print.PMID: 39536475

This malaria vaccine is delivered by a mosquito bite.

Kudiabor H.Nature. 2024 Nov 20. doi: 10.1038/d41586-024-03817-0. Online ahead of print.PMID: 39567825

Design and evaluation of vaccines for the control of the etiological agent of East Coast fever.

de la Fuente J, Sobrino I, Villar M.Parasit Vectors. 2024 Nov 20;17(1):479. doi: 10.1186/s13071-024-06517-w.PMID: 39567980

Structure-based design of glycoprotein subunit vaccines for mumps.

Loomis RJ, Lai YT, Sowers SB, Fisher B, Derrien-Colemyn A, Ambrozak DR, Tsybovsky Y, Crooke SN, Latner DR, Kong WP, Ruckwardt TJ, Plotkin SA, Kwong PD, Mascola JR, Graham BS, Hickman CJ, Stewart-Jones GBE.Proc Natl Acad Sci U S A. 2024 Nov 19;121(47):e2404053121. doi: 10.1073/pnas.2404053121. Epub 2024 Nov 11.PMID: 39527740

Human papillomavirus vaccine uptake among adolescent survivors of hematopoietic stem cell transplant.

Morrison A, Myers K, Streich-Tilles T.J Cancer Surviv. 2024 Nov 18. doi: 10.1007/s11764-024-01709-w. Online ahead of print.PMID: 39556189

A getah virus-like-particle vaccine provides complete protection from viremia and arthritis in wild-type mice.

Miao Q, Nguyen W, Zhu J, Liu G, van Oers MM, Tang B, Yan K, Larcher T, Suhrbier A, Pijlman GP.Vaccine. 2024 Nov 14;42(25):126136. doi: 10.1016/j.vaccine.2024.07.037. Epub 2024 Jul 14.PMID: 39004524

Vaccine and therapeutic agents against the respiratory syncytial virus: resolved and unresolved issue.

Li Q, Li H, Li Z, Wang Y.MedComm (2020). 2024 Nov 21;5(12):e70016. doi: 10.1002/mco2.70016. eCollection 2024 Dec.PMID: 39575302

Obesity does not influence SARS-CoV-2 humoral vaccine immunogenicity.

D'Souza M, Keeshan A, Gravel CA, Langlois MA, Cooper CL.NPJ Vaccines. 2024 Nov 18;9(1):226. doi: 10.1038/s41541-024-01022-8.PMID: 39557875

Understanding structural inequities in Covid-19 vaccine access and uptake among disability, transgender and gender-diverse communities in India.

D'souza S, Ghatole B, Raghuram H, Sukhija S, Singh S, Shaikh A, Bandewar SS, Bhan A.Vaccine. 2024 Nov 14;42 Suppl 5:126174. doi: 10.1016/j.vaccine.2024.126174. Epub 2024 Aug 8.PMID: 39117525

Quality Initiative to Increase Early Initiation and Series Completion of HPV Vaccine and its Impact on Health Disparities.

Miller CJ, Boopathi A, Slovin SR, Gao Z, Maiden K, Ray M, Miller JM.Acad Pediatr. 2024 Nov 17:102609. doi: 10.1016/j.acap.2024.102609. Online ahead of print.PMID: 39561944

Combination application of Pickering emulsion and BLS protein nanoparticles enhances vaccine efficacy.

Yang J, Liu X, Yang H, Wang H, Xie B, Gao W, Xu M, Xu X, Liu B, Chen Z.Int J Biol Macromol. 2024 Nov 14;283(Pt 2):137635. doi: 10.1016/j.ijbiomac.2024.137635. Online ahead of print.PMID: 39547601

Could senescent cells be the prescription for therapeutic cancer vaccines?

Liu Y, Kron SJ.Immunotherapy. 2024 Nov 15:1-3. doi: 10.1080/1750743X.2024.2422813. Online ahead of print.PMID: 39545612

Influenza, COVID-19, and Respiratory Syncytial Virus Vaccination Coverage Among Adults - United States, Fall 2024.

Kriss JL, Black CL, Razzaghi H, Meghani M, Tippins A, Santibanez TA, Stokley S, Chatham-Stephens K, Dowling NF, Peacock G, Singleton JA.MMWR Morb Mortal Wkly Rep. 2024 Nov 21;73(46):1044-1051. doi: 10.15585/mmwr.mm7346a1.PMID: 39570786

A highly immunogenic UVC inactivated Sabin based polio vaccine.

Tobin GJ, Tobin JK, Wiggins TJ, Bushnell RV, Kozar AV, Maale MF, MacLeod DA, Meeks HN, Daly MJ, Dollery SJ.NPJ Vaccines. 2024 Nov 14;9(1):217. doi: 10.1038/s41541-024-00995-w.PMID: 39543143

Interventions employed to address vaccine hesitancy among Black populations outside of African and Caribbean countries: a scoping review.

Majekodunmi P, Tulli-Shah M, Kemei J, Kayode I, Maduforo AN, Salami B.BMC Public Health. 2024 Nov 13;24(1):3147. doi: 10.1186/s12889-024-20641-3.PMID: 39538186

Public health and economic impact of COVID-19 vaccination with the Pfizer-BioNTech COVID-19 Vaccine, KP.2, among adults in 2024/2025 in the United States.

Yehoshua A, Di Fusco M, Rudolph AE, Thoburn E, Lopez SMC, Marczell K, Yarnoff B.J Med Econ. 2024 Nov 13:1-21. doi: 10.1080/13696998.2024.2429335. Online ahead of print.PMID: 39535316

Beyond health: exploring women's socio-cultural motivations for HPV vaccination.

Xu S, Zhang W, Zhang Y.Int J Qual Stud Health Well-being. 2024 Dec;19(1):2424494. doi: 10.1080/17482631.2024.2424494. Epub 2024 Nov 18.PMID: 39556005

Immunogenicity and protection of a triple repeat domain III mRNA vaccine against Zika virus.

Lee YS, Cheong MS, Lee J, Bang EK, Park SI, Park HJ, Bae SH, Yoon S, Roh G, Lee S, Cho Y, Ha D, Oh A, Lee SY, Choi EJ, Choi H, Jo S, Lee Y, Kim J, Kwak HW, Bang YJ, Lee D, Shim H, Park YK, Keum G, Nam JH, Kim W.Vaccine. 2024 Nov 14;43(Pt 2):126518. doi: 10.1016/j.vaccine.2024.126518. Online ahead of print.PMID: 39547049

Understanding Influenza Vaccine Clinical Performance: A Podcast.

Desai NR, Lopalco PL.Adv Ther. 2024 Nov 18. doi: 10.1007/s12325-024-03021-6. Online ahead of print.PMID: 39556294

Therapeutic BCG vaccine protects against long COVID: The BATTLE randomized clinical trial.

Jalalizadeh M, Buosi K, Giacomelli CF, Leme PAF, Ferrari KL, Dionato FAV, Brito WRS, Brunetti NS, Maia AR, Morari J, Pagliarone AC, Farias AS, Velloso LA, Queiroz MAF, Vallinoto ACR, Bajgelman MC, Reis LO.J Intern Med. 2024 Nov 19. doi: 10.1111/joim.20033. Online ahead of print.PMID: 39560319

Tragedy of the commons: the resource struggle during Plasmodium infection.

Nappi TJ, Butler NS.Trends Parasitol. 2024 Nov 14:S1471-4922(24)00303-9. doi: 10.1016/j.pt.2024.10.014. Online ahead of print.PMID: 39547909

Women's ignorance and misperception of cervical cancer: Evidence-based analysis from low- and middle-income countries.

Sudha B, Kumar NS, Sumathi S.Curr Probl Cancer. 2024 Nov 16;54:101157. doi: 10.1016/j.currproblcancer.2024.101157. Online ahead of print.PMID: 39550837

Seasonal influenza vaccination: Attitudes and practices of healthcare providers in Jordan.

Hamdan O, Amarin JZ, Potter M, Haddadin Z, Yanis A, Shawareb Y, Khuri-Bulos N, Haddadin R, Halasa NB, Spieker AJ.PLoS One. 2024 Nov 21;19(11):e0314224. doi: 10.1371/journal.pone.0314224. eCollection 2024.PMID: 39570858

COVID-19 vaccine acceptance and 5C psychological antecedents amid the omicron surge in South Korea and China.

Lee M, Qin C, Lee Y, Deng J, You M, Liu J.Vaccine. 2024 Nov 21;43(Pt 2):126515. doi: 10.1016/j.vaccine.2024.126515. Online ahead of print.PMID: 39579671

Refolding dynamics and immunoinformatic insights into Vibrio cholerae OmpA, OmpK, and OmpV for vaccine applications.

Singh B, Kodgire P.Int J Biol Macromol. 2024 Nov 14;283(Pt 2):137643. doi: 10.1016/j.ijbiomac.2024.137643. Online ahead of print.PMID: 39547634

Fatal ascending paralysis after typhoid vaccine: Guillain and Barre's description of the very first case.

Wijdicks EFM.Vaccine. 2024 Nov 12;42(26):126443. doi: 10.1016/j.vaccine.2024.126443. Online ahead of print.PMID: 39536400

Oral Bacillus subtilis spores-based vaccine for mass vaccination against porcine reproductive and respiratory syndrome.

Min H, Cho HS, Lee HS, Park YT, Lee HJ, Park HS.Sci Rep. 2024 Nov 12;14(1):27742. doi: 10.1038/s41598-024-79387-y.PMID: 39533088

Reduced cell-mediated immune response in hyperglycemic NOD mice following influenza vaccination.

Bang JY, Kim YJ, Seo YJ, Hong SH.Vaccine. 2024 Nov 14;42(25):126116. doi: 10.1016/j.vaccine.2024.07.017. Epub 2024 Jul 8.PMID: 38981742

Knowledge, attitude, and practice regarding dengue vaccine: a baseline study of community members and health providers in Indonesia.

Wahab A, Laksanawati IS, Padmawati RS, Mulyadi AWE, Triadmajani W, Thobari JA.Clin Exp Pediatr. 2024 Nov 13. doi: 10.3345/cep.2024.00962. Online ahead of print.PMID: 39533719

Integrated structural proteomics and machine learning-guided mapping of a highly protective precision vaccine against mycoplasma pulmonis.

Khan A, Ammar Zahid M, Farrukh F, Salah Abdelsalam S, Mohammad A, Al-Zoubi RM, Shkoor M, Ait Hssain A, Wei DQ, Agouni A.Int Immunopharmacol. 2024 Nov 15;141:112833. doi: 10.1016/j.intimp.2024.112833. Epub 2024 Aug 16.PMID: 39153303

Myths and misinformation associated with vaccine incompleteness: A survey study.

Kallas-Silva L, Couto MT, Soares MEM, Ferreira-Silva SN, Avelino-Silva VI.Patient Educ Couns. 2024 Nov 18;131:108556. doi: 10.1016/j.pec.2024.108556. Online ahead of print.PMID: 39579518

A self-amplifying RNA RSV prefusion-F vaccine elicits potent immunity in pre-exposed and naive non-human primates.

Vijayan A, Vogels R, Groppo R, Jin Y, Khan S, Van Kampen M, Jorritsma S, Boedhoe S, Baert M, van Diepen H, Kuipers H, Serroyen J, Del Valle JR, Broman A, Nguyen L, Ray S, Jarai B, Arora J, Lifton M, Mildenberg B, Morton G, Santra S, Grossman TR, Schuitemaker H, Custers J, Zahn R.Nat Commun. 2024 Nov 14;15(1):9884. doi: 10.1038/s41467-024-54289-9.PMID: 39543172

Regional variation in COVID-19 vaccine uptake and intention in Nigeria: A computer assisted telephone survey.

Bamgboye EA, Ndejjo R, Chen N, Afolabi RF, Kabwama SN, Salawu MM, Bello S, Adebowale AS, Dairo MD, Tsai LL, Wanyenze RK, Fawole OI.PLOS Glob Public Health. 2024 Nov 21;4(11):e0002895. doi: 10.1371/journal.pgph.0002895. eCollection 2024.PMID: 39570945

Challenges and Ongoing Actions to Address the Mpox Emergency in Africa.

Rahim FO, Fallah M, Jain U, Richardson ET, Ndembi N, Ngongo N, Kaseya J.Ann Glob Health. 2024 Nov 15;90(1):68. doi: 10.5334/aogh.4580. eCollection 2024.PMID: 39554695

How text message reminders increase COVID-19 booster vaccine uptake: Two randomized controlled trials.

Meeldijk A, Vandeberg L, Akkermans R, Hautvast J.Vaccine. 2024 Nov 18;43(Pt 2):126533. doi: 10.1016/j.vaccine.2024.126533. Online ahead of print.PMID: 39561628

A Bivalent Adenovirus-Vectored Vaccine Induces a Robust Humoral Response, but Does Not Protect Cynomolgus Macaques Against a Lethal Challenge With Sudan Virus.

van Tol S, Fletcher P, Feldmann F, Mukesh RK, Port JR, Gallogly S, Schulz JE, Rhoderick JF, Makinson R, Carmody A, Myers L, Lovaglio J, Smith BJ, Okumura A, Shaia C, Saturday G, Marzi A, Lambe T, Munster VJ, van Doremalen N.J Infect Dis. 2024 Nov 15;230(5):1083-1092. doi: 10.1093/infdis/jiae056.PMID: 38487996

Caregivers' hesitancy and outright refusal toward children's COVID-19 vaccination in the Democratic Republic of Congo: A community-based cross-sectional study.

Guillaume AS, Ndwandwe D, Nyalundja AD, Bugeme PM, Ntaboba AB, Hatu'm VU, Tamuzi JL, Iwu-Jaja C, Shindano TA, Wiysonge CS, Katoto PDMC.Hum Vaccin Immunother. 2024 Dec 31;20(1):2422686. doi: 10.1080/21645515.2024.2422686. Epub 2024 Nov 13.PMID: 39535129

The abscopal effects of sonodynamic therapy in cancer.

Collins VG, Hutton D, Hossain-Ibrahim K, Joseph J, Banerjee S.Br J Cancer. 2024 Nov 13. doi: 10.1038/s41416-024-02898-y. Online ahead of print.PMID: 39537767

Klebsiella pneumoniae bioconjugate vaccine functional durability in mice.

Wantuch PL, Knoot CJ, Marino EC, Harding CM, Rosen DA.Vaccine. 2024 Nov 20;43(Pt 2):126536. doi: 10.1016/j.vaccine.2024.126536. Online ahead of print.PMID: 39571358

Quantifying the prevalence and determinants of respiratory syncytial virus (RSV) vaccine hesitancy in US adults aged 60 or older.

Motta M, Callaghan T, Padmanabhan M, Ross J, Gargano LM, Bowman S, Yokum D.Public Health. 2024 Nov 19;238:3-6. doi: 10.1016/j.puhe.2024.08.004. Online ahead of print.PMID: 39566218

Experiences and perceptions of migrant populations in South Africa on COVID-19 immunization: an interpretative phenomenological analysis.

Mukumbang FC, Ndlovu S, Adebiyi BO.BMC Public Health. 2024 Nov 12;24(1):3126. doi: 10.1186/s12889-024-20562-1.PMID: 39533252

A Glass-Half-Full Perspective on Negative Data in Ebolavirus Vaccine Studies.

Prasad AN, Geisbert TW.J Infect Dis. 2024 Nov 15;230(5):1057-1060. doi: 10.1093/infdis/jiae109.PMID: 38488013

A whole-cell pertussis vaccine engineered to elicit reduced reactogenicity protects baboons against pertussis challenge.

Kapil P, Wang Y, Gregg K, Zimmerman L, Molano D, Maldonado Villeda J, Sebo P, Merkel TJ.mSphere. 2024 Nov 21;9(11):e0064724. doi: 10.1128/msphere.00647-24. Epub 2024 Oct 23.PMID: 39441011

Rates and determinants of COVID-19 vaccine uptake among people living with HIV in Federal Capital Territory, Nigeria.

Etuk VP, Sanni C, Omonijo O, Atema SI, Lawal T, Yashim-Ankut AM, Ejinkeonye I, Onyegbutulem HC, Oyedele OK, Williams I, Andrew NP, Okpokoro E.Trans R Soc Trop Med Hyg. 2024 Nov 19:trae094. doi: 10.1093/trstmh/trae094. Online ahead of print.PMID: 39558837

Measles vaccine effectiveness in African children: a systematic review and meta-analysis.

Endalamaw D, Nibret E, Munshea A, Mekonnen F, Tadesse S, Zeru T, Tefera M, Yismaw G.BMC Infect Dis. 2024 Nov 21;24(1):1330. doi: 10.1186/s12879-024-10239-w.PMID: 39574018

Anti-PF4 positivity and platelet activation after Ad26.COV2·S vaccination in Brazil.

Bokel J, Martins-Gonçalves R, Grinsztejn E, Mendes-de-Almeida DP, Hoagland B, Cardoso SW, Geraldo KM, Coutinho SN, Georg I, Oliveira MH, Dos Santos Souza F, Sacramento CQ, Rozini SV, Vizzoni AG, Veloso V, Bozza PT, Grinsztejn B.Vaccine. 2024 Nov 14;42(25):126175. doi: 10.1016/j.vaccine.2024.126175. Epub 2024 Aug 5.PMID: 39107160

Prospective Attitudes Towards Respiratory Syncytial Virus (RSV) Vaccine in Pregnant Women in Greece.

Damatopoulou A, Matalliotakis M, Diamanta Y, Pikrides I, Ierapetritis E, Kakouri P, Fraidakis M, Ladomenou F.Behav Med. 2024 Nov 15:1-6. doi: 10.1080/08964289.2024.2424171. Online ahead of print.PMID: 39545462

Adjuvants for *Helicobacter pylori* vaccines: Outer membrane vesicles provide an alternative strategy.

Zhang H, Liu Z, Li Y, Tao Z, Shen L, Shang Y, Huang X, Liu Q.Virulence. 2024 Dec;15(1):2425773. doi: 10.1080/21505594.2024.2425773. Epub 2024 Nov 20.PMID: 39501551

Uptake of COVID-19 vaccines and association with hospitalisation due to COVID-19 in pregnancy: Retrospective cohort study.

Ihenetu G, Aylin P, Novov V, Skirrow H, Saxena S, Majeed A, Woodcock T.Vaccine. 2024 Nov 14;42(25):126214. doi: 10.1016/j.vaccine.2024.126214. Epub 2024 Aug 13.PMID: 39142904

Predictors of COVID-19 vaccine uptake among youth with bipolar disorder spectrum disorders and their caregivers.

Keller VL, Klein CC, Wingler L, Blom TJ, Welge JA, Fornari VM, Higdon C, Crystal S, Patino LR, Correll CU, DelBello MP.J Affect Disord. 2024 Nov 15;365:400-405. doi: 10.1016/j.jad.2024.08.066. Epub 2024 Aug 13.PMID: 39147152

Pediatric HPV vaccination: Provider recommendations matter among hesitant parents.

Willis DE, Moore R, Selig JP, Shafeek Amin N, Li J, Watson D, Brimberry RK, McElfish PA.Vaccine. 2024 Nov 14;42(25):126166. doi: 10.1016/j.vaccine.2024.126166. Epub 2024 Jul 30.PMID: 39079809

A phase 2, randomized, blinded, dose-finding, controlled clinical trial to evaluate the safety, tolerability, and immunogenicity of a 24-valent pneumococcal conjugate vaccine (VAX-24) in healthy adults 65 years and older.

Wassil J, Sisti M, Fairman J, Rankin B, Clark J, Bennett S, Johnson D, Migone TS, Nguyen K, Paschenko A, Sauer P, Iki S, Hanson ME, Simon JK.Vaccine. 2024 Nov 14;42(25):126124. doi: 10.1016/j.vaccine.2024.07.025. Epub 2024 Jul 17.PMID: 39025698

Tenofovir and Hepatitis B Virus Transmission During Pregnancy: A Randomized Clinical Trial.

Pan CQ, Dai E, Mo Z, Zhang H, Zheng TQ, Wang Y, Liu Y, Chen T, Li S, Yang C, Wu J, Chen X, Zou H, Mei S, Zhu L.JAMA. 2024 Nov 14:e2422952. doi: 10.1001/jama.2024.22952. Online ahead of print.PMID: 39540799

[Human papillomavirus and systemic lupus erythematosus: A systematic review].

Goulenok T, Sacré K.Rev Med Interne. 2024 Nov 15:S0248-8663(24)01274-8. doi: 10.1016/j.revmed.2024.11.001. Online ahead of print.PMID: 39550232

Respiratory Syncytial Virus Vaccine (mRNA).

Levien TL, Baker DE.Hosp Pharm. 2024 Nov 19:00185787241298140. doi: 10.1177/00185787241298140. Online ahead of print.PMID: 39569048

Characteristics of maternal antibodies transferred to foals raised through maternal equine rotavirus A vaccination.

Eertink LG, Swope M, Uprety T, Sreenivasan C, Page AE, Adam EN, Wang D, Li F.Vet Microbiol. 2024 Nov 12;299:110304. doi: 10.1016/j.vetmic.2024.110304. Online ahead of print.PMID: 39536689

AS03-adjuvanted H5N1 vaccine enhances immune response by modulating NR4A1, SDC1, ID3 genes, and reducing cortisol.

Jin L, Li J, Zhu F.Hum Vaccin Immunother. 2024 Dec 31;20(1):2426319. doi: 10.1080/21645515.2024.2426319. Epub 2024 Nov 21.PMID: 39569615

A new S1 subunit truncation vaccine induces effective protection against porcine deltacoronavirus in suckling piglets.

Chen Z, Xiao L, Zhou J, Wang W, Guo R, Li J, Li B.Vet Microbiol. 2024 Nov 12;299:110303. doi: 10.1016/j.vetmic.2024.110303. Online ahead of print.PMID: 39536688

Identifying the intersection of parental HPV and COVID-19 vaccine hesitancy to inform health messaging interventions in community-based settings.

Garcia S, Shin M, Gill M, He Z, Dang E, Kast WM, Unger JB, Baezconde-Garbanati L, Tsui J.Vaccine. 2024 Nov 14;42(25):126129. doi: 10.1016/j.vaccine.2024.07.030. Epub 2024 Jul 12.PMID: 38997849

A randomized clinical trial of the impact of melatonin on influenza vaccine: Outcomes from the melatonin and vaccine response immunity and chronobiology study (MAVRICS).

Lee RU, Watson NL, Glickman GL, White L, Isidean SD, Porter CK, Hollis-Perry M, Walther SR, Maiolatesi S, Sedegah M, Ganeshan H, Huang J, Boulifard DA, Ewing D, Sundaram AK, Harrison EM, DeTizio K, Belmonte M, Belmonte A, Inoue S, Easterling A, Cooper ES, Danko J.Hum Vaccin Immunother. 2024 Dec 31;20(1):2419742. doi: 10.1080/21645515.2024.2419742. Epub 2024 Nov 13.PMID: 39539030

Design of a multi-epitope vaccine candidate against carrion disease by immunoinformatics approach.

Rivera-Asencios D, Espinoza-Culupú A, Carmen-Sifuentes S, Ramirez P, García-de-la-Guarda R.Comput Biol Med. 2024 Nov 19;184:109397. doi: 10.1016/j.compbiomed.2024.109397. Online ahead of print.PMID: 39566279

Susceptibility to Vaccine-Preventable Infections in Asylum Seekers.

Olivo-Freites C, Miguez-Arosemena P, Olivo-Freites C, Edelman D, Leschly K, Leschly J, Ivers LC, Mohareb AM.N Engl J Med. 2024 Nov 21;391(20):1959-1960. doi: 10.1056/NEJMc2403451.PMID: 39565996

Does Experience of Vaccination Improve Vaccine Confidence and Trust? Policy Feedback Effects of Mass COVID-19 Vaccination in the United States.

Choi Y, Fox A.J Health Polit Policy Law. 2024 Nov 15:11670176. doi: 10.1215/03616878-11670176. Online ahead of print.PMID: 39545679

Comparative Effectiveness of Licensed Influenza Vaccines in Preventing Influenza-related Medical Encounters and Hospitalizations in the 2022-2023 Influenza Season Among Adults ≥65 Years of Age.

Ku JH, Rayens E, Sy LS, Qian L, Ackerson BK, Luo Y, Tubert JE, Lee GS, Modha PP, Park Y, Sun T, Anderson EJ, Tseng HF.Clin Infect Dis. 2024 Nov 22;79(5):1283-1292. doi: 10.1093/cid/ciae375.PMID: 39166857

A phase 2 study of a brachyury-targeting vaccine in combination with radiation therapy for the treatment of advanced chordoma.

Cote GM, Conley AP, Attia S, Van Tine BA, Seetharam M, Chen YL, Gafoor Z, Heery C, Pico-Navarro C, Adams T.Cancer. 2024 Nov 15;130(22):3845-3854. doi: 10.1002/cncr.35477. Epub 2024 Jul 10.PMID: 38985843

Perceived barriers and facilitators to HPV vaccination: Insights from focus groups with unvaccinated mid-adults in a U.S. medically underserved area.

Krishna S, Polonijo AN.Hum Vaccin Immunother. 2024 Dec 31;20(1):2422681. doi: 10.1080/21645515.2024.2422681. Epub 2024 Nov 13.PMID: 39539025

Residency in Long-Term Care Facilities: An Important Risk Factor for Respiratory Syncytial Virus Hospitalization.

Branche AR, Falsey AR, Finelli L, Walsh EE.J Infect Dis. 2024 Nov 15;230(5):e1007-e1011. doi: 10.1093/infdis/jiae424.PMID: 39177782

Flt3 ligand augments immune responses to soluble PD1-based DNA vaccine via expansion of type 1 conventional DCs.

Cai Z, Qiao Y, Wuri Q, Zhang K, Qu X, Zhang S, Wu H, Wu J, Wang C, Yu X, Kong W, Zhang H.Int Immunopharmacol. 2024 Nov 15;141:112956. doi: 10.1016/j.intimp.2024.112956. Epub 2024 Aug 20.PMID: 39168022

Stability of closed and needle-punctured vials of Porvac subunit vaccine against classical swine fever subjected to thermal stress.

Sardina-González T, Vargas-Hernández M, Sordo-Puga Y, Naranjo-Valdéz P, Rodríguez-Moltó MP, Méndez-Orta MK, Hernández-García ML, Santana-Rodríguez E, Pena-Guimaraes W, Moreira-Rubio A, Mateu-Hernández R, Cabrales-Rico A, Duarte CA, Pérez-Pérez D, Suárez-Pedroso M.BMC Vet Res. 2024 Nov 15;20(1):514. doi: 10.1186/s12917-024-04354-8.PMID: 39548490

Amplifying youth voices: young people's recommendations for policy and practice to enhance vaccine acceptability.

Somefun OD, Casale M, Ronnie GH, Sumankuuro J, Akintola O, Desmond C, Cluver L.BMC Health Serv Res. 2024 Nov 18;24(1):1425. doi: 10.1186/s12913-024-11630-8.PMID: 39558407

AGS Older Adult Vaccine Initiative Update.

Supiano MA.Geriatr Nurs. 2024 Nov 15:S0197-4572(24)00405-1. doi: 10.1016/j.gerinurse.2024.10.083. Online ahead of print.PMID: 39550294

Safety and immunogenicity of full-dose quadrivalent influenza vaccine in children 6-35 months of age in China: A randomized, double-blind, clinical trial.

Wang S, Wang Y, Chen D, Xu W, Duan P, Ji W, Liu W, Huang W, Wu B, Chai W, Zhao C, Yang Y, Luo J, Zhao D, Li X.Hum Vaccin Immunother. 2024 Dec 31;20(1):2425149. doi: 10.1080/21645515.2024.2425149. Epub 2024 Nov 14.PMID: 39540202

Evaluating vaccination timing, hesitancy and effectiveness to prevent future outbreaks: insights from COVID-19 modelling and transmission dynamics.

Tanwar K, Kumawat N, Tripathi JP, Chauhan S, Mubayi A.R Soc Open Sci. 2024 Nov 13;11(11):240833. doi: 10.1098/rsos.240833. eCollection 2024 Nov.PMID: 39539502

Broadly inhibitory antibodies to severe malaria virulence proteins.

Reyes RA, Raghavan SSR, Hurlburt NK, Introini V, Bol S, Kana IH, Jensen RW, Martinez-Scholze E, Gestal-Mato M, López-Gutiérrez B, Sanz S, Bancells C, Fernández-Quintero ML, Loeffler JR, Ferguson JA, Lee WH, Martin GM, Theander TG, Lusingu JPA, Minja DTR, Ssewanyana I, Feeney ME, Greenhouse B, Ward AB, Bernabeu M, Pancera M, Turner L, Bunnik EM, Lavstsen T.Nature. 2024 Nov 20. doi: 10.1038/s41586-024-08220-3. Online ahead of print.PMID: 39567685

Disseminated vaccine-strain varicella-zoster virus reactivation in an adolescent with secondary immunodeficiency: a case report and literature review.

Fashina OA, Chuang TM, Galardy PJ, Huskins WC, Levy ER, Streck NT, Chakraborty R.BMC Infect Dis. 2024 Nov 14;24(1):1296. doi: 10.1186/s12879-024-09776-1.PMID: 39543470

Intranasal delivery of a subunit protein vaccine provides protective immunity against JN.1 and XBB-lineage variants.

Lei H, Hong W, Yang J, He C, Zhou Y, Zhang Y, Alu A, Shi J, Liu J, Qin F, Ao D, Huang X, Chen Z, Yang H, Yang Y, Yu W, Tang C, Wang J, Li B, Huang Q, Hu H, Cheng W, Dong H, Lei J, Chen L, Zhou X, Li J, Yang L, Wang Z, Wang W, Shen G, Yang J, Zhao Z, Song X, Lu G, Sun Q, Wang Y, Lu S, Wei X.Signal Transduct Target Ther. 2024 Nov 20;9(1):311. doi: 10.1038/s41392-024-02025-6.PMID: 39562542

Peer education as a strategy to promote vaccine acceptance: A randomized controlled trial within New York community healthcare practices.

Hoffman E, Kahan T, Auerbach E, Brody H, Abramson NN, Haiken S, Shields D, Elyasi A, Ifrah S, Frenkel-Schick A, Zyskind I, Knoll M, Carmody E.Vaccine. 2024 Nov 14;42 Suppl 5:126028. doi: 10.1016/j.vaccine.2024.05.076. Epub 2024 Jun 10.PMID: 38862308

Safety and immunogenicity of the Ad26/protein preF RSV vaccine in adults aged 18 to 59 years with and without at-risk comorbidities for severe respiratory syncytial virus disease: A phase 3, randomized, controlled, immunobridging trial.

Jastorff A, Gymnopoulou E, Salas J, Merrall E, Buntinx E, Martin C, Askling HH, Schenkenberger I, Yuste AC, Smith W, Sotolongo R, Von Engelhardt C, Bastian AR, Comeaux C, Ligtenberg N, Callendret B, Heijnen E.Vaccine. 2024 Nov 12;43(Pt 1):126514. doi: 10.1016/j.vaccine.2024.126514. Online ahead of print.PMID: 39536455

Bioinformatics analysis to design a multi-epitope mRNA vaccine against S. agalactiae exploiting pathogenic proteins.

Barazesh M, Abbasi M, Mohammadi M, Nasiri MN, Rezaei F, Mohammadi S, Kavousipour S.Sci Rep. 2024 Nov 16;14(1):28294. doi: 10.1038/s41598-024-79503-y.PMID: 39550419

Correction to: Immunogenicity, Safety, and Efficacy of a Tetravalent Dengue Vaccine in Children and Adolescents: An Analysis by Age Group.

[No authors listed]Clin Infect Dis. 2024 Nov 15:ciae504. doi: 10.1093/cid/ciae504. Online ahead of print.PMID: 39545821

Substantial reduction in the clinical and economic burden of disease following variant-adapted mRNA COVID-19 vaccines in immunocompromised patients in France.

Lee A, Davido B, Beck E, Demont C, Joshi K, Kohli M, Maschio M, Uhart M, El Mouaddin N.Hum Vaccin Immunother. 2024 Dec 31;20(1):2423474. doi: 10.1080/21645515.2024.2423474. Epub 2024 Nov 14.PMID: 39540209

Measles secondary vaccine failure in a childcare setting: an outbreak report.

Barnekow D, Neucom D, Tout W, Williams D, Thomas MJ, Schlebusch S, Pyke A, Roser MS, Tranter I, Dyda A, Lau CL, Smoll NR.Commun Dis Intell (2018). 2024 Nov 21;48. doi: 10.33321/cdi.2024.48.61.PMID: 39566183

Countering vaccine misinformation: Designing a learning resource for healthcare workers in eight countries.

Miller E, Michel A, Singh P, Limaye R.Vaccine. 2024 Nov 14;42 Suppl 5:126091. doi: 10.1016/j.vaccine.2024.06.058. Epub 2024 Jul 14.PMID: 38997850

Validation of the newly proposed Brighton Collaboration case definition for vaccine-induced immune thrombocytopenia and thrombosis.

Huang WT, Law B, Tran H, Schönborn L, Huang WI, Buttery J, Chen VMY, Greinacher A, Pavord S.Vaccine. 2024 Nov 14;42(25):126131. doi: 10.1016/j.vaccine.2024.07.032. Epub 2024 Jul 12.PMID: 39003103

Socioeconomic status and adherence to COVID-19 preventative measures in Australia: A national cohort study.

Aljeaidi MS, Haaksma ML, Tan ECK.Health Promot J Austr. 2024 Nov 12. doi: 10.1002/hpja.932. Online ahead of print.PMID: 39533745

Neoantigen DNA vaccines are safe, feasible, and induce neoantigen-specific immune responses in triple-negative breast cancer patients.

Zhang X, Goedegebuure SP, Chen MY, Mishra R, Zhang F, Yu YY, Singhal K, Li L, Gao F, Myers NB, Vickery T, Hundal J, McLellan MD, Sturmoski MA, Kim SW, Chen I, Davidson JT 4th, Sankpal NV, Myles S, Suresh R, Ma CX, Foluso A, Wang-Gillam A, Davies S, Hagemann IS, Mardis ER, Griffith O, Griffith M, Miller CA, Hansen TH, Fleming TP, Schreiber RD, Gillanders WE.Genome Med. 2024 Nov 14;16(1):131. doi: 10.1186/s13073-024-01388-3.PMID: 39538331

A vaccine candidate based on baculovirus displaying chikungunya virus E1-E2 envelope confers protection against challenge in mice.

Caillava AJ, Alfonso V, Tejerina Cibello M, Demaria MA, Coria LM, Cassataro J, Taboga OA, Alvarez DE.J Virol. 2024 Nov 19;98(11):e0101724. doi: 10.1128/jvi.01017-24. Epub 2024 Oct 23.PMID: 39440961

Predictors of Human Papillomavirus (HPV) Vaccine Acceptability Among Physicians, Their Knowledge on Cervical Cancer, and Factors Influencing Their Decision to Recommend It.

Alosaimi B, Fallatah DI, Abd ElHafeez S, Saleeb M, Alshanbari HM, Awadalla M, Ahram M, Khalil MA.J Multidiscip Healthc. 2024 Nov 13;17:5177-5188. doi: 10.2147/JMDH.S484534. eCollection 2024.PMID: 39558929

Advancing Tumor Vaccines: Overcoming TME Challenges, Delivery Strategies, and Biomaterial-based Vaccine for Enhanced Immunotherapy.

Zeng Q, Zhang S, Leng N, Xing Y.Crit Rev Oncol Hematol. 2024 Nov 22:104576. doi: 10.1016/j.critrevonc.2024.104576. Online ahead of print.PMID: 39581246

Tackling immunosuppression by Neisseria gonorrhoeae to facilitate vaccine design.

Jones RA, Ramirez-Bencomo F, Whiting G, Fang M, Lavender H, Kurzyp K, Thistlethwaite A, Stejskal L, Rashmi S, Jerse AE, Cehovin A, Derrick JP, Tang CM.PLoS Pathog. 2024 Nov 14;20(11):e1012688. doi: 10.1371/journal.ppat.1012688. Online ahead of print.PMID: 39541395

Rational design of uncleaved prefusion-closed trimer vaccines for human respiratory syncytial virus and metapneumovirus.

Lee YZ, Han J, Zhang YN, Ward G, Braz Gomes K, Auclair S, Stanfield RL, He L, Wilson IA, Zhu J.Nat Commun. 2024 Nov 16;15(1):9939. doi: 10.1038/s41467-024-54287-x.PMID: 39550381

Postural orthostatic tachycardia syndrome after COVID-19 vaccination: A systematic review.

Bushi G, Gaidhane S, Ballal S, Kumar S, Bhat M, Sharma S, Kumar MR, Rustagi S, Khatib MN, Rai N, Sah S, Shabil M.BMC Cardiovasc Disord. 2024 Nov 13;24(1):643. doi: 10.1186/s12872-024-04315-x.PMID: 39538129

Past, Present and Future of Phase 3 Vaccine Trial Design: Rethinking Statistics for the 21st Century.

Janani L, Phillips R, Van Vogt E, Liu X, Waddington C, Cro S.Clin Exp Immunol. 2024 Nov 21:uxae104. doi: 10.1093/cei/uxae104. Online ahead of print.PMID: 39570146

Nasal and Pharyngeal Mucosal Immunity to Poliovirus in Children Following Routine Immunization With Inactivated Polio Vaccine in the United States.

Godin A, Connor RI, Degefu HN, Rosato PC, Wieland-Alter WF, Axelrod KS, Kovacikova G, Weiner JA, Ackerman ME, Chen EY, Arita M, Bandyopadhyay AS, Raja AI, Modlin JF, Brickley EB, Wright PF.J Infect Dis. 2024 Nov 15;230(5):e1023-e1030. doi: 10.1093/infdis/jiae264.PMID: 38809190

Should SARS-CoV-2 serological testing be used in the decision to deliver a COVID-19 vaccine booster? A pro-con assessment.

Augello M, Wagenhäuser I, Krone M, Dauby N, Ferrara P, Sabbatucci M, Ruta S, Rezahosseini O, Velikov P, Gkrania-Klotsas E, Montes J, Franco-Paredes C, Goodman AL, Küçükkaya S, Tuells J, Harboe ZB, Epaulard O.Vaccine. 2024 Nov 14;42(25):126184. doi: 10.1016/j.vaccine.2024.126184. Epub 2024 Aug 3.PMID: 39097440

Progress Toward Measles Elimination - Worldwide, 2000-2023.

Minta AA, Ferrari M, Antoni S, Lambert B, Sayi TS, Hsu CH, Steulet C, Gacic-Dobo M, Rota PA, Mulders MN, Wimmer A, Bose AS, O'Connor P, Crowcroft NS.MMWR Morb Mortal Wkly Rep. 2024 Nov 14;73(45):1036-1042. doi: 10.15585/mmwr.mm7345a4.PMID: 39541251

A Vaccine Clinic for Individuals With Neurodevelopmental Disabilities.

Ma VK, Roseborough E, Tuss V, Mello M, Owens KH, Stahmer A, Akins RS.Pediatrics. 2024 Nov 13:e2023064034. doi: 10.1542/peds.2023-064034. Online ahead of print.PMID: 39533869

A mucosal vaccine formulation against tuberculosis by exploiting the adjuvant activity of S100A4-A damage-associated molecular pattern molecule.

Abil OZ, Liu S, Yeh YW, Wu Y, Sen Chaudhuri A, Li NS, Deng C, Xiang Z.Vaccine. 2024 Nov 14;42(25):126151. doi: 10.1016/j.vaccine.2024.07.052. Epub 2024 Aug 1.PMID: 39089961

The second annual Vaccination Acceptance Research Network Conference (VARN2023): Shifting the immunization narrative to center equity and community expertise.

Hopkins KL, Lihemo G, Underwood T, Sommers T, Dockery M, Boehman N, Dubé È, Qasim R, Kazi AM, Seale H, Limaye R, de Jonquieres A, Kakaire C, Knobler S, Pokharel DR, Lemango E, Gupta A.Vaccine. 2024 Nov 14;42 Suppl 5:126027. doi: 10.1016/j.vaccine.2024.05.075. Epub 2024 Jun 18.PMID: 38897893

Dimming the corona: studying SARS-coronavirus-2 at reduced biocontainment level using replicons and virus-like particles.

Neilsen G, Mathew AM, Castro JM, McFadden WM, Wen X, Ong YT, Tedbury PR, Lan S, Sarafianos SG.mBio. 2024 Nov 12:e0336823. doi: 10.1128/mbio.03368-23. Online ahead of print.PMID: 39530689

A phase 1 randomized controlled trial of a peptide-based group A streptococcal vaccine in healthy volunteers.

Meier-Stephenson V, Hawkes MT, Burton C, Calcutt A, Davis C, Dooley J, Good M, Houghton M, Keeffe E, Kim K, Lepletier A, O'Neil C, Ogbuehi I, Ozberk V, Pandey M, Reynolds S, Seth A, Stokes W, Tse-Chang A, Tyrrell B, Tyrrell DL, Tyrrell GJ, Yaskina M.Trials. 2024 Nov 19;25(1):781. doi: 10.1186/s13063-024-08634-4.PMID: 39563457

Oral biomimetic virus vaccine hydrogel for robust abscopal antitumour efficacy.

Wang C, Tang H, Duan Y, Zhang Q, Shan W, Wang X, Ren L.J Colloid Interface Sci. 2024 Nov 15;674:92-107. doi: 10.1016/j.jcis.2024.06.102. Epub 2024 Jun 13.PMID: 38917715

Progress in the application of Salmonella vaccines in poultry: A mini review.

Pan J, Wei RR, Xu P, Liu YY, Li C, Ding GW, Fan J, Li YH, Yu JY, Dai P.Vet Immunol Immunopathol. 2024 Dec;278:110855. doi: 10.1016/j.vetimm.2024.110855. Epub 2024 Nov 13.PMID: 39561520

Coverage and distributional benefit-cost of rotavirus vaccine in Uganda: an analysis of routine health facility aggregated data.

Kananura RM, de Broucker G, Ssebagereka A, Mutebi A, Kiracho EE, Patenaude B.Cost Eff Resour Alloc. 2024 Nov 22;22(1):85. doi: 10.1186/s12962-024-00586-5.PMID: 39578806

Antibody response to non-mRNA SARS-CoV-2 vaccine in kidney transplant recipients.

Bajpai D, Bose S, Saxena N, Kulkarni B, Kumar K, Rao N, Thakare S, Torane V, Nataraj G, Jamale T.Vaccine. 2024 Nov 14;42(25):126206. doi: 10.1016/j.vaccine.2024.126206. Epub 2024 Aug 8.PMID: 39122634

The protective power of dissent? A longitudinal study on cognitive and socio-emotional determinants of COVID-19 vaccine hesitancy among young people in Canada.

Miconi D, Levinsson A, Kafi MAH, Ngov C, Santavicca T, Rousseau C.Transcult Psychiatry. 2024 Nov 18:13634615241296293. doi: 10.1177/13634615241296293. Online ahead of print.PMID: 39552582

Attitudes and Experiences Regarding Communication About Maternal Vaccination: Qualitative Findings from Non-Hispanic Black Pregnant People.

Mendez I, Gilliard VG, Randall LA, Robertson A.J Womens Health (Larchmt). 2024 Nov 20. doi: 10.1089/jwh.2024.0950. Online ahead of print.PMID: 39565225

Breakthroughs and insights: A comprehensive review of yellow fever vaccine breakthrough infection across 8 decades.

Coulter FJ, Messer WB.Vaccine. 2024 Nov 20;43(Pt 1):126423. doi: 10.1016/j.vaccine.2024.126423. Online ahead of print.PMID: 39577331

Preclinical characterization of the Omicron XBB.1.5-adapted BNT162b2 COVID-19 vaccine.

Modjarrad K, Che Y, Chen W, Wu H, Cadima CI, Muik A, Maddur MS, Tompkins KR, Martinez LT, Cai H, Ramos M, Mensah S, Cumbia B, Falcao L, McKeen AP, Chang JS, Fennell KF, Huynh KW, McLellan TJ, Sahasrabudhe PV, Chen W, Cerswell M, Garcia MA, Li S, Sharma R, Li W, Dizon KP, Duarte S, Gillett F, Smith R, Illenberger DM, Efferen KS, Vogel AB, Anderson AS, Şahin U, Swanson KA.NPJ Vaccines. 2024 Nov 20;9(1):229. doi: 10.1038/s41541-024-01013-9.PMID: 39567521

CDC Recommends Mpox Vaccine for Travelers to Central and Eastern Africa.

Anderer S.JAMA. 2024 Nov 12;332(18):1508. doi: 10.1001/jama.2024.21298.PMID: 39422921

The impact of coronavirus pandemic shutdowns on immunization completion in Hadeetha, Anbar, Iraq: A case-study of vaccine completion in a recovering healthcare system.

Al-Dahir S, Hassan TAL, Moss W, Khalil A, Burnham G, Knoll MD, Hossain SMM, Talaat K.Vaccine. 2024 Nov 14;42 Suppl 5:126383. doi: 10.1016/j.vaccine.2024.126383. Epub 2024 Sep 21.PMID: 39307681

Case-cohort design as an efficient approach to evaluating COVID-19 vaccine effectiveness, waning, heterologous immune effect and optimal dosing interval.

Fisman DN, Simmons AE, Tuite AR.Vaccine. 2024 Nov 14;42(25):126134. doi: 10.1016/j.vaccine.2024.07.035. Epub 2024 Jul 14.PMID: 39004528

New pedagogical tools for vaccine education: preparing future healthcare workers for the next pandemic.

Gautier S, Hammarlin MM, Paulik E, Montagni I, Mueller JE, Vaux S, Luyt D, Hausman BL, Bosman A, Dinh A, Josseran L, Bennet L, Delarocque-Astagneau E.BMC Med Educ. 2024 Nov 14;24(1):1314. doi: 10.1186/s12909-024-06274-5.PMID: 39543606

Feasibility of incorporating collegiate EMS personnel in campus health vaccine administration efforts.

Dhrolia S, Torzone S, Sauls A, Camarena M, Pittman K, Grover J.J Am Coll Health. 2024 Nov 20:1-4. doi: 10.1080/07448481.2024.2428407. Online ahead of print.PMID: 39566047

Seroepidemiology of pertussis immunity in five provinces of China: A population-based, cross-sectional study.

Zhang Z, Wang Q, Zhu Q, Bai S, Liu Y, Ren J, Xu X, Qu J, Pan J, Lu L, Suo L, Sun X, Zhang Y, Wu J.Hum Vaccin Immunother. 2024 Dec 31;20(1):2417532. doi: 10.1080/21645515.2024.2417532. Epub 2024 Nov 15.PMID: 39544177

Meeting Report of the 37th International Conference on Antiviral Research in Gold Coast, Australia, May 20-24, 2024, organized by the International Society for Antiviral Research.

Welch SR, Bilello JP, Carter K, Delang L, Dirr L, Durantel D, Feng JY, Gowen BB, Herrero LJ, Janeba Z, Kleymann G, Lee AA, Meier C, Moffat J, Schang LM, Schiffer JT, Seley-Radtke KL, Sheahan TP, Spengler JR.Antiviral Res. 2024 Nov 12:106037. doi: 10.1016/j.antiviral.2024.106037. Online ahead of print.PMID: 39542140

Development and validation of an Arabic tool for assessment of post-vaccination confidence in COVID-19 vaccines (ARAB-VAX-CONF).

Abuyadek R, ElHafeez SA, Tahoun MM, Othman SS, Omran A, Fathy N, Ghazy RM.J Egypt Public Health Assoc. 2024 Nov 18;99(1):28. doi: 10.1186/s42506-024-00174-8.PMID: 39551890

Characteristics of reported mumps cases in the United States: 2018-2023.

Tappe J, Leung J, Mathis AD, Oliver SE, Masters NB.Vaccine. 2024 Nov 14;42(25):126143. doi: 10.1016/j.vaccine.2024.07.044. Epub 2024 Jul 16.PMID: 39019661

Astragalus polysaccharide enhances maternal mucosal immunity against PEDV.

Tang J, Wang S, Tang J, Li J.mSphere. 2024 Nov 14:e0077724. doi: 10.1128/msphere.00777-24. Online ahead of print.PMID: 39540725

Mapping global public perspectives on mRNA vaccines and therapeutics.

Xu J, Wu Z, Wass L, Larson HJ, Lin L.NPJ Vaccines. 2024 Nov 14;9(1):218. doi: 10.1038/s41541-024-01019-3.PMID: 39543153

Baculovirus surface display of a chimeric E-NS1 protein of YFV protects against YFV infection.

Tomatis C, Ferrer MF, Aquila S, Thomas PD, Arrías PN, Ferrelli L, Pidre M, Romanowski V, Carrera Silva EA, Gómez RM.Vaccine. 2024 Nov 14;42(25):126045. doi: 10.1016/j.vaccine.2024.06.013. Epub 2024 Jun 8.PMID: 38852036

Factors associated with HPV vaccine acceptance and hesitancy in Africa: a systematic review protocol.

Mavundza EJ, Jaca A, Cooper S, Ndwandwe DE, Wiysonge CS.BMJ Open. 2024 Nov 14;14(11):e082592. doi: 10.1136/bmjopen-2023-082592.PMID: 39542479

Probing novel epitopes on the Plasmodium falciparum circumsporozoite protein for vaccine development.

Krenger PS, Roques M, Vogt AS, Pardini A, Rothen DA, Balke I, Schnider ST, Mohsen MO, Heussler VT, Zeltins A, Bachmann MF.NPJ Vaccines. 2024 Nov 18;9(1):225. doi: 10.1038/s41541-024-01006-8.PMID: 39557901

Maternal-infant transfer of SARS-CoV-2 antibodies following vaccination in pregnancy: A prospective cohort study.

Korchinski I, Marquez C, McClymont E, Av-Gay G, Andrade J, Elwood C, Jassem A, Krajden M, Morshed M, Sadarangani M, Tanunliong G, Sekirov I, Money D.Vaccine. 2024 Nov 14;42(25):126123. doi: 10.1016/j.vaccine.2024.07.024. Epub 2024 Jul 9.PMID: 38981741

Attenuated Getah virus confers protection against multiple arthritogenic alphaviruses.

Jiang Z, Merits A, Qin Y, Xing G, Zhang L, Chen J, Wang N, Varjak M, Zhai X, Li D, Song W, Su S.PLoS Pathog. 2024 Nov 18;20(11):e1012700. doi: 10.1371/journal.ppat.1012700. Online ahead of print.PMID: 39556619

A Phase 1, Double-Blinded, Placebo-Controlled Clinical Trial to Evaluate the Safety and Immunogenicity of HEV-239 (Hecolin) Vaccine in Healthy US Adults.

Kao CM, Rostad CA, Nolan LE, Peters E, Kleinhenz J, Sherman JD, Tippett A, Shih JWK, Yildirim I, Agbakoba V, Beresnev T, Ballou C, Kamidani S, Karmali V, Natrajan M, Scherer EM, Rouphael N, Anderson EJ.J Infect Dis. 2024 Nov 15;230(5):1093-1101. doi: 10.1093/infdis/jiae148.PMID: 38536442

Ideological diversity of media consumption predicts COVID-19 vaccination.

Grant MD, Markowitz DM, Sherman DK, Flores A, Dickert S, Eom K, Jiga-Boy GM, Kogut T, Mayorga M, Oonk D, Pedersen EJ, Pereira B, Rubaltelli E, Slovic P, Västfjäll D, Van Boven L.Sci Rep. 2024 Nov 22;14(1):28948. doi: 10.1038/s41598-024-77408-4.PMID: 39578487

Exploring plant-based dengue therapeutics: from laboratory to clinic.

Rehman B, Ahmed A, Khan S, Saleem N, Naseer F, Ahmad S.Trop Dis Travel Med Vaccines. 2024 Nov 15;10(1):23. doi: 10.1186/s40794-024-00232-1.PMID: 39543749

Computational studies on metabolic pathways of Coxiella burnetii to combat Q fever: A roadmap to vaccine development.

Sharma A, Kumar S, Kumar R, Sharma AK, Singh B, Sharma D.Microb Pathog. 2024 Nov 19;198:107136. doi: 10.1016/j.micpath.2024.107136. Online ahead of print.PMID: 39571832

Implications of the apparent extinction of B/Yamagata-lineage human influenza viruses.

Barr IG, Subbarao K.NPJ Vaccines. 2024 Nov 16;9(1):219. doi: 10.1038/s41541-024-01010-y.PMID: 39550399

Building a way forward: Enabling community voices to forge the path toward successful immunization for all.

Peimbert-Rappaport N, Hopkins KL, Lihemo G, Underwood T, Sommers T, Cuba G, Bottallo Quadros A, Kahondwa P, Shreedhar J, Ryan N, Konne NM, Abad N, Ernst K, Omar H, Gagneur A, Leask J, Zaharia R, Abdi I, Issa M, Kakaire C, Risal Pokharel D, Lemango E, Gupta A.Vaccine. 2024 Nov 14;42 Suppl 5:126017. doi: 10.1016/j.vaccine.2024.05.065. Epub 2024 Jun 14.PMID: 38879408

Dose sparing enabled by immunization with influenza vaccine using orally dissolving film.

Yoon KW, Chu KB, Eom GD, Mao J, Heo SI, Quan FS.Int J Pharm. 2024 Nov 15;667(Pt B):124945. doi: 10.1016/j.ijpharm.2024.124945. Online ahead of print.PMID: 39550013

Structural analysis and adjuvant activity of a polysaccharide from Urtica macrorrhiza.

Wang Z, Yang Q, Wu G, Ma J, Luo L, Yin W, Wu M.Int J Biol Macromol. 2024 Nov 13;283(Pt 1):137433. doi: 10.1016/j.ijbiomac.2024.137433. Online ahead of print.PMID: 39542334

Moral foundations messaging to improve vaccine attitudes: An online randomized experiment from Argentina.

Winters M, Christie S, Melchinger H, Arias N, Lirman L, Thomson A, Omer SB.PLOS Glob Public Health. 2024 Nov 15;4(11):e0003276. doi: 10.1371/journal.pgph.0003276. eCollection 2024.PMID: 39546472

The BNT162b2 mRNA vaccine demonstrates reduced age-associated T(H)1 support in vitro and in vivo.

Brook B, Checkervarty AK, Barman S, Sweitzer C, Bosco AN, Sherman AC, Baden LR, Morrocchi E, Sanchez-Schmitz G, Palma P, Nanishi E, O'Meara TR, McGrath ME, Frieman MB, Soni D, van Haren SD, Ozonoff A, Diray-Arce J, Steen H, Dowling DJ, Levy O.iScience. 2024 Sep 26;27(11):111055. doi: 10.1016/j.isci.2024.111055. eCollection 2024 Nov 15.PMID: 39569372

Antibody dynamics for heterologous boosters with aerosolized Ad5-nCoV following inactivated COVID-19 vaccines.

Chen C, Tang T, Chen Z, Chen L, Cheng J, Li F, Sun J, Zhao J, Wang Y, Yan Q, Zhao J, Zhu A.Hum Vaccin Immunother. 2024 Dec 31;20(1):2423466. doi: 10.1080/21645515.2024.2423466. Epub 2024 Nov 13.PMID: 39535117

Federated learning as a smart tool for research on infectious diseases.

Zwiers LC, Grobbee DE, Uijl A, Ong DSY.BMC Infect Dis. 2024 Nov 21;24(1):1327. doi: 10.1186/s12879-024-10230-5.PMID: 39573994

Novel virulence determinants in VP1 regulate the assembly of enterovirus-A71.

Zhang W, Li Q, Yi D, Zheng R, Liu G, Liu Q, Guo S, Zhao J, Wang J, Ma L, Ding J, Zhou R, Ren Y, Sun T, Zhang A, Li X, Zhang Y, Cen S.J Virol. 2024 Nov 13:e0165524. doi: 10.1128/jvi.01655-24. Online ahead of print.PMID: 39535185

Author Correction: Potent and long-lasting humoral and cellular immunity against varicella zoster virus induced by mRNA-LNP vaccine.

Bhattacharya A, Jan L, Burlak O, Li J, Upadhyay G, Williams K, Dong J, Rohrer H, Pynn M, Simon A, Kuhlmann N, Pustylnikov S, Melo MB, Dey AK.NPJ Vaccines. 2024 Nov 18;9(1):224. doi: 10.1038/s41541-024-01020-w.PMID: 39557916

Characterization of mRNA-LNP structural features and mechanisms for enhanced mRNA vaccine immunogenicity.

Wu K, Xu F, Dai Y, Jin S, Zheng A, Zhang N, Xu Y.J Control Release. 2024 Nov 12;376:1288-1299. doi: 10.1016/j.jconrel.2024.11.007. Online ahead of print.PMID: 39522562

Concordance, motivations and associated factors of COVID-19 vaccination among parent-child dyads: a cross-sectional study in Caraga Region, the Philippines.

Herrera DJL, Herrera DJ, Anore KM, Herrera M, Masing ALA, Sanchez RE, Bas S, Amora D, Tabudlong RP, Berhe NM.BMJ Open. 2024 Nov 19;14(11):e089178. doi: 10.1136/bmjopen-2024-089178.PMID: 39566951

Cost of delivering childhood RSV prevention interventions to the health system in Kenya: a prospective analysis.

Baral R, Otiang E, Odiyo J, Nyawanda BO, Nyiro JU, Munywoki P, Jalang'O RE, Pecenka C.BMJ Open. 2024 Nov 21;14(11):e084207. doi: 10.1136/bmjopen-2024-084207.PMID: 39578037

Mycobacterium tuberculosis Antigen Rv1471 Induces Innate Immune Memory and Adaptive Immunity against Infection.

Huang X, Wu J, Xu J, Wang H, Chen Z, Fan XY, Hu Z.J Infect Dis. 2024 Nov 14:jiae572. doi: 10.1093/infdis/jiae572. Online ahead of print.PMID: 39541425

Dengue Virus Infection: Immune Response and Therapeutic Targets.

Tin Ern N, Komarasamy TV, Adnan NAA, Balasubramaniam VRMT.Am J Trop Med Hyg. 2024 Nov 12:tpmd230545. doi: 10.4269/ajtmh.23-0545. Online ahead of print.PMID: 39531732

A potential platform for future vaccine trials identifies high incidence of symptomatic and asymptomatic influenza infection among children aged 6-23 months in South Africa.

Cohen C, du Plessis M, Martinson N, Moyes J, Walaza S, Wolter N, Makhasi M, Moosa F, Charles M, Samuels AM, Tempia S, Moloantoa T, Ncwana B, Phalatse L, Buys A, Fry A, Baumgartner EA, von Gottberg A, Kleynhans J.J Infect Dis. 2024 Nov 14:jiae550. doi: 10.1093/infdis/jiae550. Online ahead of print.PMID: 39542652

Health impact and cost-effectiveness of vaccination using potential next-generation influenza vaccines in Thailand: a modelling study.

Procter SR, Waterlow NR, Radhakrishnan S, van Leeuwen E, Meeyai A, Cooper BS, Chuenkitmongkol S, Teerawattananon Y, Eggo RM, Jit M.BMJ Glob Health. 2024 Nov 18;9(11):e015837. doi: 10.1136/bmjgh-2024-015837.PMID: 39557448

Poxvirus vaccines: the evolution of an 18th-century vaccine to the 21st century.

Xiao Y, Isaacs SN.Trends Pharmacol Sci. 2024 Nov 12:S0165-6147(24)00225-6. doi: 10.1016/j.tips.2024.10.015. Online ahead of print.PMID: 39537527

Identification of potential antigenic proteins and epitopes for the development of a monkeypox virus vaccine: an in silico approach.

Aktaş E, Sezerman OU, Özer M, Kırboğa KK, Köseoğlu AE, Özgentürk NÖ.Mol Divers. 2024 Nov 15. doi: 10.1007/s11030-024-11033-1. Online ahead of print.PMID: 39546220

Implementation of Immunization Services Through a Pediatric Urgent Care Clinic.

Gordon DM, Vega T, Aulakh S, Bhargava-Shah A, Bardach NS, Jain S.Pediatrics. 2024 Nov 14:e2023064079. doi: 10.1542/peds.2023-064079. Online ahead of print.PMID: 39539127

Unlocking potential: Virus-like particles as a promising strategy for effective HCV vaccine development.

Ali AA, Tabll AA.Virology. 2024 Nov 15;602:110307. doi: 10.1016/j.virol.2024.110307. Online ahead of print.PMID: 39580887

Successful Implementation of Nirsevimab and Factors Influencing Uptake in Neonatal Care.

Puckett L, Kushner LE, Bio L, Cornell S, Wood M, Schwenk HT.Hosp Pediatr. 2024 Nov 21. doi: 10.1542/hpeds.2024-008070. Online ahead of print.PMID: 39568114

Vaccine efficacy induced by 2020-2021 seasonal influenza-derived H3N1 virus-like particles co-expressing M2e5x or N2.

Mao J, Kang HJ, Eom GD, Yoon KW, Chu KB, Quan FS.Vaccine. 2024 Nov 16;43(Pt 2):126530. doi: 10.1016/j.vaccine.2024.126530. Online ahead of print.PMID: 39551038

A new multi-epitope DNA vaccine against Helicobacter Pylori infection in a BALB/c mouse model.

Azami Z, Farahmand M, Kavousi M.Heliyon. 2024 Oct 17;10(21):e39433. doi: 10.1016/j.heliyon.2024.e39433. eCollection 2024 Nov 15.PMID: 39524710

Susceptibility to online misinformation: A systematic meta-analysis of demographic and psychological factors.

Sultan M, Tump AN, Ehmann N, Lorenz-Spreen P, Hertwig R, Gollwitzer A, Kurvers RHJM.Proc Natl Acad Sci U S A. 2024 Nov 19;121(47):e2409329121. doi: 10.1073/pnas.2409329121. Epub 2024 Nov 12.PMID: 39531500

Latent class analysis of post-acute sequelae of SARS-CoV-2 infection.

Sun X, DeShazo JP, Anatale-Tardiff L, Di Fusco M, Allen KE, Porter TM, Coetzer H, Lopez SMC, Puzniak L, Cappelleri JC.J Biopharm Stat. 2024 Nov 16:1-16. doi: 10.1080/10543406.2024.2424844. Online ahead of print.PMID: 39550613

Assessing yellow fever outbreak potential and implications for vaccine strategy.

Fraser K, Hamlet A, Jean K, Ramos DG, Romano A, Horton J, Cibrelus L, Ferguson NM, Gaythorpe KAM.PLOS Glob Public Health. 2024 Nov 13;4(11):e0003781. doi: 10.1371/journal.pgph.0003781. eCollection 2024.PMID: 39536033

Depletion of regulatory T cells enhances the T cell response induced by the neoantigen vaccine with weak immunogenicity.

Huang R, Zhou Q, Liu J, Xia Y, Jiao Y, Zhao B, Feng T, Zhou H, Song X, Qin H, Wang J, Cheng L, Ning Y, Sun Q, Liu Y, Su X, Dong Y, Zhang W.Neoplasia. 2024 Nov 22;59:101088. doi: 10.1016/j.neo.2024.101088. Online ahead of print.PMID: 39579711

Hidden allies: how extracellular vesicles drive biofilm formation, stress adaptation, and host-immune interactions in human fungal pathogens.

Brandt P, Singha R, Ene IV.mBio. 2024 Nov 18:e0304523. doi: 10.1128/mbio.03045-23. Online ahead of print.PMID: 39555918

Advancing the understanding of autoimmune/inflammatory syndrome induced by adjuvants (ASIA): Global research trends, key themes, and emerging frontiers.

Bai H, Tian J.Autoimmun Rev. 2024 Nov 14;24(1):103691. doi: 10.1016/j.autrev.2024.103691. Online ahead of print.PMID: 39547641

The Effect of Interventions Based on the Information-Motivation-Behavioral Skills Model on the Human Papillomavirus Vaccination Rate Among 11-13-Year-Old Girls in Central and Western China: Protocol for a Randomized Controlled Trial.

Jing S, Wu Y, Dai Z, Tang S, Su X, Qiao Y.JMIR Res Protoc. 2024 Nov 19;13:e58873. doi: 10.2196/58873.PMID: 39560975

Prevalence of Oral Human Papillomavirus Infection Among Urban Gay, Bisexual, and Other Men Who Have Sex With Men in Canada, 2017-2019.

Alessandrini J, Cox J, de Pokomandy A, Hart TA, Grace D, Grennan T, Moore D, Lambert G, Chambers C, Deeks SL, Grewal R, Lachowsky NJ, Sauvageau C, Tan DHS, Coutlée F, Burchell AN; Engage-HPV Team.J Infect Dis. 2024 Nov 15;230(5):e1039-e1048. doi: 10.1093/infdis/jiae345.PMID: 39041706

Immunogenicity of mRNA vs. BBV152 vaccine boosters against Omicron subvariants: Final results from Phase B of the PRIBIVAC study, a randomized clinical trial.

Poh XY, Torres-Ruesta A, Yoong T, Wong N, Tan CW, Rouers A, Chavatte JM, Goh YS, Rao S, Chia PY, Ong SWX, Lee TH, Sadarangani SP, Lin RJH, Neo V, Kam IKJ, Huang Y, Hor PX, Loh CY; PRIBIVAC study group; Yeoh AY, Lim DRX, Chia W, Ren EC, Lin RTP, Fong SW, Renia L, Lye DC, Wang LF, Ng LFP, Young BE.Vaccine. 2024 Nov 14;42(25):126275. doi: 10.1016/j.vaccine.2024.126275. Epub 2024 Sep 5.PMID: 39241318

Raman laser intensity and sample clarification on biochemical monitoring over Zika-VLP upstream stages.

da Silva Cavalcante PE, Públio Rabello J, Leme J, Aragão Tejo Dias V, Correia Barrence FA, de Oliveira Guardalini LG, Consoni Bernardino T, Almeida S, Tonso A, Attie Calil Jorge S, Fernández Núñez EG.Biochem Biophys Res Commun. 2024 Nov 12;733:150671. doi: 10.1016/j.bbrc.2024.150671. Epub 2024 Sep 7.PMID: 39298919

Vaccination with OprB porin, and its epitopes offers protection against A. baumannii infections in mice.

Raoufi Z, Abdollahi S.Int Immunopharmacol. 2024 Nov 15;141:112972. doi: 10.1016/j.intimp.2024.112972. Epub 2024 Aug 25.PMID: 39186832

The Impact of Zika Emergence in Remote Communities in Northwestern Ecuador.

Andrade P, Sosa-Moreno A, Vivero S, Nipaz V, Lee GO, Cevallos W, Eisenberg JNS, Coloma J.J Infect Dis. 2024 Nov 15;230(5):e1058-e1066. doi: 10.1093/infdis/jiae384.PMID: 39082780

Glycoside-Mediated Enhancement of Stability in Aluminum Oxyhydroxide Nanoadjuvants during Freeze-Drying.

Bhurt M, Li X, Zhang N, Yang W, Xu M, Liu Y, Yu Y, Sun B.Langmuir. 2024 Nov 19;40(46):24613-24621. doi: 10.1021/acs.langmuir.4c03474. Epub 2024 Nov 6.PMID: 39504510

Measuring influencing factors affecting mortality rates during the COVID-19 pandemic.

Wu JS, Huang KK.Glob Health Action. 2024 Dec 31;17(1):2428067. doi: 10.1080/16549716.2024.2428067. Epub 2024 Nov 12.PMID: 39530400

Disease-associated B cells and immune endotypes shape adaptive immune responses to SARS-CoV-2 mRNA vaccination in human SLE.

Faliti CE, Van TTP, Anam FA, Cheedarla N, Williams ME, Mishra AK, Usman SY, Woodruff MC, Kraker G, Runnstrom MC, Kyu S, Sanz D, Ahmed H, Ghimire M, Morrison-Porter A, Quehl H, Haddad NS, Chen W, Cheedarla S, Neish AS, Roback JD, Antia R, Hom J, Tipton CM, Lindner JM, Ghosn E, Khurana S, Scharer CD, Khosroshahi A, Lee FE, Sanz I.Nat Immunol. 2024 Nov 12. doi: 10.1038/s41590-024-02010-9. Online ahead of print.PMID: 39533072

First vaccine confidence and access index in Argentina: Comparison of results from 2019 to 2022.

Carlos Guillermo B, Tomas Alberto O, Julio I.Vaccine. 2024 Nov 14;42 Suppl 5:126070. doi: 10.1016/j.vaccine.2024.06.037. Epub 2024 Jun 19.PMID: 38902185

Serological Evidence of Mpox Virus Infection During Peak Mpox Transmission in New York City, July to August 2022.

Pathela P, Townsend MB, Kopping EJ, Tang J, Navarra T, Priyamvada L, Carson WC, Panayampalli SS, Fowler RC, Kyaw N, Hughes S, Jamison K.J Infect Dis. 2024 Nov 15;230(5):1102-1109. doi: 10.1093/infdis/jiae181.PMID: 38736232

NHBA antibodies elicited by 4CMenB vaccination are key for serum bactericidal activity against Neisseria gonorrhoeae.

Tzeng YL, Sannigrahi S, Stephens DS.NPJ Vaccines. 2024 Nov 18;9(1):223. doi: 10.1038/s41541-024-01018-4.PMID: 39557897

Neutralizing antibody correlate of protection against severe-critical COVID-19 in the ENSEMBLE single-dose Ad26.COV2.S vaccine efficacy trial.

Carpp LN, Hyrien O, Fong Y, Benkeser D, Roels S, Stieh DJ, Van Dromme I, Van Roey GA, Kenny A, Huang Y, Carone M, McDermott AB, Houchens CR, Martins K, Jayashankar L, Castellino F, Amoa-Awua O, Basappa M, Flach B, Lin BC, Moore C, Naisan M, Naqvi M, Narpala S, O'Connell S, Mueller A, Serebryannyy L, Castro M, Wang J, Petropoulos CJ, Luedtke A, Lu Y, Yu C, Juraska M, Hejazi NS, Wolfe DN, Sadoff J, Gray GE, Grinsztejn B, Goepfert PA, Bekker LG, Gaur AH, Veloso VG, Randhawa AK, Andrasik MP, Hendriks J, Truyers C, Vandebosch A, Struyf F, Schuitemaker H, Douoguih M, Kublin JG, Corey L, Neuzil KM, Follmann D, Koup RA, Donis RO, Gilbert PB; Immune Assays Team; Coronavirus Vaccine Prevention Network (CoVPN)/ENSEMBLE Team; United States Government (USG)/CoVPN Biostatistics Team.Nat Commun. 2024 Nov 12;15(1):9785. doi: 10.1038/s41467-024-53727-y.PMID: 39532861

Molecular mechanisms of Coxiella burnetii formalin-fixed cellular vaccine reactogenicity.

Fratzke AP, Szule JA, Butler SM, Schaik EJv, Samuel JE.Infect Immun. 2024 Nov 12;92(11):e0033524. doi: 10.1128/iai.00335-24. Epub 2024 Oct 2.PMID: 39356158

pVACview: an interactive visualization tool for efficient neoantigen prioritization and selection.

Xia H, Hoang MH, Schmidt E, Kiwala S, McMichael J, Skidmore ZL, Fisk B, Song JJ, Hundal J, Mooney T, Walker JR, Goedegebuure SP, Miller CA, Gillanders WE, Griffith OL, Griffith M.Genome Med. 2024 Nov 14;16(1):132. doi: 10.1186/s13073-024-01384-7.PMID: 39538339

FDA Greenlights Nasal Spray Flu Vaccine for Use at Home.

Anderer S.JAMA. 2024 Nov 12;332(18):1508. doi: 10.1001/jama.2024.21299.PMID: 39422920

Profiling serum immunodominance following SARS-CoV-2 primary and breakthrough infection reveals distinct variant-specific epitope usage and immune imprinting.

Seow J, Jefferson GCE, Keegan MD, Yau Y, Snell LB, Doores KJ.PLoS Pathog. 2024 Nov 18;20(11):e1012724. doi: 10.1371/journal.ppat.1012724. Online ahead of print.PMID: 39556615

Disparities in Vaccination Amongst Socially Vulnerable Patients with Inflammatory Bowel Disease.

Sheehan JL, Jordan AA, Newman KL, Johnson LA, Eloubeidi D, Cohen-Mekelburg S, Berinstein JA, Tipirneni R, Higgins PDR.Dig Dis Sci. 2024 Nov 15. doi: 10.1007/s10620-024-08733-x. Online ahead of print.PMID: 39548038

Human and hamster sera correlate well in identifying antigenic drift among SARS-CoV-2 variants, including JN.1.

Wang W, Bhushan G, Paz S, Stauft CB, Selvaraj P, Goguet E, Bishop-Lilly KA, Subramanian R, Vassell R, Lusvarghi S, Cong Y, Agan B, Richard SA, Epsi NJ, Fries A, Fung CK, Conte MA, Holbrook MR, Wang TT, Burgess TH, Pollett SD, Mitre E, Katzelnick LC, Weiss CD.J Virol. 2024 Nov 19;98(11):e0094824. doi: 10.1128/jvi.00948-24. Epub 2024 Oct 4.PMID: 39365051

Epidemiological characteristics of breakthrough mumps infection cases from 2019 to 2023 in Chongqing, China.

Liu Y, Cai X, Yang D, Xiang Y, Wang Q, Yao N, Zhang Y, Xu J.Hum Vaccin Immunother. 2024 Dec 31;20(1):2426273. doi: 10.1080/21645515.2024.2426273. Epub 2024 Nov 13.PMID: 39539039

Estimating the optimal age for infant measles vaccination.

Goult E, Barrero Guevara LA, Briga M, Domenech de Cellès M.Nat Commun. 2024 Nov 15;15(1):9919. doi: 10.1038/s41467-024-53415-x.PMID: 39548065

IL-2/anti-IL-2 antibody complexes augment immune responses to therapeutic cancer vaccines.

Sobral MC, Cabizzosu L, Kang SJ, Ruark K, Najibi AJ, Lane RS, Vitner E, Ijaz H, Dellacherie MO, Dacus MT, Tringides CM, Lázaro I, Pittet MJ, Müller S, Turley SJ, Mooney DJ.Proc Natl Acad Sci U S A. 2024 Nov 26;121(48):e2322356121. doi: 10.1073/pnas.2322356121. Epub 2024 Nov 18.PMID: 39556726

Rapid Hemostasis Tumor In Situ Hydrogel Vaccines for Colorectal Cancer Chemo-Immunotherapy.

Qiu W, Zheng Y, Shen F, Wang Z, Huang Q, Guo W, Wang Q, Yang P, He F, Cao Z, Cao J.ACS Appl Mater Interfaces. 2024 Nov 13;16(45):61679-61691. doi: 10.1021/acsami.4c13489. Epub 2024 Oct 31.PMID: 39480969

Molecular epidemiology and pathogenicity of Wesselsbron virus circulating in Africa.

Faye M, Di Paola N, Dia M, Sall AA, Faye O.Virus Res. 2024 Nov 17;350:199499. doi: 10.1016/j.virusres.2024.199499. Online ahead of print.PMID: 39547415

Rotavirus-specific-IgA and cytokines responses in *Ascaris lumbricoides*-infected preschool-aged Nigerian children following rotavirus vaccination.

Akinwande KS, Akinduti PA, Arinola O.J Immunoassay Immunochem. 2024 Nov 12:1-14. doi: 10.1080/15321819.2024.2426147. Online ahead of print.PMID: 39533525

Weighing the risks and benefits: Parental perspectives on COVID-19 vaccines for 5- to 11-year-old children.

Ataullahjan A, Piche-Renaud PP, Shahrbabak EK, Fadaleh SA, Di Chiara C, Rodriguez DA, Peresin J, Morris SK.Vaccine. 2024 Nov 14;42(25):126154. doi: 10.1016/j.vaccine.2024.126154. Epub 2024 Jul 26.PMID: 39060203

Effectiveness of influenza vaccination on hospitalization outcomes among older patients with diabetes.

Liu G, Pang Y, Lv M, Lu M, Huang Y, Ge F, Ma S, Qiu Y.Vaccine. 2024 Nov 14;42(25):126142. doi: 10.1016/j.vaccine.2024.07.043. Epub 2024 Jul 17.PMID: 39019658

The rights and interests of participants as limits to clinical trials.

Dal-Ré R.Rev Clin Esp (Barc). 2024 Nov 15:S2254-8874(24)00145-0. doi: 10.1016/j.rceng.2024.11.002. Online ahead of print.PMID: 39549914

Susceptibility to online misinformation: A systematic meta-analysis of demographic and psychological factors.

Sultan M, Tump AN, Ehmann N, Lorenz-Spreen P, Hertwig R, Gollwitzer A, Kurvers RHJM.Proc Natl Acad Sci U S A. 2024 Nov 19;121(47):e2409329121. doi: 10.1073/pnas.2409329121. Epub 2024 Nov 12.PMID: 39531500

Striving for equitable vaccination coverage: Leveraging rapid coverage and community assessments during the COVID-19 pandemic to reach missed populations in Cambodia.

R Mugali R, Ip H, Zikusooka A, Vong L, Bou S, Kros S, Vandine O.Vaccine. 2024 Nov 14;42 Suppl 5:126016. doi: 10.1016/j.vaccine.2024.05.064. Epub 2024 Jun 8.PMID: 38852038

The Application of Prostate Specific Membrane Antigen in the Diagnosis and Treatment of Prostate Cancer: Status and Challenge.

Zeng T, Xie Y, Chai K, Sang H.Onco Targets Ther. 2024 Nov 14;17:991-1015. doi: 10.2147/OTT.S485869. eCollection 2024.PMID: 39564453

Characteristics of a CCL21-gene modified dendritic cell vaccine utilized for a clinical trial in non-small cell lung cancer.

Oh MS, Dumitras C, Salehi-Rad R, Tran LM, Krysan K, Lim RJ, Jing Z, Tappuni S, Lisberg A, Garon EB, Dubinett SM, Liu B.Mol Cancer Ther. 2024 Nov 19. doi: 10.1158/1535-7163.MCT-24-0435. Online ahead of print.PMID: 39559833

DNA tetrahedron nanoparticles service as a help carrier and adjvant of mRNA vaccine.

Liu H, Li X, Yan R, Yang J, Lu Q, Wang L.J Transl Med. 2024 Nov 14;22(1):1024. doi: 10.1186/s12967-024-05837-w.PMID: 39543727

Identification of molecular and cellular infection response biomarkers associated with anthrax infection through comparative analysis of gene expression data.

Rani S, Ramesh V, Khatoon M, Shijili M, Archana CA, Anand J, Sagar N, Sekar YS, Patil AV, Palavesam A, Barman NN, Patil SS, Hemadri D, Suresh KP.Comput Biol Med. 2024 Nov 17;184:109431. doi: 10.1016/j.compbiomed.2024.109431. Online ahead of print.PMID: 39556915

An ADaptivE PrenaTal (ADEPT) intervention to increase childhood vaccinations: Protocol for a cluster randomized trial and nested mixed methods evaluation.

Vasudevan L, Porter RM, Campos I, Turner EL, Stinnett SS, Zullig LL, Walter EB, Swamy GK, Bednarczyk RA, Orenstein WA, Gray B.PLoS One. 2024 Nov 21;19(11):e0313742. doi: 10.1371/journal.pone.0313742. eCollection 2024.PMID: 39570957

Deep mutational scanning of H5 hemagglutinin to inform influenza virus surveillance.

Dadonaite B, Ahn JJ, Ort JT, Yu J, Furey C, Dosey A, Hannon WW, Vincent Baker AL, Webby RJ, King NP, Liu Y, Hensley SE, Peacock TP, Moncla LH, Bloom JD.PLoS Biol. 2024 Nov 12;22(11):e3002916. doi: 10.1371/journal.pbio.3002916. eCollection 2024 Nov.PMID: 39531474

Comparative Analysis of IMT-P8 and LDP12 Cell-Penetrating Peptides in Increasing Immunostimulatory Properties of HIV-1 Nef-MPER-V3 Antigen.

Sadat SM, Jahedian S, Sabaghzadeh S, Larijani MS, Bolhassani A.Protein Pept Lett. 2024 Nov 15. doi: 10.2174/0109298665337811241010104557. Online ahead of print.PMID: 39558498

Association between depressive symptoms and participation in influenza vaccination and health checkups: Findings from the Korea National Health and Nutrition Examination Survey.

Baek SU, Yoon JH.Gen Hosp Psychiatry. 2024 Nov 17;91:180-185. doi: 10.1016/j.genhosppsych.2024.11.006. Online ahead of print.PMID: 39571403

Evolutionary analysis of Hemagglutinin and neuraminidase gene variation in H1N1 swine influenza virus from vaccine intervention in China.

Zhao X, Shen M, Cui L, Liu C, Yu J, Wang G, Erdeljan M, Wang K, Chen S, Wang Z.Sci Rep. 2024 Nov 20;14(1):28792. doi: 10.1038/s41598-024-80457-4.PMID: 39567587

Hepatitis B Virus Treatment in Children: Common Challenges and Management Options in a Case-Based Format.

Ravanbakhsh N, Rivera Campana A, Chapin C, Jhaveri R.J Pediatric Infect Dis Soc. 2024 Nov 21;13(Supplement_5):S142-S147. doi: 10.1093/jpids/piae084.PMID: 39171575

Study: MMR Vaccine Protection Wanes Slightly Over Time.

Anderer S.JAMA. 2024 Nov 19;332(19):1602. doi: 10.1001/jama.2024.21822.PMID: 39453649

Manganese Oxide-Incorporated Hybrid Lipid Nanoparticles Amplify the Potency of mRNA Vaccine via Oxygen Generation and STING Activation.

Gan J, Lei J, Li Y, Lu M, Yu X, Yu G.J Am Chem Soc. 2024 Nov 17. doi: 10.1021/jacs.4c12166. Online ahead of print.PMID: 39552027

Longitudinal multiomic profiling and corticosteroid modulation of the immediate innate immune response to an adenovirus-vector vaccine.

Jin Choi S, Lee W, Cheol Kim S, Jo HY, Park HY, Bin Kim H, Park WY, Ho Park S, Ko JH, Seok Lee J.Vaccine. 2024 Nov 14;42(25):126118. doi: 10.1016/j.vaccine.2024.07.019. Epub 2024 Jul 18.PMID: 39025696

Behavioural economics to improve and motivate vaccination in primary care using nudges through the electronic health record: rationale and design of the BE IMMUNE randomised clinical trial.

Waddell K, Mehta SJ, Navathe A, Linn K, Park SH, White A, Staloff J, Rhodes C, Couzens C, Goel K, McDonald C, Reitz C, Williams K, Liao JM.BMJ Open. 2024 Nov 18;14(11):e086698. doi: 10.1136/bmjopen-2024-086698.PMID: 39557547

Misinformation targeting replicon vaccine recipients: an urgent public health ethical issue.

Ino H, Takimoto Y, Nakazawa E.Lancet. 2024 Nov 16;404(10466):1922-1923. doi: 10.1016/S0140-6736(24)02271-2.PMID: 39550167

Recombinant chimeric horsepox virus (TNX-801) is attenuated relative to vaccinia virus strains in both *in vitro* and *in vivo* models.

Trefry SV, Awasthi M, Raney CN, Cregger AL, Gonzales CA, Layton BL, Enamorado RN, Martinez NA, Gohegan DS, Masoud-Bahnamiri M, Cho JY, Myscofski DM, Moulaei T, Ziółkowska NE, Goebel SJ, Lederman S, Bavari S, Nasar F.mSphere. 2024 Nov 13:e0026524. doi: 10.1128/msphere.00265-24. Online ahead of print.PMID: 39535212

A Self-Amplifying Human Papillomavirus 16 Vaccine Candidate Delivered by Tobacco Mosaic Virus-Like Particles.

Karan S, Affonso De Oliveira JF, Moreno-Gonzalez MA, Steinmetz NF.ACS Appl Bio Mater. 2024 Nov 18;7(11):7675-7683. doi: 10.1021/acsabm.4c01239. Epub 2024 Nov 8.PMID: 39512153

Improving the timeliness and equity of preschool childhood vaccinations: Mixed methods evaluation of a quality improvement programme in primary care.

Marszalek M, Hawking MKD, Gutierrez A, Firman N, Wu J, Robson J, Smith K, Dostal I, Ahmed Z, Bedford H, Billington A, Dezateux C.Vaccine. 2024 Nov 16;43(Pt 1):126522. doi: 10.1016/j.vaccine.2024.126522. Online ahead of print.PMID: 39550994

mRNA compartmentalization via multimodule DNA nanostructure assembly augments the immunogenicity and efficacy of cancer mRNA vaccine.

Guo X, Guo M, Cai R, Hu M, Rao L, Su W, Liu H, Gao F, Zhang X, Liu J, Chen C.Sci Adv. 2024 Nov 22;10(47):eadp3680. doi: 10.1126/sciadv.adp3680. Epub 2024 Nov 22.PMID: 39576858

Distinct Inflammatory Programs Underlie the Intramuscular Lipid Nanoparticle Response.

Dowell W, Dearborn J, Languon S, Miller Z, Kirch T, Paige S, Garvin O, Kjendal L, Harby E, Zuchowski AB, Clark E, Lescieur-Garcia C, Vix J, Schumer A, Mistri SK, Snoke DB, Doiron AL, Freeman K, Toth MJ, Poynter ME, Boyson JE, Majumdar D.ACS Nano. 2024 Nov 20. doi: 10.1021/acsnano.4c08490. Online ahead of print.PMID: 39563529

Long-term impact of 10-valent pneumococcal conjugate vaccine in Kenya: Nasopharyngeal carriage among children in a rural and an urban site six years after introduction.

Verani JR, Omondi D, Odoyo A, Odiembo H, Ouma A, Ngambi J, Aol G, Audi A, Kiplangat S, Agumba N, Munywoki PK, Onyango C, Hunsperger E, Farrar JL, Kim L, Kobayashi M, Breiman RF, Pimenta FC, da Gloria Carvalho M, Lessa FC, Whitney CG, Bigogo G.Vaccine. 2024 Nov 14;42(25):126120. doi: 10.1016/j.vaccine.2024.07.021. Epub 2024 Aug 14.PMID: 39004525

Intradermal fractional dose vaccination as a method to vaccinate individuals with suspected allergy to mRNA COVID-19 vaccines.

Roozen GVT, Granger A, van Binnendijk RS, den Hartog G, Roestenberg M, Visser LG, Roukens AHE.Vaccine. 2024 Nov 14;42(25):126093. doi: 10.1016/j.vaccine.2024.06.060. Epub 2024 Jun 29.PMID: 38944578

Phase I Study of Adjuvant Allogeneic GM-CSF-Transduced Pancreatic Tumor Cell Vaccine, Low Dose Cyclophosphamide, and SBRT followed by FFX in High-Risk Resected Pancreatic Ductal Adenocarcinoma.

Hill CS, Parkinson R, Jaffee EM, Sugar E, Zheng L, Onners B, Weiss MJ, Wolfgang CL, Cameron JL, Pawlik TM, Rosati L, Le DT, Hacker-Prietz A, Lutz ER, Schulick R, Narang AK, Laheru DA, Herman JM.Int J Radiat Oncol Biol Phys. 2024 Nov 13:S0360-3016(24)03561-2. doi: 10.1016/j.ijrobp.2024.10.039. Online ahead of print.PMID: 39547453

Markers of T-cell dysfunction and not inflammaging predict the waning of humoral responses to SARS-CoV-2 mRNA booster vaccination in people with HIV.

Augello M, Bono V, Rovito R, Santoro A, Tincati C, Marchetti G.AIDS. 2024 Nov 15;38(14):1987-1990. doi: 10.1097/QAD.0000000000004010. Epub 2024 Oct 31.PMID: 39474654

Analysis of Measles and Rubella Immunoglobulin G Titers in COVID-19 Patients.

Başbulut E, Bilgin M, Işler H, Şen A, Kılıç SS, Çubukçu M.Risk Manag Healthc Policy. 2024 Nov 14;17:2789-2801. doi: 10.2147/RMHP.S472872. eCollection 2024.PMID: 39558910

Electronic Nudges and Influenza Vaccination Among Patients With a History of Myocardial Infarction: Insights From 3 Nationwide Randomized Clinical Trials.

Bhatt AS, Johansen ND, Vaduganathan M, Modin D, Pareek M, Chatur S, Claggett BL, Janstrup KH, Larsen CS, Larsen L, Wiese L, Dalager-Pedersen M, Dueger EL, Samson S, Loiacono MM, Harris RC, Køber L, Solomon SD, Martel CJ, Sivapalan P, Jensen JUS, Biering-Sørensen T.JAMA Cardiol. 2024 Nov 17:e244648. doi: 10.1001/jamacardio.2024.4648. Online ahead of print.PMID: 39550717

The C3d-fused Porcine circovirus type 2d virus-like particle induced early and enhanced immune response and protected pigs against challenge.

Qi X, Fang Z, Meng L, Xiang X, Ju Y, Cai X, An T, Sun M, Wang H.Vet Microbiol. 2024 Nov 12;299:110305. doi: 10.1016/j.vetmic.2024.110305. Online ahead of print.PMID: 39536690

Antibody levels against respiratory syncytial virus fusion protein conformations and lack of association with life-threatening infection in previously healthy infants.

Bonnin FA, Talarico LB, Ferolla FM, Acosta PL, Phung E, Kumar A, Toledano A, Caratozzolo A, Neira P, Mascardi N, Satragno D, Contrini MM, Graham BS, Ruckwardt TJ, López EL; GUTI Respiratory Infections Network.Vaccine. 2024 Nov 14;42(25):126119. doi: 10.1016/j.vaccine.2024.07.020. Epub 2024 Jul 12.PMID: 39003106

Safety and Immunogenicity of the H56:IC31 Tuberculosis Vaccine Candidate in Adults Successfully Treated for Drug-Susceptible Pulmonary Tuberculosis: A Phase 1 Randomized Trial.

Tait D, Diacon A, Borges ÁH, van Brakel E, Hokey D, Rutkowski KT, Hunt DJ, Russell M, Andersen PL, Kromann I, Ruhwald M, Churchyard G, Dawson R.J Infect Dis. 2024 Nov 15;230(5):1262-1270. doi: 10.1093/infdis/jiae170.PMID: 38557639

Vaccine safety in children with genetically confirmed mitochondrial disease.

de Vreugd A, Zimmermann FA, Steinbrücker K, de Vries MC, de Boer L, Janssen MC, Huemer M, Wortmann SB.Immunol Lett. 2024 Nov 17;271:106946. doi: 10.1016/j.imlet.2024.106946. Online ahead of print.PMID: 39557131

Association of Pneumococcal Conjugate Vaccination With Severe Acute Respiratory Syndrome Coronavirus 2 Infection Among Older Adult Recipients of Coronavirus Disease 2019 Vaccines: A Longitudinal Cohort Study.

Lewnard JA, Hong V, Grant LR, Ackerson BK, Bruxvoort KJ, Pomichowski M, Arguedas A, Cané A, Jodar L, Gessner BD, Tartof SY.J Infect Dis. 2024 Nov 15;230(5):e1082-e1091. doi: 10.1093/infdis/jiae387.PMID: 39101606

Assessment of the BNT162B2 COVID-19 vaccine immune response in Brazilian indigenous adolescents.

de Oliveira LA, de Morais IRB, Marchioro SB, de Almeida GB, de Almeida de Souza GH, da Silva Ferreira T, Rossoni R, de Oliveira Barbosa D, Navarini VJ, Croda J, Torres AJL, Simionatto S.Vaccine. 2024 Nov 20;43(Pt 1):126494. doi: 10.1016/j.vaccine.2024.126494. Online ahead of print.PMID: 39571350

Duration of vaccine protection against breakthrough infections during five COVID-19 waves among healthcare workers primarily vaccinated with CoronaVac.

Luna-Muschi A, Carmo Borges I, Dos Santos Barboza A, de Faria E, Farrel Cortês M, Santos RB, Costa Silva B, Alves Maia da Silva C, Coelho Rocha E, Reis de Souza V, de Araujo Eliodoro RH, Mendes de Oliveira F, Carolina Mamana A, Miyuki Hidifira A, Nishikawara M, Bertollo Gomes Porto V, Paula B Barboza A, Sampaio V, Mariângela Simão, Lazari CS, Segurado AC, Kallas EG, Marli C Sartori A, Levin AS, Cerdeira Sabino E, Figueiredo Costa S; Covid Seq group.Vaccine. 2024 Nov 14;42(25):126114. doi: 10.1016/j.vaccine.2024.07.015. Epub 2024 Jul 16.PMID: 39019656

Protein-energetic malnutrition hinders malaria vaccine-derived cellular and class-switched antibody responses against the Plasmodium vivax circumsporozoite protein in mice.

Faria ACM, Fock RA, Soares IS, Silveira ELV.Eur J Clin Nutr. 2024 Nov 20. doi: 10.1038/s41430-024-01545-2. Online ahead of print.PMID: 39562824

Quantifying the impact of vaccination on transmission and diversity of influenza A variants in pigs.

Li C, Culhane MR, Schroeder DC, Cheeran MC-J, Galina Pantoja L, Jansen ML, Torremorell M.J Virol. 2024 Nov 12:e0124524. doi: 10.1128/jvi.01245-24. Online ahead of print.PMID: 39530665

Antibody isotyping and cytokine profiling in natural cases of Burkholderia mallei infection (glanders) in equines.

Pooja, Thapa N, Rani R, Shanmugasundaram K, Jhandai P, Rakshita, Bhattacharya TK, Singha H.Cytokine. 2024 Nov 15;185:156799. doi: 10.1016/j.cyto.2024.156799. Online ahead of print.PMID: 39549470

Herpes zoster vaccination among Medicare beneficiaries with and without prescription drug coverage.

Tsai Y, Leung J, Anderson TC, Zhou F, Singleton JA.Vaccine. 2024 Nov 22;43(Pt 1):126537. doi: 10.1016/j.vaccine.2024.126537. Online ahead of print.PMID: 39579649

A multi-epitope subunit vaccine providing broad cross-protection against diverse serotypes of Streptococcus suis.

Liu J, Zhang Z, Pu W, Pan X, Li P, Bai Q, Liang S, Li C, Yu Y, Yao H, Ma J.NPJ Vaccines. 2024 Nov 14;9(1):216. doi: 10.1038/s41541-024-01015-7.PMID: 39543108

Humoral immune response against SARS-CoV-2 after adapted COVID-19 vaccine schedules in healthy adults: The IMCOVAS randomized clinical trial.

Steenackers K, Hanning N, Bruckers L, Desombere I, Marchant A, Ariën KK, Georges D, Soentjens P, D'Onofrio V, Hites M, Berens-Riha N, De Coster I, Damme PV.Vaccine. 2024 Nov 14;42(25):126117. doi: 10.1016/j.vaccine.2024.07.018. Epub 2024 Jul 16.PMID: 39019657

Flu Vaccination Among Patients with Noncommunicable Diseases: A Survey About Awareness, Usage, Gaps and Barriers in Europe.

Colombo L, Hadigal S.Patient Prefer Adherence. 2024 Nov 16;18:2311-2324. doi: 10.2147/PPA.S484302. eCollection 2024.PMID: 39568654

Inserting Omp22 into the flagellin protein, replacing its hypervariable region, results in stronger protection against lethal Acinetobacter baumannii infection.

Behrouz B, Rasooli I, Badmasti F.Sci Rep. 2024 Nov 12;14(1):27646. doi: 10.1038/s41598-024-79013-x.PMID: 39533090

Functional impact of a deletion in Mycobacterium bovis BCG Moreau celA1 gene.

Ferreira Gomes LH, Corrêa PR, Schwarz MGA, Mendonça-Lima L.Tuberculosis (Edinb). 2024 Nov 12;149:102576. doi: 10.1016/j.tube.2024.102576. Online ahead of print.PMID: 39546869

Immune persistence and booster response of a quadrivalent meningococcal conjugate vaccine (MenACYW-TT) 5 years after primary vaccination of adults at 56 years of age.

Robertson CA, Jacqmein J, Selmani A, Galarza K, Oster P.Hum Vaccin Immunother. 2024 Dec 31;20(1):2426868. doi: 10.1080/21645515.2024.2426868. Epub 2024 Nov 18.PMID: 39555800

Plasmodium vivax antigen candidate prediction improves with the addition of Plasmodium falciparum data.

Chou RT, Ouattara A, Takala-Harrison S, Cummings MP.NPJ Syst Biol Appl. 2024 Nov 13;10(1):133. doi: 10.1038/s41540-024-00465-y.PMID: 39537634

Long-term effectiveness of an ultra-rapid rollout vaccination campaign with BNT162b2 on the incidence of SARS-CoV-2 infection.

Tschiderer L, Innerhofer H, Seekircher L, Waltle L, Richter L, Kimpel J, Lass-Flörl C, Forer L, Schönherr S, Larsen DA, Krammer F, Embacher-Aichhorn S, Tilg H, Weiss G, Allerberger F, Willeit P.iScience. 2024 Oct 10;27(11):111117. doi: 10.1016/j.isci.2024.111117. eCollection 2024 Nov 15.PMID: 39555399

Clinical outcomes of Omicron infection and vaccine acceptance among pediatric liver transplant recipients: insights from a cross-sectional survey.

Zheng Z, Lu Y, Wu H, Lam PU, Sun X, Song Y, Ji H, Luo Y, Zhou T, Feng M, Wan P, Zhu J, Li P, Deng J, Shen N, Cao Q, Liang J, Xia Q, Xue F.Virol J. 2024 Nov 22;21(1):299. doi: 10.1186/s12985-024-02531-7.PMID: 39578871

Synergistic immune augmentation enabled by covalently conjugating TLR4 and NOD2 agonists.

Ding D, Gao R, Lei Y, Liu J, Zhou C, Wen Y, Zhou S, Guo J, Li T.Eur J Med Chem. 2024 Nov 15;278:116792. doi: 10.1016/j.ejmech.2024.116792. Epub 2024 Aug 26.PMID: 39217861

Mannose/stearyl chloride doubly functionalized polyethylenimine as a nucleic acid vaccine carrier to promote macrophage uptake.

Bai L, Chen X, Li C, Zhou H, Li Y, Xiao J, Zhang F, Cheng H, Zhou M.Drug Deliv. 2024 Dec;31(1):2427138. doi: 10.1080/10717544.2024.2427138. Epub 2024 Nov 14.PMID: 39540234

Rapid preparation and characterization of pan-sarbecovirus mRNA vaccine candidates based on the receptor binding domain.

Wu M, Cao TS, Xiong XC, Ming T, Shi PD, Zhang RR, Ye Q, Qin CF.Virol Sin. 2024 Nov 12:S1995-820X(24)00175-5. doi: 10.1016/j.virs.2024.11.004. Online ahead of print.PMID: 39542217

The impact of COVID-19 vaccination on patients with congenital heart disease in England: a case-control study.

Harrison C, Frain S, Jalalinajafabadi F, Williams SG, Keavney B; CVD-COVID-UK/COVID-IMPACT consortium.Heart. 2024 Nov 19;110(23):1372-1380. doi: 10.1136/heartjnl-2024-324470.PMID: 39393905

MTBVAC induces superior antibody titers and IgG avidity compared to BCG vaccination in non-human primates.

Peralta-Álvarez MP, Downward K, White A, Redondo Azema H, Sibley L, Sarfas C, Morrison A, Dennis M, Diaz-Santana D, Harris SA, Li S, Puentes E, Aguilo N, Martin C, Sharpe S, McShane H, Tanner R.NPJ Vaccines. 2024 Nov 20;9(1):230. doi: 10.1038/s41541-024-01009-5.PMID: 39567530

Phase 1 clinical trial of Hantaan and Puumala virus DNA vaccines delivered by needle-free injection.

Hooper JW, Kwilas SA, Josleyn M, Norris S, Hutter JN, Hamer M, Livezey J, Paolino K, Twomey P, Koren M, Keiser P, Moon JE, Nwaeze U, Koontz J, Ledesma-Feliciano C, Landry N, Wellington T.NPJ Vaccines. 2024 Nov 17;9(1):221. doi: 10.1038/s41541-024-00998-7.PMID: 39551791

A personalized vaccine combining immunogenic cell death-induced cells and nanosized antigens for enhanced antitumor immunity.

Yang Y, Zheng P, Duan B, Yang Y, Zheng X, Li W, Liu Q, Hu Y, Ma Y.J Control Release. 2024 Nov 12;376:1271-1287. doi: 10.1016/j.jconrel.2024.10.060. Online ahead of print.PMID: 39515613

Bioinformatics designing of an mRNA vaccine for Mokola virus (MOKV) using immunoinformatics as a secure strategy for successful vaccine development.

Oladipo EK, Ogunniran JA, Akinpelu OS, Omole TO, Adeyemo SF, Irewolede BA, Iwalokun BA, Ajani OF, Onyeaka H.BMC Immunol. 2024 Nov 20;25(1):77. doi: 10.1186/s12865-024-00668-2.PMID: 39563241

Draft genome of Aeromonas veronii DFR01, the inactivated bacterial agent in a fish oral vaccine against motile aeromonad septicemia.

Argayosa AM, Gloria PCT, Argayosa VB, Santos MNM.Microbiol Resour Announc. 2024 Nov 12;13(11):e0073324. doi: 10.1128/mra.00733-24. Epub 2024 Oct 14.PMID: 39400146

Autophagy-activating aluminum hydroxide nanovaccine for enhanced antigen presentation and anti-tumor immunity.

Chen D, Ling X, Wang Y, Zhang Q, He X, Dong Z, Li M, He Q.J Control Release. 2024 Nov 20;377:223-235. doi: 10.1016/j.jconrel.2024.11.018. Online ahead of print.PMID: 39547420

Cd loop fusion enhances the immunogenicity and the potential transmission blocking activity of Plasmodium falciparum generative cell specific 1 (GCS1) antigen.

Nourani L, Ayoub Meigouni M, Afzali S, Zargar M, Pourhashem Z, Yousefi H, Sani JJ, Vand-Rajabpour H, Pirahmadi S, Raz A, Abouie Mehrizi A.Biochem Biophys Res Commun. 2024 Nov 12;733:150599. doi: 10.1016/j.bbrc.2024.150599. Epub 2024 Aug 23.PMID: 39208643

Chimeric peptides targeting the receptor-binding domain of SARS-CoV-2 variants inhibit ACE2 interaction.

Ubonsri P, Panmanee J, Meewan I, Masrinoul P, Komaikul J, Piboonpocanun S.Asian Pac J Allergy Immunol. 2024 Nov 17. doi: 10.12932/AP-030424-1833. Online ahead of print.PMID: 39580631

Optimizing protocols for the 919 strain-based bovine ephemeral fever virus vaccine (Ultravac, Zoetis): Evaluation of dose-dependent effectiveness and long-term immunity.

Gleser D, Cohen M, Kenigswald G, Kedmi M, Sharir B, Klement E.Vaccine. 2024 Nov 22;43(Pt 2):126531. doi: 10.1016/j.vaccine.2024.126531. Online ahead of print.PMID: 39579670

Isolation and phylogenetic analysis of camel contagious ecthyma virus in Morocco.

Bamouh Z, Hamdi J, Elkarhat Z, Kichou F, Fellahi S, Watts DM, Elharrak M.Microb Pathog. 2024 Nov 17;198:107130. doi: 10.1016/j.micpath.2024.107130. Online ahead of print.PMID: 39561908

Modeling the epidemiologic impact of age-targeted vaccination for drug-resistant tuberculosis.

Zhai PY, Chen ZX, Jiang T, Feng J, Zhang B, Zang X, Zhao YL, Qin G.Drug Resist Updat. 2024 Nov 13;78:101172. doi: 10.1016/j.drup.2024.101172. Online ahead of print.PMID: 39541911

Preventing human influenza and coronaviral mono or coinfection by blocking virus-induced sialylation.

Amin MR, Anwar KN, Ashraf MJ, Ghassemi M, Novak RM.Antiviral Res. 2024 Nov 22:106041. doi: 10.1016/j.antiviral.2024.106041. Online ahead of print.PMID: 39581502

SARS-CoV-2 testing, test positivity and vaccination in social housing residents compared with the general population: a retrospective population-based cohort study.

Agarwal G, Keshavarz H, Angeles R, Pirrie M, Marzanek F, Nguyen F, Brar J, Paterson JM.J Epidemiol Community Health. 2024 Nov 15:jech-2024-222526. doi: 10.1136/jech-2024-222526. Online ahead of print.PMID: 39547795

Immunogenicity and safety of COVID-19 vaccines in patients with lung cancer : results of a systematic review and meta-analysis.

Zhang Z, Wang Y, Zhao J, Liu L, Ran P, Shu Y, Xu W, Fu G.Int Arch Allergy Immunol. 2024 Nov 18:1-18. doi: 10.1159/000542281. Online ahead of print.PMID: 39557036

Potential of histamine release factor for the utilization as a universal vaccine antigen against poultry red mites, tropical fowl mites, and northern fowl mites.

Win SY, Horio F, Sato J, Motai Y, Seo H, Fujisawa S, Sato T, Oishi E, Htun LL, Bawm S, Okagawa T, Maekawa N, Konnai S, Ohashi K, Murata S.J Vet Med Sci. 2024 Nov 20. doi: 10.1292/jvms.24-0186. Online ahead of print.PMID: 39567007

Teacher vaccinations enhance student achievement in Pakistan: The role of role models and theory of mind.

Mehmood S, Naseer S, Chen DL.Proc Natl Acad Sci U S A. 2024 Nov 26;121(48):e2406034121. doi: 10.1073/pnas.2406034121. Epub 2024 Nov 21.PMID: 39570313

Safety, efficacy, and immunogenicity of SARS-CoV-2 mRNA vaccination in children and adult patients with rheumatic diseases: a comprehensive literature review.

Dhanasekaran P, Karasu BT, Mak A.Rheumatol Int. 2024 Nov 22. doi: 10.1007/s00296-024-05734-x. Online ahead of print.PMID: 39576327

JYNNEOS vaccine safety surveillance in the vaccine safety datalink during the 2022 mpox outbreak in the United States.

Duffy J, Yih WK, Walton K, DeSilva MB, Glanz JM, Hambidge SJ, Jackson LA, Klein NP, Lewin BJ, Naleway AL, Sundaram ME, Maro JC, Weintraub E.Infection. 2024 Nov 20. doi: 10.1007/s15010-024-02428-1. Online ahead of print.PMID: 39565485

Addition of nucleotide adjuvants enhances the immunogenicity of a recombinant subunit vaccine against the Zika virus in BALB/c mice.

Valdes I, Suzarte E, Lazo L, Cobas K, Cabrales A, Pérez Y, Garateix R, Silva JA, Aguilar JC, Guzman CA, Guillén G.Vaccine. 2024 Nov 14;42(25):126213. doi: 10.1016/j.vaccine.2024.126213. Epub 2024 Aug 12.PMID: 39138071

The Rise of FLiRT Variants in the COVID-19 Pandemic: What We Know So Far.

Hussain MS, Gupta G.Curr Pharm Des. 2024 Nov 14. doi: 10.2174/0113816128355749241111045626. Online ahead of print.PMID: 39543874

Adults with low opsonic natural antibody levels against *Streptococcus pneumoniae* show enhanced response to PPSV23 vaccination.

Dharmavaram S, Nagaraj G, Natesan S, Subbanna M, Kadahalli Lingegowda R.J Immunoassay Immunochem. 2024 Nov 19:1-20. doi: 10.1080/15321819.2024.2430344. Online ahead of print.PMID: 39560284

The use of community-oriented primary care (COPC) model to generate vaccine demand: The case of a remote fishing community in Cameroon.

Sangwe CN, Budzi MN, Shifu IN, Ghangha JG, Njedock SN.Vaccine. 2024 Nov 14;42 Suppl 5:126173. doi: 10.1016/j.vaccine.2024.126173. Epub 2024 Jul 31.PMID: 39089959

Effective integration of COVID-19 vaccination with routine immunization: A case study from Kinshasa, DRC.

Mwamba G, Gibson EM, Toko C, Tunda C, Kouabenan YR, Musenga J, Waula B, Nkosi F, Nkima MMC, Mupenda J, Lawrence E, Zameer M, Musumari P.Vaccine. 2024 Nov 14;42 Suppl 5:126392. doi: 10.1016/j.vaccine.2024.126392. Epub 2024 Oct 5.PMID: 39368940

Schistosoma heamatobium tetraspanins TSP-2 and TSP-6 induce Dendritic Cells maturation, cytokine production and T helper cells differentiation in vitro.

Silvano A, Sotillo J, Cecchi M, Loukas A, Ouedraogo M, Parenti A, Bruschi F, Torcia MG, Mangano VD.Microbes Infect. 2024 Nov 15:105439. doi: 10.1016/j.micinf.2024.105439. Online ahead of print.PMID: 39549890

Optimisation of a multiplexed, high throughput assay to measure neutralising antibodies against SARS-CoV-2 variants.

Ashley CL, Bloul M, Alca S, Smith L, Jin W, Khoury D, Counoupas C, Davenport M, Triccas JA, Steain M.J Virol Methods. 2024 Nov 16;332:115073. doi: 10.1016/j.jviromet.2024.115073. Online ahead of print.PMID: 39557342

A foldon-free prefusion F trimer vaccine for respiratory syncytial virus to reduce off-target immune responses.

Bakkers MJG, Cox F, Koornneef A, Yu X, van Overveld D, Le L, van den Hoogen W, Vaneman J, Thoma A, Voorzaat R, Tettero L, Juraszek J, van der Fits L, Zahn R, Langedijk JPM.Nat Microbiol. 2024 Nov 20. doi: 10.1038/s41564-024-01860-1. Online ahead of print.PMID: 39567664

Machine learning algorithms for prediction of measles one vaccination dropout among 12-23 months children in Ethiopia.

Alemayehu MA.BMJ Open. 2024 Nov 14;14(11):e089764. doi: 10.1136/bmjopen-2024-089764.PMID: 39542486

GeM-LR: Discovering predictive biomarkers for small datasets in vaccine studies.

Lin L, Spreng RL, Seaton KE, Dennison SM, Dahora LC, Schuster DJ, Sawant S, Gilbert PB, Fong Y, Kisalu N, Pollard AJ, Tomaras GD, Li J.PLoS Comput Biol. 2024 Nov 14;20(11):e1012581. doi: 10.1371/journal.pcbi.1012581. Online ahead of print.PMID: 39541411

Bias and negative values of COVID-19 vaccine effectiveness estimates from a test-negative design without controlling for prior SARS-CoV-2 infection.

Wiegand RE, Fireman B, Najdowski M, Tenforde MW, Link-Gelles R, Ferdinands JM.Nat Commun. 2024 Nov 20;15(1):10062. doi: 10.1038/s41467-024-54404-w.PMID: 39567531

Microfluidic qPCR for detection of 21 common respiratory viruses in children with influenza-like illness.

Saville TJ, Colton H, Jarju S, Armitage EP, Drammeh S, Tazzyman S, Jagne YJ, Sallah HJ, Senghore E, Evans CM, Darton TC, de Silva TI.Sci Rep. 2024 Nov 16;14(1):28292. doi: 10.1038/s41598-024-79407-x.PMID: 39550452

Adults aged 65 years and older in South Africa have a responsibility to vaccinate against influenza.

Sarangarajan R, Ewuoso C.Dev World Bioeth. 2024 Nov 18. doi: 10.1111/dewb.12470. Online ahead of print.PMID: 39555899

Optimal timing of recombinant herpes zoster virus vaccination for a JAK inhibitor treatment in rheumatoid arthritis: a multicentre, open-label, randomised comparative study (STOP-HZ study): study protocol.

Takanashi S, Ohmura K, Misaki K, Ihata A, Matsui T, Tohma S, Saegusa J, Sato S, Matsubara T, Yamaoka K, Amano K, Miyamoto T, Mori Y, Kaneko Y.BMJ Open. 2024 Nov 17;14(11):e090668. doi: 10.1136/bmjopen-2024-090668.PMID: 39551586

Genetic analysis of the circumsporozoite gene in Plasmodium falciparum isolates from Cameroon: Implications for efficacy and deployment of RTS,S/AS01 vaccine.

Kojom Foko LP, Hawadak J, Eboumbou Moukoko CE, Das A, Singh V.Gene. 2024 Nov 15;927:148744. doi: 10.1016/j.gene.2024.148744. Epub 2024 Jul 2.PMID: 38964492

Co-expression gene module analysis in response to attenuated cercaria vaccine reveals a critical role for NK cells in protection against Schistosoma mansoni.

Neto APDS, Vitoriano-Souza J, Khouri MI, Favaro RD, Wilson RA, Leite LCC, Ramos PIP, Farias LP.Parasit Vectors. 2024 Nov 19;17(1):476. doi: 10.1186/s13071-024-06505-0.PMID: 39563428

Health and Economic Impacts of Introducing Vaccae and Enhanced Drug-Resistant Tuberculosis Management Strategies in China.

Zhai PY, Zang X, Jiang T, Feng J, Zhang B, Zhang L, Chen ZX, Zhao YL, Qin G.J Infect Dis. 2024 Nov 22:jiae590. doi: 10.1093/infdis/jiae590. Online ahead of print.PMID: 39576253

Ethical issues in vaccine trial participation by adolescents: qualitative insights on family decision making from a human papillomavirus vaccine trial in Tanzania.

Frost L, Erio MT, Whitworth H, Marwerwe MG, Hayes R, Baisley K, de SanJosé S, Watson-Jones D, Mitchell K.BMC Med Ethics. 2024 Nov 20;25(1):134. doi: 10.1186/s12910-024-01122-z.PMID: 39563292

Unlocking marine microbial treasures: new PBP2a-targeted antibiotics elicited by metals and enhanced by RSM-driven transcriptomics and chemoinformatics.

Hassan SSU, Wu J, Li T, Ye X, Rehman A, Yan S, Jin H.Microb Cell Fact. 2024 Nov 12;23(1):303. doi: 10.1186/s12934-024-02573-0.PMID: 39529027

Transcriptomic analysis of liver immune response in Chinese spiny frog (*Quasipaa spinosa*) infected with *Proteus mirabilis*.

Liu W, Tao YH, Chen J, Lu CP, Zhang L, Lin ZH.Open Life Sci. 2024 Nov 19;19(1):20221003. doi: 10.1515/biol-2022-1003. eCollection 2024.PMID: 39588112

The effect of pre-COVID and post-COVID vaccination on long COVID: a systematic review and meta-analysis.

Chow KN, Tsang YW, Chan YH, Telaga SA, Ng LYA, Chung CM, Yip YM, Cheung PPH.J Infect. 2024 Nov 21:106358. doi: 10.1016/j.jinf.2024.106358. Online ahead of print.PMID: 39580033

Researchers Are Exploring the Role of Shingles-and a Protective Role of Shingles Vaccine-in Dementia.

Rubin R.JAMA. 2024 Nov 12;332(18):1505-1507. doi: 10.1001/jama.2024.0227.PMID: 39422893

Systematic literature review on the clinical and economic burden of human papillomavirus-related diseases in select areas in the Asia-Pacific region.

Lou PJ, Phongsamart W, Sukarom I, Wu YH, Zaidi O, Du F, Simon A, Bernauer M.Hum Vaccin Immunother. 2024 Dec 31;20(1):2425535. doi: 10.1080/21645515.2024.2425535. Epub 2024 Nov 18.PMID: 39552456

Safety and immunogenicity of freeze-dried human rabies vaccines: A phase 3 clinical trial of Zagreb and Essen regimes.

Li J, Wu Z, Wu X, Wang Y, Shi L, Zhao D, Liang H, Mo Z, Cao S.Hum Vaccin Immunother. 2024 Dec 31;20(1):2426289. doi: 10.1080/21645515.2024.2426289. Epub 2024 Nov 13.PMID: 39535124

Dr. Jekyll and Mr. Hyde in sand fly saliva.

Kato H.Parasitol Int. 2024 Nov 22:102998. doi: 10.1016/j.parint.2024.102998. Online ahead of print.PMID: 39581305

Serum TARC Level as a Predictive Marker of Severe Disease in COVID-19 During the Omicron Variant Period of the Pandemic.

Isono T, Kojima A, Nishida T, Kobayashi Y, Ishiguro T, Takaku Y, Kagiyama N, Kurashima K.Intern Med. 2024 Nov 21. doi: 10.2169/internalmedicine.4276-24. Online ahead of print.PMID: 39566990

Quantitative and qualitative analysis of seroconversion after one year of vaccination with inactivated SARS-CoV-2 vaccine (CoronaVac) in healthcare workers: Cross-sectional analytical study.

da Silva JG, Arruk VG, Veiga GRLD, Sousa LVA, Alves BDCA, Fonseca FLA, van der Heijden Natário IM.J Virol Methods. 2024 Nov 15;332:115067. doi: 10.1016/j.jviromet.2024.115067. Online ahead of print.PMID: 39551445

A Lassa virus live attenuated vaccine candidate that is safe and efficacious in guinea pigs.

Carey BD, Yu S, Geiger J, Ye C, Huzella LM, Reeder RJ, Mehta M, Hirsch S, Bernbaum R, Cubitt B, Pahar B, Anthony SM, Marketon A, Bernbaum JG, Tran JP, Crozier I, Martínez-Sobrido L, Worwa G, de la Torre JC, Kuhn JH.NPJ Vaccines. 2024 Nov 17;9(1):220. doi: 10.1038/s41541-024-01012-w.PMID: 39551823

Promoting Workplace Health, Safety, and Well-Being Among Essential Agricultural Workers Through Vaccine-Preventable Infectious Diseases Training in the Rio Grande Valley.

Rodriguez A, Douphrate DI, Pineda Reyes AL, Zavala S, Cabrera Cruz AV, Alegria MD, Ukaegbu B, Keeney AJ, Berumen-Flucker B, Shipp EM, Guillot-Wright SP, Fernandez-Esquer ME, Gimeno Ruiz de Porras D.J

Agromedicine. 2024 Nov 13:1-11. doi: 10.1080/1059924X.2024.2421249. Online ahead of print.PMID: 39537616

Cross-reactivity between dengue virus and SARS-CoV-2 antibodies: Confirmation study using specimens from dengue-infected patients before the COVID-19 pandemic.

Churrotin S, Amarullah IH, Fitria AL, Khairunisa SQ, Yamani LN, Kameoka M, Anggraeni N, Nurhariansyah R, Husada D, Wungu CDK.Heliyon. 2024 Oct 18;10(21):e39099. doi: 10.1016/j.heliyon.2024.e39099. eCollection 2024 Nov 15.PMID: 39524770

PepCARES: A Comprehensive Advanced Refinement and Evaluation System for Peptide Design and Affinity Screening.

Xu W, Wu Z, Zhang C, Zhu C, Duan H.ACS Omega. 2024 Nov 11;9(46):46429-46438. doi: 10.1021/acsomega.4c07682. eCollection 2024 Nov 19.PMID: 39583700

Awareness and Knowledge of Hepatitis B Vaccination Among Newly Enrolled First-Year Medical Undergraduates in South India: A Cross-Sectional Survey.

K G R, D H K, Madalageri NK, Rangareddy H.Cureus. 2024 Nov 13;16(11):e73567. doi: 10.7759/cureus.73567. eCollection 2024 Nov.PMID: 39540194

Leveraging the potential of bacterial lateral gene transfer in boosting the efficacy of an edible probiotic prototype yogurt vaccine for COVID-19.

Vissapragada M, Addala S, Aggunna M, Sodasani M, Grandhi AVKS, Yedidi RS.Biochem Biophys Res Commun. 2024 Nov 19;734:150622. doi: 10.1016/j.bbrc.2024.150622. Epub 2024 Aug 29.PMID: 39216410

Incidence of pneumococcal disease in children in Germany, 2014-2019: a retrospective cohort study.

Weaver J, Hu T, Podmore B, Barnett R, Obermüller D, Galetzka W, Qizilbash N, Haeckl D, Weiss T, Mohanty S, White M, Boellinger T.BMC Pediatr. 2024 Nov 20;24(1):755. doi: 10.1186/s12887-024-05003-7.PMID: 39567949

A non-classical view of antibody properties: Allosteric effect between variable and constant regions.

Yu X, Zhang H, Zhou T, Pan K, Raza SHA, Shen X, Lei H.Biotechnol Adv. 2024 Nov 21;78:108482. doi: 10.1016/j.biotechadv.2024.108482. Online ahead of print.PMID: 39579911

Characterizing the interactions between influenza and respiratory syncytial viruses and their implications for epidemic control.

Kramer SC, Pirikahu S, Casalegno JS, Domenech de Cellès M.Nat Commun. 2024 Nov 20;15(1):10066. doi: 10.1038/s41467-024-53872-4.PMID: 39567519

Development of a candidate vaccine against severe fever with thrombocytopenia syndrome virus using Gn/Gc glycoprotein via multiple expression vectors delivered by attenuated Salmonella confers effective protection in hDC-SIGN transduced mice.

Park JY, Senevirathne A, Lee JH.Vaccine. 2024 Nov 14;43(Pt 1):126524. doi: 10.1016/j.vaccine.2024.126524. Online ahead of print.PMID: 39547019

Intranasal immunization with CPAF combined with ADU-S100 induces an effector CD4 T cell response and reduces bacterial burden following intravaginal infection with Chlamydia muridarum.

Poston TB, Girardi J, Kim M, Zwarycz P, Polson AG, Yount KS, Hanlan C, Jaras Salas I, Lammert SM, Arroyo D, Bruno T, Wu M, Rozzelle J, Fairman J, Esser-Kahn AP, Darville T.Vaccine. 2024 Nov 12;43(Pt 1):126526. doi: 10.1016/j.vaccine.2024.126526. Online ahead of print.PMID: 39536454

A Novel Cell- and Virus-Free SARS-CoV-2 Neutralizing Antibody ELISA Based on Site-Specific Labeling Technology.

Liu H, Liu T, Wang A, Liang C, Zhu X, Zhou J, Chen Y, Liu Y, Qi Y, Chen W, Zhang G.Anal Chem. 2024 Nov 19;96(46):18437-18444. doi: 10.1021/acs.analchem.4c03574. Epub 2024 Nov 7.PMID: 39506608

Therapeutic efficacy of SipD/LptD-specific IgY entrapped in alginate nanoparticles against *Salmonella* Typhimurium infection.

Zafarmand-Samarin M, Nazarian S, Aghaie SM, Sadeghi D, Samiei-Abianeh H, Felegary A.Heliyon. 2024 Oct 24;10(21):e39650. doi: 10.1016/j.heliyon.2024.e39650. eCollection 2024 Nov 15.PMID: 39524789

Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines.

Cortés G, Ustyugova I, Farrell T, McDaniel C, Britain C, Romano C, N'Diaye S, Zheng L, Ferdous M, Iampietro J, Pougatcheva S, La Rue L, Han L, Ma F, Stegalkina S, Ray S, Zhang J, Barro M.NPJ Vaccines. 2024 Nov 19;9(1):228. doi: 10.1038/s41541-024-01011-x.PMID: 39562599

Effects of immune response on different nano-adjuvants combined with H11 antigen of Haemonchus contortus.

Ye L, Wang T, Wu S, Liu H, Liu F, Wang C, Hu M.Int Immunopharmacol. 2024 Nov 12;143(Pt 3):113602. doi: 10.1016/j.intimp.2024.113602. Online ahead of print.PMID: 39536488

Overcoming barriers of cervical cancer elimination in India: A practice to policy level advocacy.

Poddar A, Rao SR.J Cancer Policy. 2024 Nov 13;43:100521. doi: 10.1016/j.jcpo.2024.100521. Online ahead of print.PMID: 39542420

Report from the World Health Organization's immunization and vaccines-related implementation research advisory committee (IVIR-AC) meeting, virtual gathering, 10-13 September 2024.

Lambach P, Silal S, Sbarra AN, Koh M, Aggarwal R, Farooqui HH, Flasche S, Hogan AB, Kim SY, Leung K, Moss WJ, Munywoki PK, Portnoy A, Sheel M, Wang XY.Vaccine. 2024 Nov 12;43(Pt 2):126519. doi: 10.1016/j.vaccine.2024.126519. Online ahead of print.PMID: 39536476

"Vaccines protect both you and your newborn:" A discourse analysis of risk and uncertainty in information about vaccination in pregnancy.

Manca T.Soc Sci Med. 2024 Nov 16;364:117526. doi: 10.1016/j.socscimed.2024.117526. Online ahead of print.PMID: 39577165

Challenges of using the test-negative design to measure vaccine effectiveness of multi-pathogen combination vaccines targeting one syndrome.

Kim SS, Garcia Quesada M, Prasad PV, Nelson KN, Lopman BA, Rogawski McQuade ET.Vaccine. 2024 Nov 12:126520. doi: 10.1016/j.vaccine.2024.126520. Online ahead of print.PMID: 39537464

Preclinical evaluation of a universal inactivated influenza B vaccine based on the mosaic hemagglutinin-approach.

González-Domínguez I, Puente-Massaguer E, Abdeljawad A, Lai TY, Liu Y, Loganathan M, Francis B, Lemus N, Dolange V, Boza M, Slamanig S, Martínez-Guevara JL, Krammer F, Palese P, Sun W.NPJ Vaccines. 2024 Nov 17;9(1):222. doi: 10.1038/s41541-024-01014-8.PMID: 39551795

High prevalence of 19A pneumococcal serotype carriage during the COVID-19 pandemic in Brazil.

Primon-Barros M, Varela FH, Polese-Bonatto M, Sartor ITS, Azevedo TR, de David CN, Tonini ML, Stein RT, Scotta MC, Dias CAG.Braz J Infect Dis. 2024 Nov 21;28(6):104467. doi: 10.1016/j.bjid.2024.104467. Online ahead of print.PMID: 39577042

Healthcare workers' opinions on non-medical criteria for prioritisation of access to care during the pandemic.

Haaser T, Maternowski PJ, Marty S, Duc S, Mollier O, Poullenot F, Sureau P, Avérous V.BMC Med Ethics. 2024 Nov 19;25(1):133. doi: 10.1186/s12910-024-01136-7.PMID: 39563332

Modeling the health and economic implications of adopting a 1-dose 9-valent human papillomavirus vaccination program in adolescents in low/middle-income countries: An analysis of Indonesia.

Daniels V, Saxena K, Patterson-Lomba O, Gomez-Lievano A, At Thobari J, Durand N, Myers E.PLoS One. 2024 Nov 21;19(11):e0310591. doi: 10.1371/journal.pone.0310591. eCollection 2024.PMID: 39570910

Americans' willingness to give to global immunization programs: Political heterogeneity in preferences for program management and response to priming communications.

Vásquez WF, Trudeau JM.Vaccine. 2024 Nov 14;42(25):126126. doi: 10.1016/j.vaccine.2024.07.027. Epub 2024 Jul 19.PMID: 39030081

Transcription and Copy Number Variation of Plasmodium falciparum var2csa among Nonpregnant Malaria Patients in Thailand.

Chaikitgosiyakul S, Kuamsab N, Tia T, Putaporntip C, Jongwutiwes S.Am J Trop Med Hyg. 2024 Nov 19:tpmd240065. doi: 10.4269/ajtmh.24-0065. Online ahead of print.PMID: 39561405

Zika virus remodels and hijacks IGF2BP2 ribonucleoprotein complex to promote viral replication organelle biogenesis.

Mazeaud C, Pfister S, Owen JE, Pereira HS, Charbonneau F, Robinson ZE, Anton A, Bemis CL, Sow AA, Patel TR, Neufeldt CJ, Scaturro P, Chatel-Chaix L.Elife. 2024 Nov 20;13:RP94347. doi: 10.7554/eLife.94347.PMID: 39565347

Factors related to acceptance of COVID-19 vaccine booster doses among patients with autoimmune and rheumatic diseases in Japan: A single-center cross-sectional survey.

Kurokawa R, Ohde S, Kawaai S, Tamaki H.Mod Rheumatol. 2024 Nov 16:roae102. doi: 10.1093/mr/roae102. Online ahead of print.PMID: 39548756

Shedding of nontyphoidal *Salmonella* by asymptomatic convalescing children under 5 years as a risk factor for invasive disease in Mukuru informal settlement in Nairobi, Kenya.

Kering K, Njaanake K, Wairimu C, Mureithi M, Kebenei C, Odityo G, Mugo M, Kavai SM, Mbae C, Weber K, Pietsch M, Pilz T, Drechsel O, Thürmer A, Semmler T, Fuchs S, Simon S, Flieger A, Wieler LH, Kariuki S.J Clin Microbiol. 2024 Nov 13;62(11):e0075024. doi: 10.1128/jcm.00750-24. Epub 2024 Oct 24.PMID: 39445835

Post-COVID recovery is faster after an infection with the SARS-CoV-2 Omicron variant: a population-based cohort study.

Pfrommer LR, Diexer S, Klee B, Massag J, Gottschick C, Purschke O, Binder M, Frese T, Girndt M, Sedding D, Rosendahl J, Hoell JI, Moor I, Gekle M, Allwang C, Junne F, Mikolajczyk R.Infection. 2024 Nov 18. doi: 10.1007/s15010-024-02438-z. Online ahead of print.PMID: 39556163

Real-world comparative effectiveness of a third dose of mRNA-1273 versus BNT162b2 among adults aged ≥ 65 years in the United States.

Kirk B, Bush C, Toyip A, Mues KE, Beck E, Li L, St Laurent S, Georgieva M, Marks MA, Sun T, Esposito DB, Martin D, Van de Velde N.Vaccine. 2024 Nov 14;42(25):126113. doi: 10.1016/j.vaccine.2024.07.014. Epub 2024 Jul 18.PMID: 39030080

Preclinical development of lyophilized self-replicating RNA vaccines for COVID-19 and malaria with improved long-term thermostability.

Gulati GK, Simpson AC, MacMillen Z, Krieger K, Sharma S, Erasmus JH, Reed SG, Davie JW, Avril M, Khandhar AP.J Control Release. 2024 Nov 17;377:81-92. doi: 10.1016/j.jconrel.2024.11.023. Online ahead of print.PMID: 39547422

Secondary healthcare resource utilization and related costs associated with influenza-related hospital admissions in adult patients, England 2016 - 2020.

de Courville C, Bricout H, Alvarez FP, Clouting J, Patel S, Mohamed H, Giblin S, Coles B.Expert Rev Pharmacoecon Outcomes Res. 2024 Nov 14:1-13. doi: 10.1080/14737167.2024.2427307. Online ahead of print.PMID: 39512142

Opinion Leadership and Sharing Positive and Negative Information About Vaccines on Social Media: A Mixed-Methods Approach.

Wang X, Lin Z, Shi J, Sun Y.J Health Commun. 2024 Nov 18:1-9. doi: 10.1080/10810730.2024.2426810. Online ahead of print.PMID: 39557511

Coverage with Influenza, Respiratory Syncytial Virus, and COVID-19 Vaccines Among Nursing Home Residents - National Healthcare Safety Network, United States, November 2024.

Reses HE, Segovia G, Dubendris H, Barbre K, Ananth S, Lape-Newman B, Wong E, Stillions M, Rowe T, Mothershed E, Wallender E, Twentyman E, Wiegand RE, Patel P, Benin A, Bell JM.MMWR Morb Mortal Wkly Rep. 2024 Nov 21;73(46):1052-1057. doi: 10.15585/mmwr.mm7346a2.PMID: 39570790

Origin tracking of Brucella strain B. melitensis bv.3 ARQ-070 using biochemical and genomic studies.

Ta N, Zuo KM, Gao J, Guan N, Song LT, Wen YJ, Yu RP.FEMS Microbiol Lett. 2024 Nov 13:fnae085. doi: 10.1093/femsle/fnae085. Online ahead of print.PMID: 39537199

GP consultations for menstrual disorders after COVID-19 vaccination - A self-controlled cohort study based on routine healthcare data from the Netherlands.

Jajou R, Lieber T, van Puijenbroek EP, Mulder E, Overbeek J, Hek K, van Hunsel FPAM, Kant A.Vaccine. 2024 Nov 14;42(25):126130. doi: 10.1016/j.vaccine.2024.07.031. Epub 2024 Aug 23.PMID: 39004527

A three antigen hepatitis B vaccine induces T cells to Pres1 and Pres2 which correlate with anti HBs antibody titers: An investigation into the immunological mechanisms contributing to high anti-HBs titers.

Berthoud TK, Ahmed T, Nadia W, Petrov I, Yang L, Colledge D, Hammond R, Soare C, Ontsouka B, Plaskin D, Anderson DE, Diaz-Mitoma F.Vaccine. 2024 Nov 12;43(Pt 2):126513. doi: 10.1016/j.vaccine.2024.126513. Online ahead of print.PMID: 39536477

Efficient Neutralizing Antibodies Induction by Human Parvovirus B19 Epitope-Presenting Protein Nanoparticles.

Kimura S, Suzuki H, Hatakeyama Y, Noguchi T, Ii K, Nakamura K, Ebina H, Morita E.Microbiol Immunol. 2024 Nov 15. doi: 10.1111/1348-0421.13182. Online ahead of print.PMID: 39545388

Exploring the sequence diversity and surface expression of Factor H-Binding Protein among invasive serogroup B meningococcal strains from selected European countries.

Clark SA, Willerton L, Claus H, Carannante A, Stefanelli P, Abad R, Vázquez JA, Borrow R.Hum Vaccin Immunother. 2024 Dec 31;20(1):2427471. doi: 10.1080/21645515.2024.2427471. Epub 2024 Nov 13.PMID: 39536321

Evaluation of the impact of hollow fiber pore size and membrane material on virus concentration using a handheld hollow fiber method.

Higuchi S, Satou T, Uchida Y.J Virol Methods. 2024 Nov 13:115065. doi: 10.1016/j.jviromet.2024.115065. Online ahead of print.PMID: 39547271

Randomized trial of BCG in healthcare workers to reduce absenteeism during the COVID-19 pandemic in sub-Saharan Africa.

Silva I, Nhamússua L, Ca E, Schaltz-Buchholzer F, Nhama A, Cumbe M, Delgado AP, Lima Mendonça ML, Fontoura P, Sidat M, Ferrinho P, Araújo II, Aide P, Benn C, Fronteira I, Nielsen S.Trans R Soc Trop Med Hyg. 2024 Nov 20:trae108. doi: 10.1093/trstmh/trae108. Online ahead of print.PMID: 39565890

Mesomycoplasma (Mycoplasma) ovipneumoniae dihydrolipoamide dehydrogenase is an immunogenic plasminogen binding protein and a putative adhesin.

Ge J, Tian T, Liu Y, Li X, Li Q, Song G, Gao P, Zheng F, Chu Y.Vet Microbiol. 2024 Nov 12;299:110302. doi: 10.1016/j.vetmic.2024.110302. Online ahead of print.PMID: 39550931

Vaccination strategies in a pair formation model for human papillomavirus infection: An optimal control approach.

Saldaña F.J Theor Biol. 2024 Nov 16;597:111994. doi: 10.1016/j.jtbi.2024.111994. Online ahead of print.PMID: 39557360

Immunization-related stress and stress-related responses of mucosal versus intramuscular COVID-19 vaccination among adults in China.

Jiang M, Zhang H, Yao X, Wang Y, Lai X, Fang H.Vaccine. 2024 Nov 14;42(25):126150. doi: 10.1016/j.vaccine.2024.07.051. Epub 2024 Aug 1.PMID: 39095276

The relationship between the recurrence rate of genital warts and administration of quadrivalent human papilloma virus vaccine in women.

Asl FM, Ghaffari P, Safari M.Diagn Microbiol Infect Dis. 2024 Nov 16;111(2):116607. doi: 10.1016/j.diagmicrobio.2024.116607. Online ahead of print.PMID: 39580907

The United Nations' ambitious roadmap against tuberculosis: opportunities, challenges and the imperative of equity.

Gulumbe BH, Abdulrahim A, Danlami MB.Future Sci OA. 2024 Dec 31;10(1):2418787. doi: 10.1080/20565623.2024.2418787. Epub 2024 Nov 14.PMID: 39539153

Correction to: Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged 18 Years.

[No authors listed]Clin Infect Dis. 2024 Nov 22;79(5):1327. doi: 10.1093/cid/ciae389.PMID: 39207764

Possible rapid reduction of anti-RBD antibody titre after SARS-CoV-2 mRNA vaccination in pregnant women: Multicentre prospective study.

Ohta M, Kawasaki K, Yamamoto R, Ishii K, Nakano K, Akada S, Doh K, Shimaoka M, Ota H, Moriuchi K, Shiro R, Yo Y, Yoshida K, Tohda Y, Matsumura N.J Obstet Gynaecol Res. 2024 Nov 12. doi: 10.1111/jog.16150. Online ahead of print.PMID: 39530282

Monkeypox virus A29L protein as the target for specific diagnosis and serological analysis.

Liang CY, Chao TL, Chao CS, Liu WD, Cheng YC, Chang SY, Chang SC.Appl Microbiol Biotechnol. 2024 Nov 21;108(1):522. doi: 10.1007/s00253-024-13361-6.PMID: 39570405

Non-RBD peptides of SARS-CoV-2 spike protein exhibit immunodominance as they elicit both innate and adaptive immune responses.

Rathore D, Chauhan P, Bonagiri A, Gandhi L, Maisnam D, Kumar R, Row AT, Kesavulu MM, Venkataramana M.Heliyon. 2024 Oct 29;10(21):e39941. doi: 10.1016/j.heliyon.2024.e39941. eCollection 2024 Nov 15.PMID: 39568852

Modular Display of *Plasmodium yoelii* Circumsporozoite Surface Protein and Merozoite Surface Protein-1 on Norovirus-like Particles.

Boonyakida J, Nakayama K, Kusakisako K, Ikadai H, Park EY.Bioconjug Chem. 2024 Nov 20. doi: 10.1021/acs.bioconjchem.4c00460. Online ahead of print.PMID: 39564748

Antibiotic resistance and serotype distribution of *Shigella* strains in Bangladesh over the period of 2014-2022: evidence from a nationwide hospital-based surveillance for cholera and other diarrheal diseases.

Afrad MH, Islam MT, Begum YA, Saifullah M, Ahmmed F, Khan ZH, Habib ZH, Alam AN, Shirin T, Bhuiyan TR, Ryan ET, Khan AI, Qadri F.Microbiol Spectr. 2024 Nov 14:e0073924. doi: 10.1128/spectrum.00739-24. Online ahead of print.PMID: 39540737

Medium-term immunogenicity of three doses of BNT162b2 and CoronaVac in Hong Kong neuromuscular disease patients.

Yu MKL, Chan SHS, Leung D, Cheng S, Tsang LCH, Kwan TC, Zhang K, Wang X, Tu W, Peiris M, Lau YL, Rosa Duque JS.Hum Vaccin Immunother. 2024 Dec 31;20(1):2424615. doi: 10.1080/21645515.2024.2424615. Epub 2024 Nov 13.PMID: 39539036

Control of Coxiella burnetii shedding in a dairy goat herd by annual offspring vaccination.

Bauer BU, Herms TL, Jahnke R, Ossowski N, Walter MC, Frangoulidis D, Runge M, Ganter M, Knittler MR.Vaccine. 2024 Nov 14;42(25):126125. doi: 10.1016/j.vaccine.2024.07.026. Epub 2024 Jul 18.PMID: 39025699

Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques.

Nkolola JP, Hope D, Guan R, Colarusso A, Aid M, Weiss D, Misamore J, Andersen H, Lewis MG, Williamson L, Carnahan RH, Crowe JE Jr, Barouch DH.J Virol. 2024 Nov 15:e0142924. doi: 10.1128/jvi.01429-24. Online ahead of print.PMID: 39545728

Dissecting immunological mechanisms underlying influenza viral nucleoprotein-induced mucosal immunity against diverse viral strains.

Zhang W, Sloan A, Prévost J, Tamming L, Raman S, Pfeifle A, Gravel C, Chen W, Hashem AM, Wu J, Cao J, Johnston MJW, Wang L, Sauve S, Rosu-Myles M, Kobasa D, Safronetz D, Li X.Emerg Microbes Infect. 2024 Dec;13(1):2427792. doi: 10.1080/22221751.2024.2427792. Epub 2024 Nov 21.PMID: 39508450

VP8 Mosaic Nanoparticles Elicit Cross-Neutralizing Immune Responses and Provide Protection Against Heterotypic Rotavirus Challenge in Mice.

Song F, Zeng Y, Sheng R, Lin Y, Wang X, Hong C, Luo G, Wang Y, Fang M, He S, Zhang S, Zheng Q, Li T, Ge S, Zhang J, Xia N.ACS Nano. 2024 Nov 19;18(46):31809-31822. doi: 10.1021/acsnano.4c07061. Epub 2024 Nov 5.PMID: 39497609

Detection of *Hepatovirus A* (HAV) in wastewater indicates widespread national distribution and association with socioeconomic indicators of vulnerability.

Zulli A, Chan EMG, Boehm AB.mSphere. 2024 Nov 21;9(11):e0064524. doi: 10.1128/msphere.00645-24. Epub 2024 Oct 30.PMID: 39475316

Identification of raccoon rabies virus variant in a stray kitten: the role of veterinary practitioners in detection and reporting of a non-native zoonotic pathogen-Nebraska, 2023.

Carpenter A, Price ER, Stein SR, Beron AJ, Divis A, Mix S, Hess AR, Nelson KM, Wetzel CT, Fredrick J, Huse L, Horn A, Loy DS, Loy JD, Morgan CN, Rodriguez SE, Shelus V, Gigante CM, Hutson CL, Orciari LA, Swedberg C, Boutelle C, Chipman RB, Donahue M, Wallace RM, Buss BF.J Am Vet Med Assoc. 2024 Nov 15:1-4. doi: 10.2460/javma.24.08.0542. Online ahead of print.PMID: 39549410

Mucosal immunization with the lung Lactobacillus-derived amphiphilic exopolysaccharide adjuvanted recombinant vaccine improved protection against P. aeruginosa infection.

Zhang H, Sheng S, Li C, Bao X, Zhao L, Chen J, Guan P, Li X, Pan N, Liang Y, Wang X, Sun J, Wang X.PLoS Pathog. 2024 Nov 18;20(11):e1012696. doi: 10.1371/journal.ppat.1012696. Online ahead of print.PMID: 39556597

Evaluation of the Immunoadjuvant Effects of miR-155-Chitosan Polyplex on *Leishmania major* Infected Mice.

Pourabbasi Ardekan A, Haghighi A, Mohammadi-Yeganeh S, Ghorbani-Bidkorpeh F, Kashefi S, Koochaki A, Movahedi S, Rahmani Y, Najafi Dastenaei A, Haji Molla Hoseini M.Immunol Invest. 2024 Nov 21:1-17. doi: 10.1080/08820139.2024.2430695. Online ahead of print.PMID: 39569986

A statistically established reference value determined for the Vaxarray Coronavirus (CoV) seroassay to characterize vaccination and natural infection.

Porras FM, Pineda G, Mangilog A, Hernandez K, Sikorski C, Lane M.BMC Infect Dis. 2024 Nov 15;24(1):1308. doi: 10.1186/s12879-024-10117-5.PMID: 39548371

Declining genetic polymorphism of the C-terminus Merozoite Surface Protein-1 amidst increased Plasmodium knowlesi transmission in Thailand.

Tapaopong P, Chainarin S, Mala A, Rannarong A, Kangkasikorn N, Kusolsuk T, Roobsoong W, Cui L, Nguitragool W, Sattabongkot J, Bantuchai S.Malar J. 2024 Nov 13;23(1):342. doi: 10.1186/s12936-024-05162-z.PMID: 39538241

Public Health Policy that Leads with Equity in Rural Appalachia: Recommendations to Confirm Vaccination Status in an Equitable Manner.

Tyson JS, Scalise D, Hege A, Sugg M, Roy M.Disaster Med Public Health Prep. 2024 Nov 22;18:e284. doi: 10.1017/dmp.2024.277.PMID: 39573912

Development of a Versatile Cancer Vaccine Format Targeting Antigen-Presenting Cells Using Proximity-Based Sortase A-Mediated Ligation of T-Cell Epitopes.

Wang AZ, Brink HJ, Bouma RG, Affandi AJ, Nijen Twilhaar MK, Heijnen DAM, van Elk J, Maaskant JJ, Konijn VAL, Stolwijk JGC, Kalay H, Olesek K, van Kooyk Y, van der Schoot JMS, Bentlage AEH, Scheeren FA, Verdoes M, Vidarsson G, Kuijl CP, den Haan JMM.Bioconjug Chem. 2024 Nov 20;35(11):1805-1814. doi: 10.1021/acs.bioconjchem.4c00403. Epub 2024 Nov 7.PMID: 39511711

Design of logistics indicators for monitoring the COVID-19 vaccination process in Colombia : Logistic indicators for vaccination process.

Velasco N, Herrera A, Trujillo-Diaz J, Amaya CA, González-Uribe C, Hernandez E.BMC Health Serv Res. 2024 Nov 13;24(1):1397. doi: 10.1186/s12913-024-11843-x.PMID: 39538269

Trends and characteristics of herpes zoster vaccination among older adults with asthma in the United States, 2008-2023: Findings from self-reported national surveys.

Hung CT, Wang LM, Hung YC.Vaccine. 2024 Nov 18;43(Pt 2):126523. doi: 10.1016/j.vaccine.2024.126523. Online ahead of print.PMID: 39561629

Prospective longitudinal study of men who have sex with men and transgender women to determine HIV incidence in two provinces in Thailand.

Namwat C, Leela-Apiradee W, Tiawilai T, Dear N, Wansom T, Kitsiripornchai S, Premsri N, Akapirat S, Crowell TA, Francisco L, Li Q, Robb ML, Smith KS, Heger EA, Fukuda MM, O'Connell RJ, Rerks-Ngarm S, Vasan S; RV348M Study Group.PLoS One. 2024 Nov 14;19(11):e0309355. doi: 10.1371/journal.pone.0309355. eCollection 2024.PMID: 39541303

Optimizing the production of recombinant human papilloma virus type 52 major capsid protein L1 in Hansenula polymorpha.

Phimsen W, Kopitak N, Boontawon T, Theeranan T, Boonchird C, Pongtharangkul T.Sci Rep. 2024 Nov 18;14(1):28555. doi: 10.1038/s41598-024-79764-7.PMID: 39558031

Greater preservation of SARS-CoV-2 neutralising antibody responses following the ChAdOx1-S (AZD1222) vaccine compared with mRNA vaccines in haematopoietic cell transplant recipients.

Colton H, Barratt N, Temperton N, Hornsby H, Angyal A, Grouneva I, Lindsey BB, Kearns P, Barnes E, Goodyear CS, Richter A, Thomas D, Cook G, McInnes IB, Willicombe M, Siebert S, Orchard K, Selby R, Bowden S, Collini PJ, Pope A, Kirkham A, Kronsteiner B, Dunachie SJ, Miller P, Clay J, Hurst E, Malladi R, Kesavan M, Kinsella F, Sanderson R, Yong KL, Rea D, Parry H; PITCH Consortium, OCTAVE Collaborative Group, OCTAVE-DUO Investigators, PROSECO Investigators; Lim SH, Snowden JA, de Silva TI.Br J Haematol. 2024 Nov 17. doi: 10.1111/bjh.19874. Online ahead of print.PMID: 39551718

HPV vaccination is highly effective and cost-effective for cervical cancer prevention in women living with HIV in China: A cost-effectiveness analysis.

Liu H, Zou M, Shen M, Kamarulzaman A, Chen S, Li J, Li R, Liu H, Zou Z, Zhang L.Int J Cancer. 2024 Nov 17. doi: 10.1002/ijc.35242. Online ahead of print.PMID: 39551969

Vaccination with outer membrane vesicles from Neisseria Meningitidis and SBa15, SBa16 mesoporous silica associated with SARS-CoV-2 induces protective humoral and cellular response against COVID-19 in mice.

Bernardes BG, Moura AD, Guarnieri JPO, Silva CFMD, Costa HHMD, Silva IGMD, Cordeiro KBB, Báo SN, Prudêncio CR, Lancellotti M.Braz J Infect Dis. 2024 Nov 14;28(6):104479. doi: 10.1016/j.bjid.2024.104479. Online ahead of print.PMID: 39547005

Development and validation of a standardized human complement serum bactericidal activity assay to measure functional antibody responses to Neisseria gonorrhoeae.

Matthias KA, Reveille A, Dhara K, Lyle CS, Natuk RJ, Bonk B, Bash MC.Vaccine. 2024 Nov 15;43(Pt 2):126508. doi: 10.1016/j.vaccine.2024.126508. Online ahead of print.PMID: 39549368

A single immunization of *Borreliella burgdorferi*-infected mice with Vanguard crLyme elicits robust antibody responses to diverse strains and variants of outer surface protein C.

Chambers GZ, Chambers KMF, Marconi RT.Infect Immun. 2024 Nov 12;92(11):e0039624. doi: 10.1128/iai.00396-24. Epub 2024 Oct 22.PMID: 39436053

Near-atomic structures of RHDV reveal insights into capsid assembly and different conformations between mature virion and VLP.

Ruan Z, Shao Q, Song Y, Hu B, Fan Z, Wei H, Liu Y, Wang F, Fang Q.J Virol. 2024 Nov 19;98(11):e0127524. doi: 10.1128/jvi.01275-24. Epub 2024 Oct 22.PMID: 39436094

Impact of propensity to COVID-19 vaccination/vaccine on influenza vaccination from willingness to behavior among older adults in rural China.

Zhang SS, Shi W, Du J, Zhang WX, Yuan M, Zhou Y, Wang L, Zhao T, Ma QY, Zhang S, Yang H, Zhang X, Wang M, Huang N, Zeng J, Liu Y, Zhang Y, Cui F, Lu QB.Hum Vaccin Immunother. 2024 Dec 31;20(1):2428017. doi: 10.1080/21645515.2024.2428017. Epub 2024 Nov 13.PMID: 39539085

Erratum In: "Health Care Delivery Site- and Patient-Level Factors Associated With COVID-19 Primary Vaccine Series Completion in a National Network of Community Health Centers".

[No authors listed]Am J Public Health. 2024 Nov 21:e1. doi: 10.2105/AJPH.2024.307773e. Online ahead of print.PMID: 39571133

Clinical Informatics Foundations of 57 Years Sentinel and Genomic Surveillance: Data Quality, Linkage and Access.

de Lusignan S, Joy M, Zambon M.Stud Health Technol Inform. 2024 Nov 22;321:129-133. doi: 10.3233/SHTI241077.PMID: 39575794

Association between use of a voluntary isolation centre and reduced household SARS-CoV-2 transmission: A matched cohort study from Toronto, Canada.

Brown KA, Ulloa AC, Buchan SA, Daneman N, Gournis E, Laxer R, Schwartz KL, Edwards J.Clin Infect Dis. 2024 Nov 20:ciae526. doi: 10.1093/cid/ciae526. Online ahead of print.PMID: 39565934

Real-world effectiveness of COVID-19 vaccine in people with HIV compared with a matched HIV-negative cohort: a test-negative design.

Yang X, Zhang J, Liu Z, Chen S, Weissman S, Poland GA, Phaswana-Mafuya RN, Olatosi B, Li X.Int J Infect Dis. 2024 Nov 22:107310. doi: 10.1016/j.ijid.2024.107310. Online ahead of print.PMID: 39581372

Mobile outreach clinics for improving health care services accessibility in vulnerable populations of the Diffa Region in Niger: a descriptive study.

Rabiou LM, Oumarou B, Mor D, Abdou M, Ibrahim C, Tamuzi JL, Katoto PDMC, Wiysonge CS, Anya BM, Manengu TC.Int J Equity Health. 2024 Nov 12;23(1):235. doi: 10.1186/s12939-024-02322-0.PMID: 39529116

Differential Immune Responses of Th1 Stimulatory Chimeric Antigens of *Leishmania donovani* in BALB/c Mice.

Gupta N, Yadav AK, Verma PK, Srivastava M, Sahasrabuddhe AA, Dube A.ACS Infect Dis. 2024 Nov 22. doi: 10.1021/acsinfecdis.4c00608. Online ahead of print.PMID: 39575598

Case-fatality rate of invasive pneumococcal disease caused by various serotypes - an analysis of nationwide surveillance data from Israel, 2009-2018.

Wieder-Finesod A, Yahav D, Rubin C, Hashkor S, Southern J, Mircus G, Theilacker C, Dagan R, Regev-Yochay G; Israeli Adult Invasive Pneumococcal Disease (IAIPD) Group.Clin Microbiol Infect. 2024 Nov 15:S1198-743X(24)00544-5. doi: 10.1016/j.cmi.2024.11.018. Online ahead of print.PMID: 39551343

Insights into cancer characteristics among SARS-CoV-2 infected hospitalized patients: a comprehensive analysis from the National Clinical Registry for COVID-19.

Chatterji S, Turuk A, Das P, Bhattacharya S, Mukherjee S, Ghosh PS, Chatterjee A, Mukerjee A, Kumar G, Satija A, Josten K, Bhalla A, Malhotra P, Bhuniya S, Talukdar A, Ghosh S, Misra S, Bhardwaj P, Chatterjee S, Menon GR, Deo V, Rao VV; National Clinical Registry for COVID Team.J Cancer Res Clin Oncol. 2024 Nov 15;150(11):500. doi: 10.1007/s00432-024-05966-1.PMID: 39546022

The PvRBP2b-TfR1 interaction is not essential for reticulocytes invasion by Plasmodium vivax isolates from Cambodia.

Feufack-Donfack LB, Baldor L, Roesch C, Tat B, Orban A, Seng D, Salvador J, Khim N, Carias L, King CL, Russell B, Nosten F, Ong AS, Mao H, Renia L, Lo E, Witkowski B, Popovici J.NPJ Vaccines. 2024 Nov 22;9(1):232. doi: 10.1038/s41541-024-01031-7.PMID: 39578462

Longitudinal Analysis of Antibody Dynamics in Severe Fever with Thrombocytopenia Syndrome Patients - High-Incidence Regions of China, 2010-2023.

Wen Y, Song D, Li A, Sun L, Ma S, Liu T, Huang X, Huang T, Li B, Wang M, Li J, Liang M, Li D, Wu W, Dai X, Wang S.China CDC Wkly. 2024 Nov 15;6(46):1211-1217. doi: 10.46234/ccdcw2024.244.PMID: 39582902

Surveillance and agnostic capture sequencing of samples from individual with rash-associated illness in Mali indicates regional transmission of measles virus from west and Central Africa.

Kané F, Collins J, Koné A, Keita NY, Cisse I, Koné KM, Diallo D, Konate I, Dabitao DK, Diarra B, Sanogo I, Coulibaly T, Diallo M, Keita D, Tangara CO, Diakité M, Dao S, Fouth-Tchos K, Aboulhab J, Neal A, Saliba-Shaw K, Lu XJ, Briese T, Lipkin WI, Guindo I, Chen RY, Wickiser JK, Doumbia S.Infect Genet Evol. 2024 Nov 19:105691. doi: 10.1016/j.meegid.2024.105691. Online ahead of print.PMID: 39571670

Genotype III-Based Japanese Encephalitis Vaccines Exhibit Diminished Neutralizing Response to Re-emerging Genotype V.

Lee AR, Kim WJ, Choi H, Kim SH, Hong SY, Shim SM, Lee HI, Song JM, Kim SJ, Ishikawa T, Kang JM, Eom HS, Seo SU.J Infect Dis. 2024 Nov 22:jiae589. doi: 10.1093/infdis/jiae589. Online ahead of print.PMID: 39574290

Correction to: Safety and Immunogenicity of a 4-Component Generalized Modules for Membrane Antigens Shigella Vaccine in Healthy European Adults: Randomized, Phase 1/2 Study.

[No authors listed]J Infect Dis. 2024 Nov 20:jiae564. doi: 10.1093/infdis/jiae564. Online ahead of print.PMID: 39566030

PD-1 and CD73 on naive CD4^{+} T cells synergistically limit responses to self.

Nettersheim FS, Brunel S, Sinkovits RS, Armstrong SS, Roy P, Billitti M, Kobiyama K, Alimadadi A, Bombin S, Lu L, Zoccheddu M, Oliaeimotlagh M, Benedict CA, Sette A, Ley K.Nat Immunol. 2024 Nov 21. doi: 10.1038/s41590-024-02021-6. Online ahead of print.PMID: 39572641

The T cell response to SARS-CoV-2 mRNA vaccine in adults with high exposure to perfluoroalkyl substances from Ronneby, Sweden.

Andersson AG, Lundgren A, Xu Y, Nielsen C, Lindh CH, Pineda D, Vallin J, Johnsson C, Fletcher T, Bemark M, Jakobsson K, Li Y.Chemosphere. 2024 Nov 18:143770. doi: 10.1016/j.chemosphere.2024.143770. Online ahead of print.PMID: 39566685

Epidemiology of norovirus disease in the first two years of life: a prospective multisite cohort study in Lima, Peru.

Lanata CF, Soto G, Gil AI, Neyra J, Cornejo R, Romero C, Ecker L, Huaylinos ML, La Rosa S, Goios A, Borkowski A, Weil J.Int J Infect Dis. 2024 Nov 21:107308. doi: 10.1016/j.ijid.2024.107308. Online ahead of print.PMID: 39579923

Correction: Design of an observational multi-country cohort study to assess immunogenicity of multiple vaccine platforms (InVITE).

Sereti I, Shaw-Saliba K, Dodd LE, Dewar RL, Laverdure S, Brown S, Mbaya OT, Muyembe Tamfum JJ, Mblala-Kingebeni P, Sow Y, Akpa E, Haidara MC, Tchos KF, Beavogui AH, Neal A, Arlinda D, Lokida D, Grue L, Smolskis M, McNay LA, Gayedyu-Dennis D, Ruiz-Palacios GM, Montenegro-Liendo A, Tounkara M, Samake S, Jargalsaikhan G, Zulkhuu D, Weyers S, Bonnett T, Potter GE, Stevens R, Rupert A, Aboulhab J, Biampata JL, Delamou A, Camara BS, Indonesia HK, Karyana M, Duworko JT, Regalado-Pineda J, Guerra-de-Blas PDC, Doumbia S, Dabitao D, Dashdorj N, Dashdorj N, Newell K, Francis A, Rubenstein K, Bera V, Gulati I, Sardana R, Millard M, Ridzon R, Hunsberger S.PLoS One. 2024 Nov 14;19(11):e0314048. doi: 10.1371/journal.pone.0314048. eCollection 2024.PMID: 39541305

Mpox Vaccine Appears Safe for Use in Adolescents.

Anderer S.JAMA. 2024 Nov 22. doi: 10.1001/jama.2024.23619. Online ahead of print.PMID: 39576618

Unravelling the Association Between Uncertainties in Model-based Economic Analysis and Funding Recommendations of Medicines in Australia.

Chen Q, Hoyle M, Jeet V, Gu Y, Sinha K, Parkinson B.Pharmacoeconomics. 2024 Nov 15. doi: 10.1007/s40273-024-01446-z. Online ahead of print.PMID: 39546247

Report of a SPEAC webinar 22 september 2023: Sensorineural hearing loss, lassa virus disease and vaccines.

Reed NS, Brewer CC, Akintunde G, Blackie FF, Charles L, Fast P, Lambert PH, Okogbenin S, Paessler S, Pinschewer DD, Top KA, Black SB, Dekker CL.Vaccine. 2024 Nov 22;43(Pt 1):126525. doi: 10.1016/j.vaccine.2024.126525. Online ahead of print.PMID: 39579650

Modulating the immunodominance hierarchy of immunoglobulin germline-encoded structural motifs targeting the influenza hemagglutinin stem.

Ataca S, Sangesland M, de Paiva Fróes Rocha R, Torrents de la Peña A, Ronsard L, Boyoglu-Barnum S, Gillespie RA, Tsybovsky Y, Stephens T, Moin SM, Lederhofer J, Creanga A, Andrews SF, Barnes RM, Rohrer D, Lonberg N, Graham BS, Ward AB, Lingwood D, Kanekiyo M.Cell Rep. 2024 Nov 22;43(12):114990. doi: 10.1016/j.celrep.2024.114990. Online ahead of print.PMID: 39580804

The association of maternal mental health with vaccination coverage and timeliness in early childhood - A historical cohort study in England using electronic health records.

Suffel AM, Carreira H, Walker J, Grint D, Osborn D, McDonald HI, Warren-Gash C.Vaccine. 2024 Nov 19;43(Pt 2):126529. doi: 10.1016/j.vaccine.2024.126529. Online ahead of print.PMID: 39566366

VRK2 inhibits the replication of infectious bursal disease virus by phosphorylating RACK1 and suppressing apoptosis.

Ma YH, Liang ZS, Shao HC, Ren H, Pan XY, Zi MH, Shi LF, Zhang Y, Han S, Wan B, Yuan J, Lin W, He WR.Int J Biol Macromol. 2024 Nov 21:137940. doi: 10.1016/j.ijbiomac.2024.137940. Online ahead of print.PMID: 39579830

Parasite-microbiota interactions: a pathway to innovative interventions for Chagas disease, leishmaniasis, and ascariasis.

Ramírez JD, Castañeda S, Weatherhead J, Poveda C.Future Microbiol. 2024 Nov 22:1-13. doi: 10.1080/17460913.2024.2431417. Online ahead of print.PMID: 39574234

Assessment of the Communicable Disease Status of Children in Türkiye: A Community-Based Cross-Sectional Study.

Çakır M, Boydak ZB, İkiışık H, Maral I.Public Health Nurs. 2024 Nov 12. doi: 10.1111/phn.13489. Online ahead of print.PMID: 39533440

Evaluating the Impact of Moderate and Severe Varicella Infections on Danish Children Under 18 Years Old: A Comprehensive Analysis From 2015 to 2023.

Egeskov-Cavling AM, Johannesen CK, Folke F, Fischer TK.Pediatr Infect Dis J. 2024 Nov 22. doi: 10.1097/INF.0000000000004612. Online ahead of print.PMID: 39569903

Evaluation of waning of IgG antibody responses after rVSVΔG-ZEBOV-GP and Ad26.ZEBOV, MVA-BN-Filo Ebola virus disease vaccines: a modelling study from the PREVAC randomized trial.

Valayer S, Alexandre M, Prague M, Beavogui AH, Doumbia S, Kieh M, Greenwood B, Leigh B, Poupelin M, Schwimmer C, Sow SO, Berry IM, Kuhn JH, Fusco D, Cauwelaert ND, Watson-Jones D, Thiébaut R, Lévy Y, Yazdanpanah Y, Richert L, Lhomme E; PREVAC Study Team.Emerg Microbes Infect. 2024 Nov 19:2432353. doi: 10.1080/22221751.2024.2432353. Online ahead of print.PMID: 39559990

Distribution of group B streptococci serotypes on women nasopharynx.

Pereira MDCA, Hilário FF, Campana EH, Sousa ESS, Perez VP.Braz J Infect Dis. 2024 Nov 21;28(6):104469. doi: 10.1016/j.bjid.2024.104469. Online ahead of print.PMID: 39577041

Mapping priority areas for measles surveillance: stratifying reintroduction and transmission risk in Rio de Janeiro, Brazil.

Dos Santos YT, Praça HL, San Pedro A, Reis LNM, Conceição PB, Gibson G.Rev Panam Salud Publica. 2024 Nov 20;48:e123. doi: 10.26633/RPSP.2024.123. eCollection 2024.PMID: 39569081

Do SMS/e-mail reminders increase influenza vaccination of rheumatoid arthritis patients under anti-TNF: a nested randomized controlled trial in the ART e-cohort.

Nguyen Y, Baron G, Hamamouche N, Belkhir R, Miconnet S, Soubrier M, Hostachy C, Thevenot P, Basch A, Truchetet ME, Claudepierre P, Dernis E, Marotte H, Flipo RM, Brocq O, Morel J, Fautrel B, Salliot C, Saraux A, Leske C, Schaeverbeke T, Ravaud P, Mariette X, Ruyssen-Witrand A, Seror R; ART study group.Rheumatology (Oxford). 2024 Nov 22:keae599. doi: 10.1093/rheumatology/keae599. Online ahead of print.PMID: 39576675

Incidence of Anaphylaxis in Patients with Alpha-Gal Syndrome Receiving Gelatin-Containing Vaccines: A Large Database Analysis.

Chiu CY, Henao-Martínez AF, Higuita NIA.J Allergy Clin Immunol Pract. 2024 Nov 21:S2213-2198(24)01176-0. doi: 10.1016/j.jaip.2024.11.010. Online ahead of print.PMID: 39579978

COVID-19 knowledge, attitudes, and behaviors of STEM vs. non-STEM college students in Central Appalachia in 2021, a student-led project.

Orusa A, Wahlquist A, Lawson D, Riaz O, Mitchell J, Tafesse Y, Pettyjohn S.J Am Coll Health. 2024 Nov 20:1-5. doi: 10.1080/07448481.2024.2418519. Online ahead of print.PMID: 39566045

Leveraging Walnut Somatic Embryos as a Biomanufacturing Platform for Recombinant Proteins and Metabolites.

Zaini PA, Haddad KR, Feinberg NG, Ophir Y, Nandi S, McDonald KA, Dandekar AM.BioTech (Basel). 2024 Nov 15;13(4):50. doi: 10.3390/biotech13040050.PMID: 39584907

The evolutionary cost of homophily: Social stratification facilitates stable variant coexistence and increased rates of evolution in host-associated pathogens.

Li S, Gulisija D, Carja O.PLoS Comput Biol. 2024 Nov 22;20(11):e1012619. doi: 10.1371/journal.pcbi.1012619. Online ahead of print.PMID: 39576842

Understanding the public's decision-making about seasonal flu vaccination during a pandemic: Application of the precaution adoption process model.

Meyer C, Antonopoulou V, Goffe L, Grimani A, Graham F, Lecouturier J, Tang MY, Chadwick P, Sniehotta FF.J Health Psychol. 2024 Nov 22:13591053241296650. doi: 10.1177/13591053241296650. Online ahead of print.PMID: 39575985

Optimising vaccination strategies to prevent invasive pneumococcal disease in the elderly. Which vaccine should come first?

Humphreys H, Corcoran M.Clin Microbiol Infect. 2024 Nov 22:S1198-743X(24)00556-1. doi: 10.1016/j.cmi.2024.11.025. Online ahead of print.PMID: 39581539

Patentes registradas en Patentscope

Estrategia de búqueda: (Vaccine) AND DP:([11.11.2024 TO 22.11.2024]) *as the publication date 59 records.*

1.WO/2024/237773METHOD FOR PRODUCING A CONDITIONED BLOOD COMPOSITION FOR TREATING DISEASES

WO - 21.11.2024

Clasificación Internacional A61K 35/00Nº de solicitud PCT/KZ2023/000026Solicitante YUCHT, RomanInventor/a YUCHT, Roman

The invention relates to medicine, and more particularly to blood-based medicinal preparations containing induced cytokines for the treatment of human diseases. A method for producing a conditioned blood composition for treating diseases includes taking a sample of blood from a patient, incubating the blood sample in a vessel, and centrifuging, wherein the patient's blood sample is mixed with a vaccine containing fragments of viruses, and/or with a vaccine containing bacterial toxins, and/or with a vaccine containing attenuated bacterial DNA, before being incubated and centrifuged, thereby producing a cytokine-enriched conditioned blood composition. In the method for producing a conditioned blood composition, the patient's blood sample is mixed with the Vaxigrip influenza vaccine or the Influvac Tetra vaccine, and/or with a hepatitis B vaccine, and/or with a tetanus vaccine, and/or with a rubella vaccine. The proposed method for producing a conditioned blood composition for treating diseases provides for an increased activation rate, as well as a high content of interleukin B in the conditioned blood composition.

2.20240374709VACCINE COMPOSITIONS

US - 14.11.2024

Clasificación Internacional A61K 39/145Nº de solicitud 18690650Solicitante EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC.Inventor/a James Paul LATA

The present invention relates to a vaccine composition comprising an influenza Type A hemagglutinin stabilized stem nanoparticle (HA-ss-np); an aluminum hydroxide; a synthetic oligodeoxynucleotide adjuvant containing at least one CpG motif (CpG ODN); and a phosphate salt, wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide in the composition. The present disclosure also provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering an immunologically effective amount of the vaccine composition described herein. The present disclosure further provides a method of inducing an immunological response against an influenza virus in a subject in need thereof, comprising administering a dose of about 20 µg to about 300 µg of an HA-ss-np in a vaccine composition, wherein the vaccine composition further comprises an aluminum hydroxide; CpG ODN; and a phosphate salt, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide, and wherein at least a portion of the CpG ODN is adsorbed to the aluminum hydroxide. Also provided herein is a method of producing a vaccine composition, comprising combining HA-ss-np with an adjuvant mixture, wherein the adjuvant mixture comprises a diluent solution comprising a phosphate salt; aluminum hydroxide; and CpG ODN, wherein the adjuvant mixture comprises CpG ODN-adsorbed aluminum hydroxide, and wherein the HA-ss-np is not substantially adsorbed to the aluminum hydroxide.

3.WO/2024/232415COMBINATION VACCINE FOR PREVENTION OF INFLUENZA AND CORONAVIRUS INFECTIONS

WO - 14.11.2024

Clasificación Internacional A61K 39/145Nº de solicitud PCT/JP2024/017278Solicitante NATIONAL UNIVERSITY CORPORATION HOKKAIDO UNIVERSITYInventor/a SHINGAI Masashi

Disclosed is a combination vaccine for the prevention of influenza and new coronavirus infections. As a combination vaccine for vaccination against influenza and new coronaviruses, an inactivated whole virus particle vaccine, in which viral particles of an influenza virus and viral particles of a new coronavirus are inactivated respectively, is prepared. This vaccine induces neutralizing antibodies against the respective viruses without affecting vaccine effects so that protective effects against the attacks of the respective viruses are obtained. Further, the combination vaccine having this combination well induces neutralizing antibodies and exhibits protective effects against the attacks of the viruses even without adding an adjuvant.

4.4464658ALUMINIUMNANOKRISTALLABGABESYSTEM UND SELBSTANGEORDNETER PARTIKELADJUVANZIMPFSTOFF AUF BASIS DER BINDUNG DES ALUMINIUMNANOKRISTALLABGABESYSTEMS UND IMPFSTOFFANTIGENMOLEKÜLS

EP - 20.11.2024

Clasificación Internacional B82Y 5/00Nº de solicitud 23740123Solicitante GUANGZHOU REALBENEFITSPOT PHARMACEUTICAL CO LTDInventor/a WANG YALING

The present invention relates to the technical field of biomedicine technology and vaccines, and particularly relates to an aluminum nanocrystal delivery system with a surface covered with an Fc affinity protein and a preparation method for a self-assembled particle adjuvant vaccine. An aluminum nanocrystal is used as a carrier, the surface of the aluminum nanocrystal is covered with an Fc affinity protein molecular layer and an antigen molecule, and the antigen of a recombinant Fc Tag specifically binds to an Fc affinity protein, so that

antigen self-assembly is realized, a virus-like particle vaccine is formed, and the antigen density is improved. The present vaccine can generate a high-titer specific antibody by inducing a body fluid and cell immunity.

5.WO/2024/235705A COMBINATION VACCINE AGAINST ERYSIPELOTHRIX RHUSIOPATHIAE, PORCINE PARVO VIRUS AND LEPTOSPIRA BACTERIUM

WO - 21.11.2024

Clasificación Internacional A61K 39/02Nº de solicitud PCT/EP2024/062431Solicitante INTERVET INTERNATIONAL B.V.Inventor/a JACOBS, Antonius, Arnoldus, Christiaan

The invention pertains to a combination of a first vaccine comprising a non-replicating immunogen of *Erysipelothrix rhusiopathiae* and a non-replicating immunogen of porcine parvo virus, and a second vaccine comprising a non-replicating immunogen of a Leptospira bacterium, for use in prophylactically treating a pig against an infection with *Erysipelothrix rhusiopathiae*, an infection with porcine parvo virus and an infection with Leptospira bacterium, by associated separate injection of the first vaccine and the second vaccine into the dermis of the pig at a first and a second injection site of that pig respectively.

6.4460325GEFLÜGEL-ADENOVIRUS-UNTEREINHEITS-IMPFSTOFF UND HERSTELLUNGSVERFAHREN DAFÜR

EP - 13.11.2024

Clasificación Internacional A61K 39/12Nº de solicitud 23701235Solicitante VETERINAERMEDIZINISCHE UNIV WIENInventor/a HESS MICHAEL

The present invention provides a fowl adenovirus (FAdV) subunit vaccine, comprising at least a chimeric FAdV fiber protein and an adjuvant. This vaccine may be used to ameliorate or prevent adenoviral gizzard erosion (AGE), inclusion body hepatitis (IBH) or hepatitis-hydropericardium syndrome (HHS) in birds. The invention further relates to a method of producing an FAdV subunit vaccine, comprising the steps of expressing a chimeric FAdV fiber protein in an expression system, purifying the fiber protein, and combining the fiber protein with an adjuvant to obtain the FAdV subunit vaccine.

7.20240386992NEW CORONAVIRUS VACCINE AND METHOD FOR DESIGNING AND OBTAINING A VIRUS VACCINE

US - 21.11.2024

Clasificación Internacional G16B 15/30Nº de solicitud 18687263Solicitante Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-GemeinschaftInventor/a KATHRIN DE LA ROSA

The present invention relates to a mutant receptor-binding domain (mRBD) of a coronavirus (mRBD-CORONA) or a fragment thereof and mutant spike protein of the coronavirus (CORONA-mSpike) or a fragment thereof comprising the CORO-NA-mRBD or the fragment thereof. Furthermore, the present invention relates to a polypeptide or protein comprising the mRBD-CORONA or the fragment thereof or CORONA-mSpike or the fragment thereof and a nucleic acid comprising a nucleotide sequence encoding for the mRBD-CORONA or the fragment thereof or the CORONA-mSpike or the fragment thereof. Furthermore, the present invention relates to a vaccine composition comprising one or more CORONA-mRBDs or fragments thereof, one or more CORONA-mSpikes, one or more polypeptides or proteins and/or one or more nucleic acids according to the present invention. Furthermore, the present invention relates to the one or more

CORONA-mRBDs or fragments thereof, the one or more CORONA-mSpikes, the one or more polypeptides or proteins, the one or more nucleic acids and/or the vaccine composition according to the present invention for use in the prevention and/or treatment of diseases caused by coronaviruses in a subject. Furthermore, the present invention relates to a method for designing and/or obtaining an active ingredient for a vaccine composition and to a VIRUS-mRBD or a fragment thereof designed and/or obtained by the method for obtaining the VIRUS-mRBD according to the present invention.

8.20240374700SYNTHETIC GLYCOCONJUGATE VACCINE PROTOTYPE AGAINST STREPTOCOCCUS SUIS

US - 14.11.2024

Clasificación Internacional A61K 39/09Nº de solicitud 18704158Solicitante UNIVERSITÉ DE MONTRÉALInventor/a Mariela SEGURA

The invention provides for a vaccine against *S. suis* serotype 2. The vaccine comprises chemically synthesized fragments and thus may be made widely commercially available. The vaccine is used in the livestock production and may be adapted for use against other serotypes of *S. suis* such as serotypes 1, 1/2, 3, 9, and 14. Also, the vaccine may be adapted for use in humans.

9.WO/2024/237672VACCINE COMPOSITION FOR PREVENTING INFECTION WITH CHICKEN INFECTIOUS ANEMIA VIRUS

WO - 21.11.2024

Clasificación Internacional C12N 7/00Nº de solicitud PCT/KR2024/006589Solicitante REPUBLIC OF KOREA(ANIMAL AND PLANT QUARANTINE AGENCY)Inventor/a SONG, Hye Soon

The present invention relates to an attenuated strain of chicken infectious anemia virus (CIAV), a vaccine composition for preventing chicken infectious anemia by using same, and a vaccination method. According to the present invention, the attenuated strain of CIAV obtained through 100 consecutive subcultures of a parent virus has significantly lower pathogenicity than the parent virus and a virus obtained by 45 consecutive subcultures of the parent virus, and exhibits a higher antibody titer and a longer maintenance period than commercial vaccines, and thus can be effectively utilized as a vaccine composition for preventing CIAV.

10.WO/2024/233425POLYNUCLEOTIDES ENCODING NOROVIRUS VP1 ANTIGENS AND USES THEREOF

WO - 14.11.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2024/027914Solicitante MERCK SHARP & DOHME LLCInventor/a AUSTIN, Lauren A.

The present invention is directed to nucleic acids and related immunogenic polypeptides for the prevention or treatment of infectious diseases. In particular, the nucleic acids and immunogenic polypeptides provide utility for the prophylactic prevention of norovirus infections in a mammal. The invention is further directed to nucleic acid-based vaccine compositions and a kit of parts comprising the vaccine compositions, as well as methods of treatment and medical uses relating to the nucleic acids, vaccine compositions, and kit of parts.

11.WO/2024/235713A VACCINE AGAINST ERYSIPELOTHRIX RHUSIOPATHIAE AND PORCINE PARVO VIRUS

WO - 21.11.2024

Clasificación Internacional A61K 39/02Nº de solicitud PCT/EP2024/062452Solicitante INTERVET INTERNATIONAL B.V.Inventor/a JACOBS, Antonius, Arnoldus, Christiaan

The invention pertains to the use of a vaccine comprising a non-replicating immunogen of *Erysipelothrix rhusiopathiae* and a non-replicating immunogen of porcine parvo virus, in prophylactically treating a pig against an infection with *Erysipelothrix rhusiopathiae* and an infection with porcine parvo virus, by injection of the first vaccine into the dermis of the pig.

12.20240376157POLYNUCLEOTIDES ENCODING NOROVIRUS VP1 ANTIGENS AND USES THEREOF

US - 14.11.2024

Clasificación Internacional C07K 14/005Nº de solicitud 18655408Solicitante Merck Sharp & Dohme LLCInventor/a Lauren A. Austin

The present invention is directed to nucleic acids and related immunogenic polypeptides for the prevention or treatment of infectious diseases. In particular, the nucleic acids and immunogenic polypeptides provide utility for the prophylactic prevention of norovirus infections in a mammal. The invention is further directed to nucleic acid-based vaccine compositions and a kit of parts comprising the vaccine compositions, as well as methods of treatment and medical uses relating to the nucleic acids, vaccine compositions, and kit of parts.

13.WO/2024/238940VACCINE COMPOSITIONS AND METHODS OF USE THEREOF

WO - 21.11.2024

Clasificación Internacional C07C 211/03Nº de solicitud PCT/US2024/029982Solicitante REGENTS OF THE UNIVERSITY OF MINNESOTAInventor/a PRAVETONI, Marco

The present disclosure provides methamphetamine conjugate, and/or opioid conjugate(s) vaccine compositions and methods thereof. The present disclosure also provides multivalent vaccine compositions.

14.WO/2024/235714A VACCINE AGAINST LEPTOSPIRA BACTERIUM

WO - 21.11.2024

Clasificación Internacional A61K 39/02Nº de solicitud PCT/EP2024/062453Solicitante INTERVET INTERNATIONAL B.V.Inventor/a JACOBS, Antonius, Arnoldus, Christiaan

The invention pertains to a vaccine comprising a non-replicating Leptospira immunogen, for use in prophylactically treating a pig against an infection with a Leptospira bacterium, by injection of the first vaccine into the dermis of the pig.

15.20240383963METHOD OF COMPACT PEPTIDE VACCINES USING RESIDUE OPTIMIZATION

US - 21.11.2024

Clasificación Internacional C07K 14/74Nº de solicitud 18793638Solicitante Think Therapeutics, Inc.Inventor/a David Kenneth GIFFORD

A system for selecting an immunogenic peptide composition comprising a processor and a memory storing processor-executable instructions that, when executed by the processor, cause the processor to create a first peptide set by selecting a plurality of base peptides, wherein at least one peptide of the plurality of base peptides is associated with a disease, create a second peptide set by adding to the first peptide set a modified peptide, wherein the modified peptide comprises a substitution of at least one residue of a base peptide selected from the plurality of base peptides, and create a third peptide set by selecting a subset of the second peptide set, wherein the selected subset of the second peptide set has a predicted vaccine performance, wherein the predicted vaccine performance has a population coverage above a predetermined threshold, and wherein the subset comprises at least one peptide of the second peptide set.

16.WO/2024/238735COMPOUNDS AND FORMULATIONS USEFUL AS VACCINE ADJUVANTS

WO - 21.11.2024

Clasificación Internacional A61K 31/395Nº de solicitud PCT/US2024/029596Solicitante MERCK SHARP & DOHME LLCInventor/a AHL, Patrick L.

The invention relates to novel compounds having a structure as set forth in any one of Formulas I, Ia, II, IIa, III, IIIa, IV or IVa, as described herein, and formulations comprising such novel compounds. The novel compounds and formulations of the invention may be useful in vaccine compositions. In some embodiments, the invention relates to compositions comprising at least one antigen and compounds having a structure as set forth in any one of Formulas I, Ia, II, IIa, III, IIIa, IV or IVa, as described herein, or pharmaceutically acceptable salt(s) thereof, wherein the compositions are prepared as stable nanoemulsions (herein referred to as "SNE adjuvant compositions" or "SNEs").

17.WO/2024/238822HEROIN VACCINE COMPOSITIONS AND METHODS THEREOF

WO - 21.11.2024

Clasificación Internacional A61K 31/395Nº de solicitud PCT/US2024/029740Solicitante REGENTS OF THE UNIVERSITY OF MINNESOTAInventor/a PRAVETONI, Marco

The present disclosure provides vaccine compositions that induce opioid specific antibodies.

18.20240374695VACCINE COMPOSITIONS DEPLETING HEMATOPOIETIC GROWTH FACTORS FOR THE TREATMENT OF INFLAMMATORY DISEASES

US - 14.11.2024

Clasificación Internacional A61K 39/00Nº de solicitud 18285011Solicitante CENTRO DE INMUNOLOGIA MOLECULARInventor/a Agustín Bienvenido Lage Dávila

The present invention is related to the fields of Biotechnology and Medicine. Particularly, it describes therapeutic vaccine compositions able to produce an autoimmune reaction against haemopoietic growth factors such as G-SCF and/or GM-CSF bounded to other molecules or a fragment thereof by chemical conjugation or fusion. Such vaccines compositions are useful for the treatment of inflammatory diseases, especially wherein a pathological increasing of the circulating neutrophils occurs.

19.WO/2024/231810VACCINE COMPOSITIONS

WO - 14.11.2024

Clasificación Internacional C07K 14/52Nº de solicitud PCT/IB2024/054366Solicitante SEQIRUS INC.Inventor/a WIDMAN, Douglas

The present disclosure relates to RNAs and other polynucleotides encoding an antigen, which can be used in vaccine compositions. In some examples, the RNA also encodes a chemoattractant, such as chemerin, C-X-C motif chemokine ligand 9 (CXCL9), C-X-C motif chemokine ligand 10 (CXCL10) or C-X-C motif chemokine ligand 11 (CXCL11). The present disclosure also relates to use of the RNAs and compositions in methods of inducing an immune response in a subject.

20.WO/2024/234567BROAD-SPECTRUM ANTI-BOVINE VIRAL DIARRHEA VIRUS MRNA VACCINE AND USE THEREOF

WO - 21.11.2024

Clasificación Internacional C07K 14/18Nº de solicitud PCT/CN2023/127676Solicitante NANJING CHENGSHI BIOMEDICAL TECHNOLOGY CO., LTD.Inventor/a HAN, Tiyun

Provided are a broad-spectrum anti-bovine viral diarrhea virus (BVDV) mRNA vaccine, a preparation method, a use thereof, etc. Specifically, provided is a trivalent BVDV mRNA against multiple genotype BVDV strains, which sequentially comprises, from the N-terminus to the C-terminus, a bovine IgG1 secretion signal peptide, a bovine IgG1 Fc fragment, a BVDV1a E2 protein domain I-II, a BVDV1b E2 protein domain I-II, and a BVDV2 E2 protein domain I-II. By using an mRNA to simultaneously express antigens of different genotype BVDVs, the present invention has strong immunogenicity and can realize effective and high-level secretion in animal bodies, so as to induce the generation of higher-level specific neutralizing antibodies against BVDV1a, BVDV1b, and BVDV2, and can realize an ideal immune effect against multiple BVDV genotype strains.

21.WO/2024/234498BROAD-SPECTRUM MRN VACCINE AGAINST BOVINE VIRAL DIARRHEA VIRUS AND USE THEREOF

WO - 21.11.2024

Clasificación Internacional C07K 14/18Nº de solicitud PCT/CN2023/115458Solicitante NANJING CHENGSHI BIOMEDICAL TECHNOLOGY CO., LTD.Inventor/a HAN, Tiyun

The present invention relates to a broad-spectrum mRNA vaccine against bovine viral diarrhea virus (BVDV), a preparation method therefor and the use thereof. Specifically provided is a trivalent BVDV mRNA for multiple genotypes of a BVDV strain. The trivalent BVDV mRNA sequentially comprises, from the N-terminal to the C-terminal, a bovine IgG1 secretion signal peptide, a bovine IgG1 Fc fragment, a BVDV1a E2 protein domain I-II, a BVDV1b E2 protein domain I-II and a BVDV2 E2 protein domain I-II. The present invention enables the simultaneous expression of antigens from different genotypes of BVDV using a single mRNA. The antigens exhibit strong immunogenicity and are effectively secreted at a high level in an animal, thereby inducing the production of a higher level of a specific neutralizing antibody against BVDV1a, BVDV 1b, and BVDV 2, which enables an ideal immunization effect against multiple genotypes of a BVDV strain to be achieved.

22.WO/2024/231886COMBINATION VACCINE

WO - 14.11.2024

Clasificación Internacional A61K 39/295Nº de solicitud PCT/IB2024/054549Solicitante SEQIRUS INC.Inventor/a CHANG, Cheng

The present disclosure relates to compositions comprising multiple antigens of interest for use in vaccine formulations. The compositions comprise (a) a polynucleotide (such as an RNA) comprising a nucleotide sequence encoding an antigen and (b) an antigen polypeptide. The compositions can be used in inducing an immune response in a subject and/or in the treatment or prevention of a disease, such as a respiratory viral infection.

23.20240374710VACCINE COMPOSITIONS FOR PREVENTING CORONAVIRUS DISEASE

US - 14.11.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18396370Solicitante International AIDS Vaccine Initiative Inc.Inventor/a Christopher Lee Parks

The present disclosure provides Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2) vaccines, recombinant vesicular stomatitis virus (VSV) vectors encoding the SARS-CoV-2 spike(S) protein or an immunogenic variant thereof, recombinant replicable VSV particles having a SARS-CoV-2 S protein or an immunogenic variant thereof on the surface of the particles, and immunogenic recombinant proteins comprising a SARS-CoV-2 S protein or a variant thereof. Immunogenic compositions comprising the SARS-CoV-2 vaccines, the recombinant VSV vectors, the recombinant replicable VSV particles and/or the immunogenic recombinant proteins may be used for inducing an immune response to the SARS-CoV-2, preventing infection by the SARS-CoV-2, vaccinating against the SARS-CoV-2 and/or producing adaptive mutants of the recombinant replicable VSV particles.

24.WO/2024/234756METHOD FOR CONSTRUCTING MRNA AND VACCINE TARGETING M AND N ANTIGENS OF FELINE FIPV

WO - 21.11.2024

Clasificación Internacional A61K 39/215Nº de solicitud PCT/CN2024/077002Solicitante BEIJING SYNGENTECH CO., LTD.Inventor/a LIU, Qiang

Provided is a method for constructing mRNA and a vaccine targeting M and N antigens of feline FIPV. The method involves an isolated nucleic acid molecule, and the nucleic acid molecule comprises: a first nucleic acid fragment, the first nucleic acid fragment encoding the M protein of the feline infectious peritonitis virus; and a second nucleic acid fragment, the second nucleic acid fragment encoding the N protein of the feline infectious peritonitis virus. The first nucleic acid fragment is connected or not connected to the second nucleic acid fragment. The nucleic acid molecule is mRNA.

25.20240382579METHOD OF PRODUCING A FOOT AND MOUTH DISEASE VIRUS VIRUS-LIKE PARTICLE

US - 21.11.2024

Clasificación Internacional A61K 39/135Nº de solicitud 18683835Solicitante Intervet Inc.Inventor/a Erwin Van Den Born

The invention concerns a method of producing a foot and mouth disease virus (FMDV) virus-like particle (VLP) in a baculovirus expression system, the method comprising the steps of (i) infecting an insect cell with a baculovirus expression vector, (ii) culturing the insect cell in cell culture medium for 4 days or more post infection, (iii) separating the insect cells from the cell culture to obtain cell-free cell culture medium, and (iv) harvesting the FMDV VLP from the cell-free cell culture medium. The invention further relates to a vaccine for use in the protection of a subject against an infection with FMDV, the vaccine being obtainable by the method of the invention.

26.WO/2024/236458VACCINE ADJUVANTS

WO - 21.11.2024

Clasificación Internacional A61K 31/7105Nº de solicitud PCT/IB2024/054623Solicitante SEQIRUS INC.Inventor/a WIDMAN, Douglas G.

The present disclosure relates to RNAs and other polynucleotides encoding an antigen, which can be used in vaccine compositions. In some examples, the RNA or polynucleotide also encodes an adjuvant, such as cathelicidin or a fragment thereof. The present disclosure also relates to use of the RNAs, polynucleotides or compositions in methods of inducing an immune response in a subject.

27.4461365IMPFSTOFF GEGEN DAS RESPIRATORISCHE SYNZYTIALVIRUS

EP - 13.11.2024

Clasificación Internacional A61P 31/14Nº de solicitud 24200911Solicitante CUREVAC SEInventor/a KRAMPS THOMAS

The present invention relates to an mRNA sequence, comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Additionally the present invention relates to a composition comprising a plurality of mRNA sequences comprising a coding region, encoding at least one antigenic peptide or protein of RSV infections Respiratory syncytial virus (RSV) or a fragment, variant or derivative thereof. Furthermore it also discloses the use of the mRNA sequence or the composition comprising a plurality of mRNA sequences for the preparation of a pharmaceutical composition, especially a vaccine, e.g. for use in the prophylaxis or treatment of RSV infections Respiratory syncytial virus (RSV) infections. The present invention further describes a method of treatment or prophylaxis of RSV infections using the mRNA sequence.

28.20240374717NANOFIBER COMPOSITIONS FOR A VACCINE ADJUVANT, POROUS SCAFFOLD OR POROUS MEMBRANE

US - 14.11.2024

Clasificación Internacional A61K 39/39Nº de solicitud 18783076Solicitante Sila Nanotechnologies, Inc.Inventor/a Gleb YUSHIN

An aspect is directed to a vaccine adjuvant including a nanofiber that comprises an oxide or a salt of one, two, three or more metals selected from the group of Al, Ca, Mg, Li, Na, K, La, Y, Si, Fe and Zn. Another

aspect is directed to a porous scaffold or a porous membrane that comprises nanofibers comprising an oxide or a salt of one, two, three or more metals selected from the group of Al, Ca, Mg, Li, Na, K, La, Y, Si, Fe and Zn, where the porous scaffold or the porous membrane is configured for use in an environment where the nanofibers are exposed to a direct contact with extracellular body fluids.

29.20240382584HBV VACCINE INDUCING PRES-SPECIFIC NEUTRALIZING ANTIBODIES

US - 21.11.2024

Clasificación Internacional A61K 39/29Nº de solicitud 18693176Solicitante Viravaxx AGInventor/a Inna TULAEVA

A Hepatitis B virus (HBV) vaccine comprising a fusion protein of a preS polypeptide fused to at least one grass pollen allergen peptide, for use in the treatment of a subject to induce HBV neutralizing antibodies, wherein the subject is an immune tolerant human subject and said treatment comprises repeated vaccination to break immune tolerance against HBV.

30.WO/2024/234754METHOD FOR CONSTRUCTING CIRCULAR RNA AND VACCINE AGAINST FIPV

WO - 21.11.2024

Clasificación Internacional A61K 39/215Nº de solicitud PCT/CN2024/077000Solicitante BEIJING SYNGENTECH CO., LTD.Inventor/a LIU, Qiang

Provided is a method for constructing a circular RNA and a vaccine against a feline infectious peritonitis virus (FIPV). The present method relates to a pharmaceutical preparation. The pharmaceutical preparation comprises a nucleic acid fragment, wherein the nucleic acid fragment is a circular RNA, and comprises a first nucleic acid fragment and a second nucleic acid fragment; the first nucleic acid fragment encodes an M protein of the FIPV; the second nucleic acid fragment encodes an N protein of the FIPV; and the first nucleic acid fragment is connected or not connected to the second nucleic acid fragment.

31.20240374708UNIVERSAL INFLUENZA VACCINE AND METHODS OF USE

US - 14.11.2024

Clasificación Internacional A61K 39/145Nº de solicitud 18689656Solicitante The Trustees of the University of PennsylvaniaInventor/a Scott Hensley

Provided is a twenty-hemagglutinin antigen (HA) universal influenza vaccine comprising HA antigens from each known influenza A and influenza B lineage and methods of use thereof to treat or prevent influenza.

32.20240376492FULLY SYNTHETIC, LONG-CHAIN NUCLEIC ACID FOR VACCINE PRODUCTION TO PROTECT AGAINST CORONAVIRUSES

US - 14.11.2024

Clasificación Internacional C12N 15/86Nº de solicitud 17909145Solicitante ROCKETVAX AGInventor/a Matthias CHRISTEN

This invention describes a fully synthetic, long-chain nucleic acid that can be used in biotechnological manufacturing processes to produce envelope proteins, virus envelopes and fragments of virus envelopes of SARS-CoV-2 and related coronaviruses in highly purified form, which, as a vaccine protect against COVID-19 and other viral diseases

33.4461309VERWENDUNG VON TRIMANGANTETRAOXIDPARTIKELN BEI DER HERSTELLUNG EINES IMPFSTOFFADJUVANS

EP - 13.11.2024

Clasificación Internacional A61K 39/39Nº de solicitud 23737218Solicitante GUANGZHOU REALBENEFITSPOT PHARMACEUTICAL CO LTDInventor/a WANG YALING

Disclosed is a use of trimanganese tetraoxide particles in preparation of a vaccine adjuvant. The adjuvant is a particle adjuvant, the particle adjuvant is trimanganese tetraoxide particles externally wrapped with or without an excipient, and the particle size of the particle adjuvant is 5nm to 3000 nm. The trimanganese tetraoxide particle adjuvant provided in the present invention can be effectively combined with a single-stranded nucleotide adjuvant and can effectively carry an immune antigen, and a more excellent immunotherapy effects can be achieved when a fewer antigen dose and a relatively low injection amount are used; immune cells are efficiently activated, and body fluid balance and cellular immunity are achieved.

34.20240374707EXPRESSION SYSTEM AND NUCLEIC ACID-BASED PHARMACEUTICAL COMPOSITION COMPRISING SAME

US - 14.11.2024

Clasificación Internacional A61K 39/145Nº de solicitud 18291589Solicitante SML BIOPHARM CO, LTD.Inventor/a Jae Hwan NAM

A nucleic acid molecule including a translation control element having a translation initiation activity and a coding region operably linked to the translation control element and encoding an immunogen of an influenza virus or a severe fever with thrombocytopenia syndrome virus (SFTSV) or fragments thereof is disclosed. The nucleic acid molecule or an expression system where the nucleic acid molecule is inserted can be used in a pharmaceutical composition for treating or preventing influenza or SFTS, for example, that an mRNA vaccine or a gene therapy platform.

35.WO/2024/233388SARCOMA CANCER VACCINES AND USES THEREOF

WO - 14.11.2024

Clasificación Internacional A61K 39/00Nº de solicitud PCT/US2024/027836Solicitante MEMORIAL SLOAN-KETTERING CANCER CENTERInventor/a KLEBANOFF, Christopher A.

The present disclosure provides vaccine compositions comprising recombinant SS 18 : : SSX fusion peptide epitopes and at least one cancer-testis antigen (CTA) epitope, or nucleic acids (e.g., mRNA, cDNA) encoding the same, and methods for using the same to treat sarcoma (e.g., synovial sarcoma) in a subject in need thereof.

36.20240374713SARS-COV-2 IMMUNIZING COMPOSITIONS AND METHODS

US - 14.11.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18660537Solicitante UNM RAINFOREST INNOVATIONSInventor/a David S. Peabody

In one aspect, an immunogen includes an immunogenic carrier comprising an RNA bacteriophage virus-like particle (VLP) and an antigenic SARS-CoV-2 stem-helix peptide linked to the immunogenic carrier. In another aspect, an immunogen includes an immunogenic carrier comprising an RNA bacteriophage virus-like particle (VLP) and an antigenic SARS-CoV-2 nucleocapsid (N) protein peptide linked to the immunogenic carrier. In one or more embodiments of either aspect, the immunogen may be a component of a pharmaceutical composition. In one or more embodiments of either aspect, the immunogen may be a component of a vaccine.

37.WO/2024/235367PROTEÍNA QUIMÉRICA MULTIBLANCO PARA LA INMUNOTERAPIA DE LA ENFERMEDAD DE ALZHEIMER

WO - 21.11.2024

Clasificación Internacional A61K 39/00Nº de solicitud PCT/CU2024/050004Solicitante CENTRO DE NEUROCIENCIAS DE CUBAInventor/a LEÓN ARCIA, Karen

La presente invención se relaciona con los sectores biomédicos y biofarmacéutico. Específicamente se refiere a un antígeno quimérico que comprende la combinación de las regiones amino y carboxilo terminales del péptido beta amiloide (Aβ), las regiones amino y carboxilo terminales de la proteína tau y un epítopo de células T. La composición farmacéutica que comprende este antígeno quimérico y al menos un adyuvante vacunal farmacéuticamente aceptable incrementa la eficacia de la inmunoterapia para la prevención y el tratamiento de la Enfermedad de Alzheimer (EA). El antígeno quimérico ejerce su acción mediante la estimulación de una respuesta humoral multiblanco con altos títulos de anticuerpos anti-Aβ y anti-tau simultáneamente. Con ello, se favorece la eliminación combinada de las especies tóxicas tanto de Aβ como de tau del cerebro lo que previene o mejora significativamente los síntomas clínicos y neuropatología de la EA.

38.WO/2024/236192HETERODIMER OF POXVIRUS A16 AND G9 PROTEINS AS AN IMMUNOGEN

WO - 21.11.2024

Clasificación Internacional A61K 39/285Nº de solicitud PCT/EP2024/063801Solicitante INSTITUT PASTEURInventor/a MEOLA, Annalisa

The invention relates to an isolated heterodimer of poxvirus A16 and G9 proteins as an immunogen in a subunit or nucleic acid vaccine against poxvirus. The invention provides an engineered heterodimer, nucleic acid encoding the heterodimer, neutralizing antibodies directed against said heterodimer and their use for the prevention, treatment and diagnostics of poxvirus infections and related diseases.

39.WO/2024/236527A NOVEL NON-STOICHIOMETRIC MULTI-ELEMENT ADJUVANT (NSMA) AND COMPOSITION THEREOF

WO - 21.11.2024

Clasificación Internacional A61K 39/39Nº de solicitud PCT/IB2024/054766Solicitante MAGVITAE INNOVATIONS INCInventor/a KOYAKUTTY, Manzoor

The present invention broadly relates to the field of immunology. Particularly, the present invention relates to a non-stoichiometric multi element adjuvant (NSMA) as immunomodulatory material, a method for preparing the same, a composition comprising the non-stoichiometric adjuvant. Also, the present invention relates to

non-stoichiometric multi-element adjuvant (NSMA) doped with various ions and application of non-stoichiometric adjuvant in various forms of vaccine, immunotherapy and theranostics (diagnosis and therapy).

40.20240376161RECOMBINANT CHIMERIC PROTEIN, USE THEREOF, AND COMPOSITION

US - 14.11.2024

Clasificación Internacional C07K 14/44Nº de solicitud 18564843Solicitante FUNDAÇÃO OSWALDO CRUZInventor/a Ricardo Tostes Gazzinelli

The present invention relates to a recombinant chimeric protein containing immunogenic regions from the trans-sialidase (TS) protein and amastigote surface protein-2 (ASP-2) from *Trypanosoma cruzi* and a composition containing said protein that displayed vaccine potential in a murine model. The invention also comprises the use of the chimeric protein for manufacturing vaccines.

41.20240374702RECOMBINANT HERPESVIRUS OF TURKEY VECTORS EXPRESSING ANTIGENS OF AVIAN PATHOGENS AND USES THEREOF

US - 14.11.2024

Clasificación Internacional A61K 39/12Nº de solicitud 18542330Solicitante Zoetis Services LLCInventor/a Sing RONG

The invention relates to recombinant viral vectors for the insertion and expression of foreign genes for use in safe immunizations to protect against a variety of pathogens. The invention also relates to multivalent compositions or vaccine comprising one or more recombinant viral vectors for protection against a variety of pathogens. The present invention relates to methods of making an using said recombinant viral vectors.

42.20240374712SARS-COV-2 VACCINE COMPOSITIONS

US - 14.11.2024

Clasificación Internacional A61K 39/215Nº de solicitud 18645259Solicitante Novavax, Inc.Inventor/a Gale SMITH

Disclosed herein are coronavirus (CoV) Spike(S) polypeptides, including naturally and non-naturally occurring polypeptides, and nanoparticles and immunogenic compositions comprising the same, which are useful for stimulating immune responses against various SARS-COV-2 strains. The nanoparticles present antigens from pathogens surrounded to and associated with a detergent core resulting in enhanced stability and good immunogenicity. Dosages, formulations, and methods for preparing the vaccines and nanoparticles are also disclosed.

43.WO/2024/233416MODELS FOR DETERMINING RETROTRANSPOSON (RT) INSERTION BURDEN AND IMPLICATIONS IN CANCER THERAPY

WO - 14.11.2024

Clasificación Internacional C12Q 1/6886Nº de solicitud PCT/US2024/027900Solicitante MEMORIAL SLOAN-KETTERING CANCER CENTERInventor/a GREENBAUM, Benjamin

The present disclosure provides methods, devices, and systems for determining the retrotransposon (RT) burden, RT expression and fitness of mutant p53 in a subject. The RT burden, RT RNA expression and fitness of mutant p53 may be used to determine whether a subject is at risk for cancer and will benefit from a particular

anti -cancer therapy such as immune checkpoint inhibitor therapy, adoptive cell therapy, or prophylactic cancer vaccine therapy.

44.4461737POLYPEPTID ZUR ABGABE VON ANTIGEN AN IMMUNZELLEN

EP - 13.11.2024

Clasificación Internacional C07K 7/06Nº de solicitud 22916735Solicitante JW SHINYAK CORPInventor/a JEON YOON JAE

The present invention relates to a polypeptide for delivering an antigen to immune cells and, specifically, to: a novel polypeptide comprising a cell membrane penetrating peptide and a peptide binding to a surface molecule on immune cells; a fusion polypeptide in which an antigen is coupled to the polypeptide; a nucleic acid coding for the polypeptide or the fusion polypeptide; an immune cell sensitized with the fusion polypeptide or the nucleic acid coding therefor; and an immunotherapeutic agent, antitumor or anticancer vaccine, and a composition for treating a tumor or cancer, each comprising the immune cell.

45.4464380HIV-IMPFSTOFF-IMMUNOGENE

EP - 20.11.2024

Clasificación Internacional A61P 31/18Nº de solicitud 24191310Solicitante UNIV ROCKEFELLERInventor/a NUSSENZWEIG MICHEL

This disclosure provides HIV immunogens and use thereof for generating an immune response in a subject. Also disclosed is a method of isolating anti-HIV antibodies and use thereof. This disclosure further provides a method for treating or preventing a human immunodeficiency type 1 (HIV-1) infection in a subject using the disclosed HIV immunogens and/or antibodies.

46.20240382585GLYCONJUGATE VACCINES

US - 21.11.2024

Clasificación Internacional A61K 39/385Nº de solicitud 18742842Solicitante London School of Hygiene & Tropical MedicineInventor/a Brendan WREN

This invention relates to the use of *S. pneumoniae* protein antigens, such as NanA, PluA and Sp0148, as carriers for immunogenic *S. pneumoniae* capsular polysaccharide. This may be useful for example in glycoconjugate vaccines able to generate a protective immune response against multiple capsuler serotypes. Glycoconjugates, vaccine compositions and methods of manufacture and use are provided.

47.WO/2024/235368COMPOSICION VACUNAL CONTRA EL VIRUS DE LA PESTE PORCINA AFRICANA

WO - 21.11.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/CU2024/050005Solicitante CENTRO DE INGENIERÍA GENÉTICA Y BIOTECNOLOGÍAInventor/a ESTRADA GARCIA, Mario Pablo

Antígenos quiméricos que comprenden un fragmento de los amino ácidos del 1 al 324 o del 1 al 430 de la proteína p72 del virus de la Peste Porcina Africana (VPPA) fusionado al segmento extracelular de la proteína CD154 de cerdos y antígenos quiméricos que comprenden un fragmento de los amino ácidos del 1 al 430 de

la proteína p72 del VPPA fusionado a un fragmento de la proteína B602L del VPPA comprendido entre los aminoácidos del 384 al 538 o del 398 al 465 fusionados al segmento extracelular del CD154 de cerdos. Composición farmacéutica para la prevención de la enfermedad conocida como Peste Porcina Africana.

48.WO/2024/230722PICHIA PASTORIS ENGINEERED STRAIN FOR PRODUCING RECOMBINANT ANTIGEN OF SARS-COV-2, PREPARATION METHOD THEREFOR, AND USE THEREOF

WO - 14.11.2024

Clasificación Internacional C07K 14/165Nº de solicitud PCT/CN2024/091667Solicitante INSTITUTE OF MICROBIOLOGY, CHINESE ACADEMY OF SCIENCESInventor/a GAO, Fu

Provided are a modified Pichia pastoris strain and a preparation method therefor, a recombinant Pichia pastoris engineered strain, based on the modified Pichia pastoris strain, expressing a SARS-CoV-2 antigen, a preparation method therefor, and a use thereof, and a method for preparing a SARS-CoV-2 recombinant protein vaccine. A modified Pichia pastoris expression vector can not only express and secrete recombinant proteins at a high level, but also enable the expressed recombinant proteins to retain a core glycosylation modification. Glycoproteins secreted thereby have good uniformity. The recombinant Pichia pastoris engineered strain, based on the Pichia pastoris expression vector, expressing the SARS-CoV-2 antigen can produce, in a highly efficient manner, high-quality RBD dimer antigens having uniform glycosylation. The produced RBD dimer antigens can be used as immunogens to induce the production of high-level neutralizing antibodies against a SARS-CoV-2 prototype strain and variants thereof.

49.20240376158PREFUSION-STABILIZED HMPV F PROTEINS

US - 14.11.2024

Clasificación Internacional C07K 14/08Nº de solicitud 18779961Solicitante BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventor/a Jason McLELLAN

Provided herein are engineered hMPV F proteins. In some aspects, the engineered F proteins exhibit enhanced conformational stability and/or antigenicity. Methods are also provided for use of the engineered F proteins as diagnostics, in screening platforms, and/or in vaccine compositions.

50.20240382379SYSTEMS AND METHODS FOR FLUID DELIVERY

US - 21.11.2024

Clasificación Internacional A61J 1/20Nº de solicitud 18786555Solicitante Koska Family LimitedInventor/a Marc Andrew Koska

The invention provides for a delivery system including a delivery assembly configured to allow delivery of a single dose of a therapeutic agent (e.g., vaccine, drug, medicament, etc.) from a Blow-Fill-Seal (BFS) vial to a patient.

51.4464724VERFAHREN ZUR HERSTELLUNG VON CHIMÄREM PROTEIN, CHIMÄRES PROTEIN, GEN, IMMUNOGENE ZUSAMMENSETZUNG UND VERWENDUNGEN

EP - 20.11.2024

Clasificación Internacional C07K 19/00Nº de solicitud 22919311Solicitante UNIV MINAS GERAISInventor/a TOSTES GAZZINELI RICARDO

The present technology discloses the process of producing a chimeric protein of SEQ ID No. 1, using the nucleotide sequence of SEQ ID No. 2. It also discloses the chimeric protein defined by SEQ ID No. 1, the gene of SEQ ID No. 2 used to its production, immunogenic compositions containing such protein and its use to prepare vaccines for the prophylaxis and prevention of infection with and moderate and severe forms of COVID-19. The present technology is included in the field of human health, specifically in the field of prevention measures against infection with SARS-CoV2. It addresses to the production of a vaccine composition comprising a chimeric protein that prevents high viral loads and moderate and severe clinical forms of the disease by stimulating the immune system.

52.WO/2024/234755DEVELOPMENT OF MULTI-ANTIGEN MRNA VACCINE AGAINST FELINE FIPV

WO - 21.11.2024

Clasificación Internacional A61K 39/215Nº de solicitud PCT/CN2024/077001Solicitante BEIJING SYNGENTECH CO., LTD.Inventor/a LIU, Qiang

Provided is a pharmaceutical preparation. The pharmaceutical preparation comprises a nucleic acid fragment, wherein the nucleic acid fragment is mRNA, and the nucleic acid fragment comprises at least one of a first nucleic acid fragment, a second nucleic acid fragment and a third nucleic acid fragment; the first nucleic acid fragment encodes an M protein of a feline infectious peritonitis virus; the second nucleic acid fragment encodes an N protein of the feline infectious peritonitis virus; the third nucleic acid fragment encodes an S, S-ec or SII protein of the feline infectious peritonitis virus; and the first nucleic acid fragment, the second nucleic acid fragment and the third nucleic acid fragment are connected or not connected.

53.20240374701VACCINE COMPOSITIONS COMPRISING BRUCELLA STRAINS AND METHODS THEREOF

US - 14.11.2024

Clasificación Internacional A61K 39/02Nº de solicitud 18292542Solicitante THE TEXAS A&M UNIVERSITY SYSTEMInventor/a Paul DE FIGEIREDO

The present disclosure provides pharmaceutical compositions comprising a live attenuated bacterial strain of *Brucella melitensis*, in particular a live attenuated bacterial strain of *Brucella melitensis* is *Brucella melitensis* 16M ΔvjbR (BmΔvjbR). Methods of utilizing the live attenuated bacterial strain of *Brucella melitensis* for treatment of a patient are also provided, including wherein the patient is in need of treatment for cancer, an autoimmune disorder, and/or an inflammatory disorder.

54.20240374706FMDV VIRUS-LIKE PARTICLE WITH DOUBLE STABILIZING MUTATION

US - 14.11.2024

Clasificación Internacional A61K 39/135Nº de solicitud 18684496Solicitante THE PIRBRIGHT INSTITUTEInventor/a Claudine Porta

The invention concerns a modified recombinant foot and mouth disease virus (FMDV) VP2 protein and further concerns an FMDV capsid precursor protein P1 comprising the modified VP2 protein. In a specific aspect,

the present invention concerns a VP2 protein or a capsid precursor protein P1 comprising the VP2 protein, wherein the amino acid sequence of the VP2 protein is modified to improve the stability of FMDV capsids. The invention further relates to an isolated nucleic acid molecule and an expression vector comprising the nucleic acid molecule for recombinant expression of the modified VP2 protein or a capsid precursor protein P1 comprising the VP2 protein. In further aspects, the invention relates to a virus-like particle (VLP) obtained from the modified capsid precursor protein P1 and a vaccine for use in the protection of a subject against an infection with FMDV produced from the VLP.

55.20240383947VIRUS VACCINE

US - 21.11.2024

Clasificación Internacional C07K 14/005Nº de solicitud 18287608Solicitante BioNTech SEInventor/a Ugur Sahin

This disclosure relates to the field of preventing or treating virus infection, in particular, the disclosure relates to agents for vaccination against virus infection and inducing effective virus antigen-specific immune responses such as antibody and/or T cell responses and methods for generating and using such agents. Administration of agents such as RNA disclosed herein to a subject can protect the subject against virus infection. Specifically, the present disclosure relates to amino acid sequences comprising at least a portion of a virus protein having amino acid modifications found in other variants of the virus protein. Administration of RNA encoding one or more of the amino acid sequences may provide protection against diverse virus variants. Methods and agents described herein are, in particular, useful for the prevention or treatment of coronavirus infection such as SARS-CoV-2 infection.

56.20240374731IMMUNOGENIC TRIMERS

US - 14.11.2024

Clasificación Internacional A61K 45/06Nº de solicitud 18733214Solicitante International AIDS Vaccine Initiative, Inc.Inventor/a Jon Steichen

The invention relates to PGT121-germline-targeting designs, trimer stabilization designs, combinations of those two, trimers designed with modified surfaces helpful for immunization regimens, other trimer modifications and on development of trimer nanoparticles and methods of making and using the same.

57.WO/2024/233873RESPIRATORY SYNCYTIAL VIRUS VACCINE AND METHODS OF USE

WO - 14.11.2024

Clasificación Internacional A61K 39/12Nº de solicitud PCT/US2024/028751Solicitante SANOFI PASTEUR INC.Inventor/a CARAYOL, Sebastien

Disclosed herein are respiratory syncytial virus vaccines and methods of immunization to deliver respiratory syncytial virus vaccines in subjects.

58.WO/2024/234991IMIDAZOQUINOLINE COMPOUND, PREPARATION METHOD THEREFOR, AND USE AND COMPOSITION THEREOF

WO - 21.11.2024

Clasificación Internacional C07D 471/04Nº de solicitud PCT/CN2024/090446Solicitante SHENZHEN VACCINE BIOPHARMACEUTICALS LIMITEDInventor/a LIU, Huitao

An imidazoquinoline compound, a preparation method therefor, and a use and composition thereof. The imidazoquinoline compound is a compound represented by formula I or a pharmaceutically acceptable salt thereof. X comprises any one of n-propyl, n-butyl, n-butylamine, n-pentyl, and 2-methoxyethyl. R_1 comprises any one of a C_1-C_{36} alkyl and a C_1-C_{36} alkoxy. R_2 comprises any one of hydrogen, a substituted or unsubstituted aryl, a condensed-ring aryl, a heteropolycyclic group, and -S-R_3, wherein R_3 comprises any one of a substituted or unsubstituted aryl, a condensed-ring aryl, and a heteropolycyclic group. The imidazoquinoline compound selectively releases molecules having TLR7/8 receptor stimulating activity in a tumor and acts on immune cells in the tumor, while reducing the activity of immune cells outside the tumor, so that the imidazoquinoline compound has the characteristic of low systemic immunotoxicity while having anti-tumor activity.

59.20240382576COMPOSITIONS COMPRISING STREPTOCOCCUS PNEUMONIAE POLYSACCHARIDE-PROTEIN CONJUGATES AND METHODS OF USE THEREOF

US - 21.11.2024

Clasificación Internacional A61K 39/09Nº de solicitud 18792658Solicitante Merck Sharp & Dohme LLCInventor/a Chitrananda Abeygunawardana

The invention is related to multivalent immunogenic compositions comprising more than one *S. pneumoniae* polysaccharide protein conjugates, wherein each of the conjugates comprises a polysaccharide from an *S. pneumoniae* serotype conjugated to a carrier protein, wherein the serotypes of *S. pneumoniae* are as defined herein. Also provided are methods for inducing a protective immune response in a human patient comprising administering the multivalent immunogenic compositions of the invention to the patient. The multivalent immunogenic compositions are useful for providing protection against *S. pneumoniae* infection and/or pneumococcal diseases caused by *S. pneumoniae*. The compositions of the invention are also useful as part of treatment regimes that provide complementary protection for patients that have been vaccinated with a multivalent vaccine indicated for the prevention of pneumococcal disease.

***NOTA ACLARATORIA**: Las noticias y otras informaciones que aparecen en este boletín provienen de sitios públicos, debidamente referenciados mediante vínculos a Internet que permiten a los lectores acceder a las versiones electrónicas de sus fuentes originales. Hacemos el mayor esfuerzo por verificar de buena fe la objetividad, precisión y certeza de las opiniones, apreciaciones, proyecciones y comentarios que aparecen en sus contenidos, pero este boletín no puede garantizarlos de forma absoluta, ni se hace responsable de los errores u omisiones que pudieran contener. En este sentido, sugerimos a los lectores cautela y los alertamos de que asumen la total responsabilidad en el manejo de dichas informaciones; así como de cualquier daño o*

perjuicio en que incurran como resultado del uso de estas, tales como la toma de decisiones científicas, comerciales, financieras o de otro tipo.

Edición: Annia Ramos Rodríguez aramos@finlay.edu.cu
Randelys Molina Castro rmolina@finlay.edu.
Claudia Camejo Salas ccamejo@finlay.edu.cu
Yamira Puig Fernández yamipuig@finlay.edu.cu

FINLAY EDICIONES